0001683168-21-003464.txt : 20210812 0001683168-21-003464.hdr.sgml : 20210812 20210812163111 ACCESSION NUMBER: 0001683168-21-003464 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210812 DATE AS OF CHANGE: 20210812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenetic Biosciences, Inc. CENTRAL INDEX KEY: 0001534525 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452952962 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37937 FILM NUMBER: 211168068 BUSINESS ADDRESS: STREET 1: 40 SPEEN STREET, SUITE 102 CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: 781-778-7720 MAIL ADDRESS: STREET 1: 40 SPEEN STREET, SUITE 102 CITY: FRAMINGHAM STATE: MA ZIP: 01701 FORMER COMPANY: FORMER CONFORMED NAME: General Sales & Leasing, Inc. DATE OF NAME CHANGE: 20130227 FORMER COMPANY: FORMER CONFORMED NAME: GENERAL AIRCRAFT INC. DATE OF NAME CHANGE: 20111108 10-Q 1 xenetic_i10q-063021.htm FORM 10-Q FOR JUNE 30, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ______________

Commission File Number: 001-37937

XENETIC BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada	45-2952962
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

40 Speen Street, Suite 102

Framingham, Massachusetts

01701

(Address of principal executive offices)

(Zip Code)

781-778-7720

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	XBIO	The Nasdaq Stock Market LLC
Purchase Warrants	XBIOW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of August 6, 2021 was 9,703,845.

XENETIC BIOSCIENCES, INC.

FORM 10-Q

QUARTERLY PERIOD ENDED JUNE 30, 2021

PART I	FINANCIAL INFORMATION

Item 1	Condensed Consolidated Financial Statements:	3

	Condensed Consolidated Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020	3

	Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2021 and 2020	4

	Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) for the three and six months ended June 30, 2021 and 2020	5

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2021 and 2020	7

	Notes to Condensed Consolidated Financial Statements (Unaudited)	8

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3	Quantitative and Qualitative Disclosures About Market Risk	23

Item 4	Controls and Procedures	23

PART II	OTHER INFORMATION

Item 1	Legal Proceedings	24

Item 1A	Risk Factors	24

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3	Defaults Upon Senior Securities	24

Item 4	Mine Safety Disclosures	24

Item 5	Other Information	24

Item 6	Exhibits	24

Signatures		25

PART I – FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2021			December 31, 2020
		(Unaudited)

ASSETS
Current assets:
Cash	$	9,281,554		$	11,527,552
Prepaid expenses and other		917,826			841,958
Total current assets		10,199,380			12,369,510

Other assets		715,898			809,985
Total assets	$	10,915,278		$	13,179,495

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	305,088		$	327,396
Accrued expenses and other current liabilities		653,126			609,532
Total current liabilities		958,214			936,928

Other long-term liabilities		7,957			27,043
Total liabilities		966,171			963,971

Commitments (Note 11)
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized
Series B, $0.001 par value: 1,804,394 shares issued and outstanding as of June 30, 2021 and December 31, 2020		1,804			1,804
Series A, $0.001 par value: 970,000 shares issued and outstanding as of June 30, 2021 and December 31, 2020		970			970
Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 8,773,683 and 8,772,198 shares issued as of June 30, 2021 and December 31, 2020, respectively; 8,746,692 and 8,745,207 shares outstanding as of June 30, 2021 and December 31, 2020, respectively		8,772			8,771
Additional paid in capital		194,319,716			194,133,511
Accumulated deficit		(179,354,709	)		(176,902,086	)
Accumulated other comprehensive income		253,734			253,734
Treasury stock		(5,281,180	)		(5,281,180	)
Total stockholders' equity		9,949,107			12,215,524
Total liabilities and stockholders' equity	$	10,915,278		$	13,179,495

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2021			2020			2021			2020
Revenue:
Royalty revenue	$	287,603		$	112,927		$	478,819		$	169,676
Total revenue		287,603			112,927			478,819			169,676

Operating costs and expenses:
Research and development		(524,550	)		(307,900	)		(1,154,279	)		(667,551	)
General and administrative		(890,704	)		(787,486	)		(1,821,282	)		(1,715,366	)
Total operating costs and expenses		(1,415,254	)		(1,095,386	)		(2,975,561	)		(2,382,917	)
Loss from operations		(1,127,651	)		(982,459	)		(2,496,742	)		(2,213,241	)

Other income:
Other income		238			192			1,122			58
Interest income, net		20,735			28,625			42,997			80,112
Total other income		20,973			28,817			44,119			80,170

Net loss	$	(1,106,678	)	$	(953,642	)	$	(2,452,623	)	$	(2,133,071	)

Basic and diluted net loss per share	$	(0.13	)	$	(0.15	)	$	(0.28	)	$	(0.34	)

Weighted-average shares of common stock outstanding, basic and diluted		8,746,692			6,288,351			8,746,479			6,260,841

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

THREE MONTHS ENDED JUNE 30, 2021


	Preferred Stock				Common Stock									Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital		Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity
Balance as of April 1, 2021		2,774,394	$	2,774		8,773,683	$	8,772	$	194,209,794	$	(178,248,031	)	$	253,734	$	(5,281,180	)	$	10,945,863
Share-based expense		–		–		–		–		109,922		–			–		–			109,922
Net loss		–		–		–		–		–		(1,106,678	)		–		–			(1,106,678	)
Balance as of June 30, 2021		2,774,394	$	2,774		8,773,683	$	8,772	$	194,319,716	$	(179,354,709	)	$	253,734	$	(5,281,180	)	$	9,949,107

SIX MONTHS ENDED JUNE 30, 2021

	Preferred Stock				Common Stock										Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital			Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity
Balance as of January 1, 2021		2,774,394	$	2,774		8,772,198	$	8,771	$	194,133,511		$	(176,902,086	)	$	253,734	$	(5,281,180	)	$	12,215,524
Share-based expense		–		–		–		–		186,206			–			–		–			186,206
Exercise of purchase warrants		–		–		1,485		1		(1	)		–			–		–			–
Net loss		–		–		–		–		–			(2,452,623	)		–		–			(2,452,623	)
Balance as of June 30, 2021		2,774,394	$	2,774		8,773,683	$	8,772	$	194,319,716		$	(179,354,709	)	$	253,734	$	(5,281,180	)	$	9,949,107

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

THREE MONTHS ENDED JUNE 30, 2020

	Preferred Stock				Common Stock										Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital			Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity
Balance as of April 1, 2020		2,774,394	$	2,774		6,311,906	$	6,311	$	188,405,830		$	(167,188,049	)	$	253,734	$	(5,281,180	)	$	16,199,420
Issuance of common stock to vendor		–		–		1,188		1		(1	)		–			–		–			–
Share-based expense		–		–		–		–		111,734			–			–		–			111,734
Exercise of purchase warrants		–		–		10,124		10		(10	)		–			–		–			–
Net loss		–		–		–		–		–			(953,642	)		–		–			(953,642	)
Balance as of June 30, 2020		2,774,394	$	2,774		6,323,218	$	6,322	$	188,517,553		$	(168,141,691	)	$	253,734	$	(5,281,180	)	$	15,357,512

SIX MONTHS ENDED JUNE 30, 2020

	Preferred Stock				Common Stock										Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital			Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity
Balance as of January 1, 2020		2,774,394	$	2,774		6,092,432	$	6,092	$	188,240,451		$	(166,008,620	)	$	253,734	$	(5,281,180	)	$	17,213,251
Issuance of common stock to vendor		–		–		1,188		1		(1	)		–			–		–			–
Share-based expense		–		–		–		–		277,332			–			–		–			277,332
Exercise of purchase warrants		–		–		229,598		229		(229	)		–			–		–			–
Net loss		–		–		–		–		–			(2,133,071	)		–		–			(2,133,071	)
Balance as of June 30, 2020		2,774,394	$	2,774		6,323,218	$	6,322	$	188,517,553		$	(168,141,691	)	$	253,734	$	(5,281,180	)	$	15,357,512

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Six Months Ended June 30,
	2021			2020

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,452,623	)	$	(2,133,071	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		–			757
Amortization of right of use asset		17,160			13,765
Gain on settlement with vendor		–			(143,639	)
Share-based expense		186,206			277,332
Changes in operating assets and liabilities:
Prepaid expenses and other assets		1,059			167,586
Accounts payable, accrued expenses and other liabilities		2,200			(484,190	)
Net cash used in operating activities		(2,245,998	)		(2,301,460	)

Net change in cash		(2,245,998	)		(2,301,460	)
Cash at beginning of period		11,527,552			10,367,920

Cash at end of period	$	9,281,554		$	8,066,460

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	–		$	–

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock from cashless exercise of purchase warrants	$	1		$	229

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.	The Company

Background

Xenetic Biosciences, Inc. (“Xenetic” or the “Company”), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on progressing XCART^™, a personalized Chimeric Antigen Receptor (“CAR”) T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The XCART technology, developed by the Scripps Research Institute (“Scripps Research”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.

Additionally, Xenetic is leveraging its proprietary drug delivery platform, PolyXen^®, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid to prolong a drug’s circulating half-life and potentially improve other pharmacological properties. Xenetic incorporates its patented and proprietary technologies into drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what the Company believes will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics.

As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,” the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries.

The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (“Hesperix”) and Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various United States (“U.S.”) federal trademark registrations and applications, and unregistered trademarks and service marks, including but not limited to XCART, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which are used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated.

Going Concern and Management’s Plan

Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On December 4, 2020, the Company closed on a $6.0 million registered direct offering of the Company’s common stock, par value $0.001, resulting in $5.4 million of net proceeds to the Company. On July 28, 2021, the Company completed a $12.5 million private placement of the Company’s common stock, par value $0.001, resulting in approximately $11.4 million of net proceeds to the Company. The Company believes that these financings, coupled with the Company’s existing resources, will be adequate for the Company to continue as a going concern. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives. The terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its clinical development programs, its ability to identify and enter into licensing or other strategic arrangements, and factors related to financial, economic and market conditions, many of which are beyond its control.

2.	Impact of COVID-19

3.	Summary of Significant Accounting Policies

Preparation of Interim Financial Statements

The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 and amended on April 28, 2021.

Principles of Consolidation

The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.

Basic and Diluted Net Loss per Share

The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive.

For the three and six months ended June 30, 2021 and 2020, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.

Recent Accounting Standards

In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. ASU 2016-13 is effective for smaller reporting public entities for fiscal years beginning after December 15, 2022 but early adoption is permitted. The Company is currently evaluating the impact of adoption, but it does not anticipate that it will have a material effect on the Company’s consolidated financial statements.

4.	Significant Strategic Collaborations

The Company has entered into various research, development, license and supply agreements with Takeda Pharmaceuticals Co. Ltd. (“Takeda”), Serum Institute of India (“Serum Institute”), Pharmsynthez and SynBio LLC (“SynBio”), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through June 30, 2021.

In October 2017, the Company granted to Takeda the right to grant a non-exclusive sublicense to certain patents related to the Company’s PolyXen technology that were previously exclusively licensed to Takeda in connection with products related to the treatment of blood and bleeding disorders. Royalty payments of approximately $0.3 million and $0.5 million were recorded as revenue by the Company during the three and six months ended June 30, 2021, respectively, and approximately $0.1 million and $0.2 million were recorded as revenue by the Company during the three and six months ended June 30, 2020, respectively. The Company’s policy is to recognize royalty payments as revenue when they are reliably measurable, which is upon receipt of reports from Takeda. The Company receives these reports in the quarter subsequent to the actual sublicensee sales. At the time the revenue was received, there were no remaining performance obligations and all other revenue recognition criteria were met. There are no active projects under the Exclusive Research, Development and License Agreement, dated August 15, 2005, by and between Lipoxen and Baxter Healthcare SA, as amended, (the “Takeda Agreement”), and the parties are discussing a potential termination of the agreement. Any such termination of the Takeda Agreement would have no impact on the Company and its non-exclusive sublicense agreement and the royalties being generated. No amounts were recognized as revenue related to the Serum Institute, Pharmsynthez or SynBio agreements during the three months ended June 30, 2021 and 2020, respectively.

On May 15, 2020, the Company and Scripps Research entered into a Research Funding and Option Agreement (the “Scripps Agreement”), pursuant to which the Company has agreed to provide Scripps Research an aggregate of up to $3.0 million to fund research relating to advancing the pre-clinical development of XCART. The research funding is payable by the Company to Scripps Research on a quarterly basis in accordance with a negotiated budget, which provides for an initial payment of approximately $300,000 on the date of the Scripps Agreement and subsequent quarterly payments of approximately $300,000 over a 27-month period. Under the Scripps Agreement, Scripps Research has granted the Company a license within the Field (as defined in the Scripps Agreement) to any Patent Rights or Technology (as defined in the Scripps Agreement) under the terms of that certain license agreement with Scripps Research, dated February 25, 2019, assigned to the Company on March 1, 2019. Additionally, the Company has the option to acquire a worldwide exclusive license to Scripps Research’s rights in the Technology or Patent Rights not already licensed to the Company, as well as a non-exclusive, royalty-free, non-transferrable license to make and use Scripps Research Technology (as defined in the Scripps Agreement) solely for the Company’s internal research purposes during the performance of the research program contemplated by the Scripps Agreement. The Company has paid $1.5 million to Scripps Research under this agreement through June 30, 2021. As of June 30, 2021 and December 31, 2020, approximately $0.2 million has been recognized as an advance payment under this agreement and is included in Prepaid expenses and other current assets.

5.	Property and Equipment, net

Property and equipment, net consists of the following:

Schedule of Property and Equipment, Net
	June 30, 2021			December 31, 2020
Office and computer equipment	$	42,289		$	42,289
Furniture and fixtures		14,738			14,738
Property and equipment – at cost		57,027			57,027
Less accumulated depreciation		(57,027	)		(57,027	)
Property and equipment – net	$	–		$	–

Depreciation expense was approximately $200 and $800 for the three and six months ended June 30, 2020. There was no depreciation expense for the three and six months ended June 30, 2021.

6.	Indefinite-Lived Intangible Assets

The Company’s indefinite-lived intangible asset, OncoHist, is in-process research and development (“IPR&D”) relating to the Company’s business combination with SymbioTec in 2012. IPR&D is tested for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable, although it is to be tested at least annually until the project is completed or abandoned. The Company completed an impairment analysis of the IPR&D during 2020 and concluded that the following factors indicated that the IPR&D was impaired: a decision by management to delay indefinitely any further development of the IPR&D and to not support the underlying intellectual property; the failure to sell or license the IPR&D to a third party; and the reduction in market capitalization. The Company recorded an asset impairment charge of $9.2 million during the third quarter of 2020 representing the excess of the IPR&D asset’s carrying value over its estimated fair value. A reconciliation of the change in the carrying value of Indefinite-Lived Intangible Assets is as follows:


Balance as of January 1, 2020	$	9,243,128
Impairment		(9,243,128	)
Balance as of December 31, 2020	$	–

7.	Fair Value Measurements

Accounting Standards Codification Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. The carrying amount of certain of the Company’s financial instruments approximate fair value due to their short maturities. As of June 30, 2021 and December 31, 2020, the carrying amounts of the Company’s financial instruments approximates fair value due to their short maturities. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three and six months ended June 30, 2021 and 2020.

8.	Stockholders’ Equity

Warrants

In connection with certain of the Company’s collaboration agreements and consulting arrangements, the Company has issued warrants to purchase shares of common stock as payment for services. As of June 30, 2021 and December 31, 2020, collaboration warrants to purchase 0 and 30,307 shares of common stock were outstanding. No collaboration warrants were granted or exercised in connection with collaboration or consulting services during the three and six months ended June 30, 2021. Collaboration warrants to purchase 30,307 shares expired during the three and six months ended June 30, 2021. No collaboration warrants were granted or exercised and none expired in connection with collaboration or consulting services during the three and six months ended June 30, 2020, respectively.

In addition, the Company has outstanding warrants to purchase an aggregate of 347,505 and 378,453 shares of common stock in connection with debt and equity financing arrangements as of June 30, 2021 and December 31, 2020, respectively. As of June 30, 2021, these warrants have an average weighted exercise price of $36.74 per share and expiration dates ranging from July 2021 through September 2026. No debt and equity financing warrants were granted during the three and six months ended June 30, 2021 and 2020. During the six months ended June 30, 2021 and 2020, debt and equity financing warrants to purchase approximately 1,485 and 0.2 million shares of common stock, respectively, were exercised on a cashless one-for-one basis. No debt and equity financing warrants were exercised during the three months ended June 30, 2021 and 2020, respectively. In addition, approximately 0 and 29,000 debt and equity warrants expired during the three and six months ended June 30, 2021. No debt and equity warrants expired during the three and six months ended June 30, 2020.

9.	Share-Based Expense

Total share-based expense related to stock options, restricted stock units (“RSUs”) and common stock awards was approximately $0.1 million during the three months ended June 30, 2021 and 2020 and approximately $0.2 million and $0.3 million for the six months ended June 30, 2021 and 2020, respectively.

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Research and development expenses	$	19,026	$	12,936	$	29,736	$	26,294
General and administrative expenses		90,896		98,798		156,470		251,038
	$	109,922	$	111,734	$	186,206	$	277,332

Employee Stock Options

During the six months ended June 30, 2021, the Company granted 200,000 stock option awards to purchase shares of common stock. The weighted average grant date fair value per option share was $2.34. Key assumptions used in the Black-Scholes option pricing model for options granted during the six months ending June 30, 2021 were the Company’s stock price, a risk free rate of 1.08%, an expected life of 5.88 years and an expected volatility rate of 134.47%. There were no employee stock options or RSUs granted or exercised during the six months ended June 30, 2020. The Company recognized a total of $0.1 million of compensation expense related to employee stock options during the three months ended June 30, 2021 and 2020 and $0.2 million and $0.3 million during the six months ended June 30, 2021 and 2020, respectively.

Non-Employee Stock Options

The Company did not grant any non-employee stock options during the six months ended June 30, 2021 and 2020. The Company did not recognize any expense related to non-employee stock options during the three and six months ended June 30, 2021. The Company recognized approximately $4,000 and $7,000 of expense during the three and six months ended June 30, 2020, respectively.

10.

Income Taxes

During the three and six months ended June 30, 2021 and 2020, there was no provision for income taxes as the Company incurred losses during both periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company records a valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized. The valuation allowance against deferred tax assets was approximately $30.2 million and $29.6 million as of June 30, 2021 and December 31, 2020, respectively.

As of June 30, 2021 and December 31, 2020, the Company did not record any unrecognized tax positions.

11.

Commitments

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

Cash flow information regarding leases
	Six Months Ended June 30,
	2021
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$	17,160

Supplemental balance sheet information related to our operating leases are as follows:


	Balance Sheet Classification	June 30, 2021
Right-of-use assets - ST	Prepaid expenses and other	$	37,408
Right-of-use assets - LT	Other assets	$	7,957
Current lease liabilities	Accrued expenses and other current liabilities	$	37,408
Non-current lease liabilities	Other long-term liabilities	$	7,957

12.

Related Party Transactions

The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez (as well as SynBio), each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021.

During the fourth quarter of 2019, the Company entered into a loan agreement with Pharmsynthez (the “Pharmsynthez Loan”), pursuant to which the Company advanced Pharmsynthez an aggregate principal amount of up to $500,000 to be used for the development of a specific product under the Company’s co-development agreement with SynBio. The Pharmsynthez Loan had a term of 15-months and accrued interest at a rate of 10% per annum. The Pharmsynthez Loan is guaranteed by all of the operating subsidiaries of Pharmsynthez, including SynBio and AS Kevelt, and is secured by all of the equity interests of the Company owned by Pharmsynthez and SynBio. The Company recognized approximately $11,000 and $23,000 of interest income related to this loan during the three and six months ended June 30, 2021, respectively. The Company recognized approximately $13,000 and $25,000 of interest income related to this loan during the three and six months ended June 30, 2020, respectively.

Effective January 23, 2021, the Company entered into a First Amendment to Loan Agreement and Other Loan Documents with Pharmsynthez, Kevelt and SynBio (the “Pharmsynthez Loan Extension”) to modify the repayment terms and maturity of the Pharmsynthez Loan to January 2022. The terms of the Pharmsynthez Loan Extension called for two (2) equal monthly principal payments of $25,000 in each of January 23, 2021 and February 28, 2021 and the payment of all outstanding accrued interest in six (6) equal monthly installments from January 31, 2021 through June 30, 2021. In addition, the Pharmsynthez Loan Extension requires monthly interest payments and the repayment of the remaining principal amount in six (6) equal monthly installments from August 2021 through January 2022. All other terms of the Pharmsynthez Loan remain in effect. As of June 30, 2021, approximately $0.5 million was included in Prepaid expenses and other on the condensed consolidated balance sheet. As of December 31, 2020, approximately $0.5 million was classified within Prepaid expenses and other and approximately $0.1 million was classified within Other assets on the consolidated balance sheet.

During the third quarter of 2019, the Company entered into a Sponsored Research Agreement with Pharmsynthez (the “SRA”) related to experiments identified by the Company to support its efforts for initial tech transfer of the XCART methods to a future academic collaborator. Under the agreement, the Company made a $350,000 payment to Pharmsynthez during the third quarter of 2019, which was refundable on pro rata basis if the project is terminated prematurely as a result of Pharmsynthez failing to perform the work. On June 12, 2020, the Company and Pharmsynthez entered into a Master Services Agreement (“MSA”) to advance the development of the Company’s XCART technology for B-cell malignancies. The MSA terminated and superseded the SRA. The Company expensed approximately $10,000 and $0.1 million related to work performed under these agreements during the three and six months ended June 30, 2021. The Company expensed approximately $0.1 million related to work performed under these agreements during the six months ended June 30, 2020. No expense was recorded during the three months ended June 30, 2020. As of June 30, 2021, approximately $40,000 was accrued and included in Accrued expenses and other current liabilities on the condensed consolidated balance sheet. As of December 31, 2020, approximately $25,000 was recorded as an advanced payment and included in Prepaid expenses and other on the consolidated balance sheet.

Under the MSA, Pharmsynthez agreed to provide services pursuant to work orders agreed upon by the parties from time to time, which services include, but are not limited to, acting as the Company’s primary contract research organization to assist in managing collaborations with multiple academic institutions in Russia and Belarus. The Company is required to pay reasonable fees, expenses and pass-through costs incurred by Pharmsynthez in providing the services in accordance with a budget and payment terms set forth in each work order. Additionally, in the event that a work order provides for milestone payments, the Company is required to make such payments to Pharmsynthez, or third party service providers designated by Pharmsynthez, in accordance with the terms set forth in the work order, which milestone payments may be made, at the sole discretion of the Company, in cash or shares of the Company’s common stock.

The Company and Pharmsynthez executed a work order on June 12, 2020 (the “Work Order”) under the MSA pursuant to which Pharmsynthez agreed to conduct a Stage 1 study of the Company’s XCART technology under the research program as set forth in the Work Order. The activities to be performed under the Work Order are expected to take approximately 20 months unless earlier terminated in accordance with the MSA. Under the terms of the Work Order, the Company paid Pharmsynthez $51,000 as an initial payment for trial startup costs, which amount was credited against the amounts paid under the SRA. The Work Order provides for additional pass-through costs to be invoiced by Pharmsynthez upon execution of contracts with third party sites, which will be further credited against the SRA. The total cost under the Work Order is currently estimated to be approximately $1.8 million. Through June 30, 2021, all costs incurred under the MSA were credited against the amounts paid under the SRA. Additionally, the Work Order provides for milestone payments of up to an aggregate of $1,050,000, or, in the Company’s sole discretion, up to an aggregate of 1,000,000 shares of the Company’s common stock, to be paid or issued, as applicable, by the Company upon achievement of milestones associated with completion of early stages of the research program as set forth in the Work Order. As of June 30, 2021, approximately $0.1 million of milestone payments has been paid.

13.

Subsequent Events

The Company performed a review of events subsequent to the balance sheet date through the date the financial statements were issued and determined that there were no such events requiring recognition or disclosure in the financial statements except as described below.

Financing

On July 26, 2021, the Company entered into a securities purchase agreement in connection with a private placement (the “Purchase Agreement”) with the purchaser named on the signature page thereto (“Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser, in a private placement priced at-the-market under Nasdaq rules, (i) 950,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), (ii) warrants to purchase an aggregate of 4,629,630 shares of the Company’s common stock, with an exercise price of $3.30 per share (the “Series A Warrants”) which expire three and one half years from the earlier of (a) the six month anniversary of the initial exercise date and (b) the date that the registration statement registering all of the warrant shares underlying the Series A Warrants is declared effective, and (iii) pre-funded warrants to purchase up to 3,679,630 shares of the Company’s common stock, with an exercise price of $0.001 per share (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) with no expiration (the “Private Placement”), at a purchase price of $2.70 per one Share and one Series A Warrant and $2.699 per one Series B Warrant and one Series A Warrant. The Company received aggregate gross proceeds from the Private Placement of approximately $12.5 million, before deducting placement agent fees and offering expenses, and excluding the exercise of any Warrants.

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 27A of the Securities Act of 1933, as amended. All statements contained in this Quarterly Report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, future revenues, projected costs, prospects and our objectives for future operations, are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the anticipated effects and duration of the novel coronavirus, or COVID-19, global pandemic and the responses thereto, including the pandemic’s impact on general economic and market conditions, as well as on our business, results of operations and financial condition; our plans to develop our proposed drug candidates; our expectations regarding the nature, timing and extent of clinical trials and proposed clinical trials; our expectations regarding the timing for proposed submissions of regulatory filings, including, but not limited to, any Investigational New Drug filing or any New Drug Application; the nature, timing and extent of collaboration arrangements; the expected results pursuant to collaboration arrangements including the receipts of future payments that may arise pursuant to collaboration arrangements; the outcome of our plans to obtain regulatory approval of our drug candidates; the outcome of our plans for the commercialization of our drug candidates; our plans to address certain markets, engage third party manufacturers, and evaluate additional drug candidates for subsequent commercial development, and the likelihood and extent of competition to our drug candidates; the development of the XCART^™ Chimeric Antigen Receptor (“CAR”) T technology; our plans to apply the XCART technology to advance cell-based therapeutics by targeting the unique B cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas; our beliefs regarding the expected results of the XCART technology, including its potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells; and our anticipation that our primary focus will now be on advancing the XCART technology through regulatory approval and commercialization.

In some cases, these statements may be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, or “continue”, or the negative of such terms and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, we cannot guarantee future results, the levels of activity, performance or achievements. These statements involve known and unknown risks and uncertainties that may cause our or our industry’s results, levels of activity, performance or achievements to be materially different from those expressed or implied by forward-looking statements.

The Management’s Discussion and Analysis of Financial Condition and Results of Operations (the “MD&A”) should be read together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report. This Quarterly Report, including the MD&A, contains trend analysis and other forward-looking statements. Any statements in this Quarterly Report that are not statements of historical facts are forward-looking statements. These forward-looking statements made herein are based on our current expectations, involve a number of risks and uncertainties and should not be considered as guarantees of future performance.

Some factors that could cause actual results to differ materially include without limitation:


	·	failure to realize the anticipated potential of the XCART or PolyXen technology;
	·	our ability to implement our business strategy;
	·	the failure of the holder to exercise the warrants issued in the Private Placement;
	·	our use of proceeds from the Private Placement and warrant exercise;
	·	our need to raise additional working capital in the future for the purpose of further developing our XCART technology and to continue as a going concern;
	·	our ability to finance our business;
	·	our ability to successfully execute, manage and integrate key acquisitions and mergers, including integration of the acquisition of the XCART technology;
	·	product development and commercialization risks, including our ability to successfully develop the XCART technology;
	·	the impact of adverse safety outcomes and clinical trial results for CAR-T cell therapies;
	·	our ability to secure and maintain a manufacturer for the XCART technology;

	·	our ability to successfully commercialize our current and future drug candidates;
	·	our ability to achieve milestone and other payments associated with our current and future co-development collaborations and strategic arrangements;
	·	the impact of new technologies on our drug candidates and our competition;
	·	changes in laws or regulations of governmental agencies;
	·	interruptions or cancellation of existing contracts;
	·	impact of competitive products and pricing;
	·	product demand and market acceptance and risks;
	·	the presence of competitors with greater financial resources;
	·	continued availability of supplies or materials used in manufacturing at the current prices;
	·	the ability of management to execute plans and motivate personnel in the execution of those plans;
	·	our ability to attract and retain key personnel;
	·	adverse publicity related to our products or the Company itself;
	·	adverse claims relating to our intellectual property;
	·	the adoption of new, or changes in, accounting principles;
	·	the costs inherent with complying with statutes and regulations applicable to public reporting companies, such as the Sarbanes-Oxley Act of 2002;
	·	other new lines of business that the Company may enter in the future;
	·	general economic and business conditions, as well as inflationary trends;
	·	the impact of natural disasters or public health emergencies, such as the COVID-19 global pandemic (including any new variant strains of the underlying virus), on our financial condition and results of operations; and
	·	other factors set forth in the Risk Factors section of our Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission (“SEC”).

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in the forward-looking statements in this Quarterly Report. Other unknown or unpredictable factors also could have material adverse effects on our future results, including, but not limited to, those discussed in the section titled “Risk Factors.” The forward-looking statements in this Quarterly Report are made only as of the date of this Quarterly Report, and we do not undertake any obligation to publicly update any forward-looking statements to reflect subsequent events or circumstances. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

BUSINESS OVERVIEW

We are a biopharmaceutical company focused on progressing XCART^™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. We are initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of the therapeutic assets targeting high-value oncology indications. The XCART technology, developed by the Scripps Research Institute (“Scripps Research”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells. We are currently advancing XCART preclinical efforts through strategic collaborations, including with Scripps Research and Pharmsynthez.

Additionally, we are leveraging our proprietary drug delivery platform, PolyXen^®, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid to prolong a drug’s circulating half-life and potentially improve other pharmacological properties.

We incorporate our patented and proprietary technologies into a number of drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what we believe will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics. Our drug candidates have resulted from our research activities or that of our collaborators and are in the development stage. As a result, we continue to commit a significant amount of our resources to our research and development activities and anticipate continuing to do so for the near future. To date, none of our drug candidates have received regulatory marketing authorization in the United States (“U.S.”) by the Food and Drug Administration nor in any other territories by any applicable agencies. We are receiving ongoing royalties pursuant to a license of our PolyXen technology to an industry partner.

We also have oncology therapeutic investigational drug candidate XBIO-101^™ (sodium cridanimod) for the treatment of progestin resistant endometrial cancer. We commenced a Phase 2 trial under an Investigational New Drug filing in 2017, for the potential treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy, with the first patient dosed in October 2017. We closed patient enrollment in the trial in March 2019 as a result of slower than expected progress on the trial resulting from patient enrollment and retention challenges and have suspended further development of XBIO-101. We currently have no plans to continue development of XBIO-101.

Although we hold a broad patent portfolio, the focus of our internal development efforts during the three and six months ended June 30, 2021 was on advancing the development of our XCART platform technology.

Critical Accounting Estimates

The preparation of our financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue, costs and expenses during the reporting period. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results and outcomes could differ materially from our estimates, judgments and assumptions.

There has been no material change to our critical accounting estimates since those critical accounting estimates described in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021, as amended on April 28, 2021.

Effects of the COVID-19 Pandemic

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus, or COVID-19. The pandemic has significantly affected economic conditions in the U.S., accelerating during the first half of March 2020 and continuing into 2021, as federal, state and local governments react to the public health crisis with mitigation measures, creating significant uncertainties in the U.S. economy. We continue to evaluate the effects of the COVID-19 pandemic on our business, and while our operations were not materially affected during the three and six months ended June 30, 2021 despite social distancing and other measures taken in response to the pandemic, the ultimate impact of the COVID-19 pandemic on our results of operations and financial condition is dependent on future developments, including the duration of the pandemic and the related extent of its severity, the pace and rate at which vaccines are administered, as well as its impact on macroeconomic conditions, which are uncertain and cannot be predicted at this time. If the global response to contain the COVID-19 pandemic escalates further or is unsuccessful, or if governmental decisions to ease pandemic related restrictions are ineffective, premature or counterproductive, we could experience a material adverse effect on our business, financial condition, results of operations and cash flows.

RESULTS OF OPERATIONS

Comparison of Quarter Ended June 30, 2021 and 2020

The comparison of our historical results of operations for the fiscal quarter ended June 30, 2021 to the fiscal quarter ended June 30, 2020 is as follows:

Description	Quarter Ended June 30, 2021			Quarter Ended June 30, 2020			Increase (Decrease)			Percentage Change
Revenues:
Royalty revenue	$	287,603		$	112,927		$	174,676			154.7%
Operating costs and expenses:
Research and development		(524,550	)		(307,900	)		216,650			70.4
General and administrative		(890,704	)		(787,486	)		103,218			13.1
Total operating costs and expenses		(1,415,254	)		(1,095,386	)		319,868			29.2
Loss from operations		(1,127,651	)		(982,459	)		145,192			14.8
Other income:
Other income		238			192			46			24.0
Interest income, net		20,735			28,625			(7,890	)		(27.6	)

Net loss	$	(1,106,678	)	$	(953,642	)	$	153,036			16.1

Revenue

Revenue for the three months ended June 30, 2021 increased by $0.2 million, or 154.7%, to $0.3 million from approximately $0.1 million for the three months ended June 30, 2020. This increase represents an increase in royalty revenue related to our sublicense agreement with Takeda Pharmaceuticals Co. Ltd. as compared to the same period in 2020, as the sublicensee continued its worldwide launch of the product.

Research and Development Expenses

Research & development (“R&D”) expenses for the three months ended June 30, 2021 increased by $0.2 million, or 70.4% to $0.5 million from $0.3 million in the comparable quarter in 2020. The table below sets forth the R&D costs incurred by the Company by category of expense for the quarters ended June 30, 2021 and 2020:

	Quarter Ended,
Category of Expense	June 30, 2021		June 30, 2020
Outside services and contract research organizations	$	358,389	$	150,668
Salaries and wages		108,747		112,055
Share-based expense		19,026		12,936
Other		38,388		32,241
Total research and development expense	$	524,550	$	307,900

The increase in outside services and contract research organizations expense was primarily due to increased spending related to our XCART platform technology during the three months ended June 30, 2021 as compared to the same period in the prior year. Costs related to our XCART program were higher in 2021 as compared to the same period in 2020 as we continued to invest in our pre-clinical developments efforts. This increase was partially offset by a decrease in spending on our XBIO-101 Phase 2 clinical trial, which was closed during the first quarter of 2021.

General and Administrative Expenses

General and administrative expenses for the three months ended June 30, 2021 was $0.9 million, increasing $0.1 million, or 13.1%, compared to the same period in the prior year. The increase was primarily due to a gain on settlement of certain vendor amounts to close out our XBIO-101 trial that reduced general and administrative expenses by $0.1 million during the three months ended June 30, 2020.

Other Income

Other income was approximately $200 for both the three months ended June 30, 2021 and 2020. Other income relates to changes in foreign currency exchange rates during both periods.

Interest Income, net

Interest income decreased to approximately $21,000 during the three months ended June 30, 2021 as compared to approximately $29,000 for the same period in the prior year. This decrease is primarily due to a decrease in interest income on invested funds due to lower interest rates during the second quarter of 2021 compared to the same period in 2020.

Comparison of Six Months Ended June 30, 2021 and 2020

The comparison of our historical results of operations for the six months ended June 30, 2021 to the six months ended June 30, 2020 is as follows:

Description	Six Months Ended June 30, 2021			Six Months Ended June 30, 2020			Increase (Decrease)			Percentage Change
Revenues:
Royalty revenue	$	478,819		$	169,676		$	309,143			182.2%
Operating costs and expenses:
Research and development		(1,154,279	)		(667,551	)		486,728			72.9
General and administrative		(1,821,282	)		(1,715,366	)		105,916			6.2
Total operating costs and expenses		(2,975,561	)		(2,382,917	)		592,644			24.9
Loss from operations		(2,496,742	)		(2,213,241	)		283,501			12.8
Other income:
Other income		1,122			58			1,064			1,834.5
Interest income, net		42,997			80,112			(37,115	)		(46.3	)

Net loss	$	(2,452,623	)	$	(2,133,071	)	$	319,552			15.0

Revenue

Revenue for the six months ended June 30, 2021 increased by $0.3 million, or 182.2%, to $0.5 million from approximately $0.2 million for the six months ended June 30, 2020. This increase represents an increase in royalty revenue related to our sublicense agreement with Takeda Pharmaceuticals Co. Ltd. as compared to the same period in 2020, as the sublicensee continued its worldwide launch of the product.

Research and Development Expenses

R&D expenses increased approximately $0.5 million, or 72.9% to $1.2 million for the six months ended June 30, 2021, from $0.7 million for the six months ended June 30, 2020. The table below sets forth the R&D costs incurred by us, by category of expense, for the six months ended June 30, 2021 and 2020:

	Six Months Ended,
Category of Expense	June 30, 2021		June 30, 2020
Outside services and contract research organizations	$	811,013	$	374,289
Salaries and wages		238,795		201,897
Share-based expense		29,736		26,294
Other		74,735		65,071
Total research and development expense	$	1,154,279	$	667,551

The increase in outside services and contract research organizations expense was primarily due to increased spending related to our XCART platform technology during the six months ended June 30, 2021 as compared to the same period in the prior year. Costs related to our XCART program were higher in 2021 as compared to the same period in 2020 as we continued to invest in our pre-clinical developments efforts. This increase was partially offset by a decrease in spending on our XBIO-101 Phase 2 clinical trial, which was closed during the first quarter of 2021. Salaries and wages increased during the six months ended June 30, 2021 due to slightly higher employee related costs.

General and Administrative Expenses

General and administrative expenses for the six months ended June 30, 2021 was $1.8 million, increasing $0.1 million, or 6.2%, compared to the same period in the prior year. Increases in employee related and consulting costs during the six months ended June 30, 2021 compared to the same period in 2020 were substantially offset by lower share-based expense and legal and accounting costs. In addition, general and administrative expenses for the six months ended June 30, 2020 were lower than the same period in 2021 due to a $0.1 million gain on settlement of certain vendor amounts to close out our XBIO-101 trial recognized during 2020.

Other Income

Other income was approximately $1,000 for the six months ended June 30, 2021 compared to approximately $100 for the same period in 2020. This increase was primarily related to changes in foreign currency exchange rates during the six months ended June 30, 2021 as compared to the same period in 2020.

Interest Income

Interest income decreased to approximately $43,000 during the six months ended June 30, 2021 as compared to approximately $80,000 for the same period in the prior year. This decrease is primarily due to a decrease in interest income on invested funds due to lower interest rates during 2021 compared to the same period in 2020.

Liquidity and Capital Resources

We incurred a net loss of approximately $2.5 million for the six months ended June 30, 2021. We had an accumulated deficit of approximately $179.4 million at June 30, 2021 as compared to an accumulated deficit of approximately $176.9 million at December 31, 2020. Working capital was approximately $9.2 million at June 30, 2021 and $11.4 million at December 31, 2020, respectively. During the six months ended June 30, 2021, our working capital decreased by $2.2 million primarily due to our net loss for the six months ended June 30, 2021. We expect to continue incurring losses for the foreseeable future and may need to raise additional capital or pursue other strategic alternatives in the long-term in order to continue the pursuit of our business plan.

Our principal source of liquidity consists of cash. At June 30, 2021, we had approximately $9.3 million in cash and $1.0 million in current liabilities. At December 31, 2020, we had approximately $11.5 million in cash and $0.9 million in current liabilities. We have historically relied upon sales of our equity securities to fund our operations. We expect the majority of our funding through equity or equity-linked instruments, debt financings, corporate collaborations, related party funding and/or licensing agreements to continue as a trend for the foreseeable future.

Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. We have incurred substantial losses since our inception, and we expect to continue to incur operating losses in the near-term. These factors raise substantial doubt about our ability to continue as a going concern. We believe that we have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On December 4, 2020, we closed on a $6.0 million registered direct Common Stock offering resulting in $5.4 million of net proceeds to us. On July 28, 2021, we completed a $12.5 million private placement of our Common Stock resulting in approximately $11.4 million of net proceeds to us. We believe that these financings, coupled with our existing resources, will be adequate for us to continue as a going concern. However, we anticipate we may need additional capital in the long-term to pursue our business initiatives. The terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in our clinical development programs, our ability to identify and enter into licensing or other strategic arrangements, and factors related to financial, economic and market conditions, many of which are beyond our control.

Cash Flows from Operating Activities

Cash flows used in operating activities for the six months ended June 30, 2021 totaled approximately $2.2 million, which was primarily due to our net loss for the period, partially offset by non-cash charges associated with share-based expense. Cash flows used in operating activities for the six months ended June 30, 2020 totaled approximately $2.3 million, which was primarily due to our net loss for the period, partially offset by non-cash charges associated with share-based expense, and settlement of certain amounts payable to a vendor related to the close-out of our XBIO-101 trial.

Cash Flows from Investing Activities

There were no cash flows from investing activities for the six months ended June 30, 2021 and 2020.

Cash Flow from Financing Activities

There were no cash flows from financing activities for the six months ended June 30, 2021 and 2020.

Contractual Obligations and Commitments

As of June 30, 2021, there were no material changes in our contractual obligations and commitments from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021.

Off Balance Sheet Arrangements

We do not have any off-balance sheet financing arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Recent Accounting Standards

See Note 3 in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021, for a discussion of recent accounting standards.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. There have been no material changes in our critical accounting policies from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are not required to provide the information required by this Item because we are a “smaller reporting company” (as defined in Rule 12b-2 of the Exchange Act).

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report.

Based on this evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report that would have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

We are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations.

ITEM 1A – RISK FACTORS

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 – MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5 – OTHER INFORMATION

None.

ITEM 6 – EXHIBITS

The following exhibits are incorporated herein by reference or filed as part of this report.

EXHIBIT NUMBER	DESCRIPTION
31.1*	Certification of Jeffrey F. Eisenberg, Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of James Parslow, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certifications of Jeffrey F. Eisenberg, Principal Executive Officer, and James Parslow, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*	The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, formatted in inline XBRL, include: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements.
104*	Cover Page Interactive Data File (formatted in inline XBRL and included in Exhibit 101).
*	Filed herewith.
**	Exhibit 32.1 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended, except as otherwise stated in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Xenetic Biosciences, Inc.


August 12, 2021	By:	/S/ JEFFREY F. EISENBERG
		Jeffrey F. Eisenberg
		Chief Executive Officer (Principal Executive Officer)

	By:	/S/ JAMES PARSLOW
		James Parslow Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 xenetic_ex3101.htm CERTIFICATION

EXHIBIT 31.1

I, Jeffrey F. Eisenberg, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Xenetic Biosciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2021

By: /s/ JEFFREY F. EISENBERG

Jeffrey F. Eisenberg
Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 xenetic_ex3102.htm CERTIFICATION

EXHIBIT 31.2

I, James Parslow, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Xenetic Biosciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2021

By: /s/ JAMES PARSLOW

James Parslow
Chief Financial Officer
(Principal Financial and Principal Accounting Officer)

EX-32.1 4 xenetic_ex3201.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic Biosciences, Inc. (the “Company”), and James Parslow, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2021, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 12, 2021

In Witness Whereof, the undersigned have set their hands hereto as of the 12th day of August 2021.

/s/ Jeffrey F. Eisenberg	/s/James Parslow
Jeffrey F. Eisenberg	James Parslow
Chief Executive Officer	Chief Financial Officer

“This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Xenetic Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.”

EX-101.SCH 5 xbio-20210630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Impact of COVID-19 link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Significant Strategic Collaborations link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Indefinite-Lived Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Indefinite-Lived Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Significant Strategic Collaborations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Property and Equipment, net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Indefinite-Lived Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Commitments (Details - Cash flow Information) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Commitments (Details - lease information) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 xbio-20210630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 xbio-20210630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 xbio-20210630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, $0.001 par value per share Purchase Warrants [Member] Preferred Class B [Member] Series B Preferred Stock [Member] Preferred Class A [Member] Series A Preferred Stock [Member] Product and Service [Axis] Royalty [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Stock [Member] Transaction Type [Axis] Direct Offering [Member] Private Placement [Member] Counterparty Name [Axis] Takeda [Member] Royalty Revenue [Member] Serum Institute [Member] Syn Bio [Member] Pharmsynthez [Member] Scripps Agreement [Member] Long-Lived Tangible Asset [Axis] Office and Computer Equipment [Member] Furniture and Fixtures [Member] Indefinite-lived Intangible Assets [Axis] OncoHist [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Award Type [Axis] Colllaboration Warrants [Member] Debt And Equity Financing Warrants [Member] Restricted Stock Units (RSUs) [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Share-based Payment Arrangement, Option [Member] Non Employee Stock Options [Member] Related Party [Axis] Co Development Agreement [Member] Sponsored Research Agreement [Member] Balance Sheet Location [Axis] Prepaid Expenses And Other [Member] Statement [Table] Affiliate, Collateralized Security [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Line Items] ASSETS Current assets: Cash Prepaid expenses and other Total current assets Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Total current liabilities Other long-term liabilities Total liabilities Commitments (Note 11) Stockholders' equity: Preferred Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 8,773,683 and 8,772,198 shares issued as of June 30, 2021 and December 31, 2020, respectively; 8,746,692 and 8,745,207 shares outstanding as of June 30, 2021 and December 31, 2020, respectively Additional paid in capital Accumulated deficit Accumulated other comprehensive income Treasury stock Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, shares authorized Preferred stock, par value Preferred stock shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Revenue: Total revenue Operating costs and expenses: Research and development General and administrative Total operating costs and expenses Loss from operations Other income: Other income Interest income, net Total other income Net loss Basic and diluted net loss per share Weighted-average shares of common stock outstanding, basic and diluted Beginning balance, value Beginning balance, shares Issuance of common stock to vendor Issuance of common stock to vendor, shares Share-based expense Exercise of purchase warrants, shares Exercise of purchase warrants Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization of right of use asset Gain on settlement with vendor Share-based expense Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable, accrued expenses and other liabilities Net cash used in operating activities Net change in cash Cash at beginning of period Cash at end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Issuance of common stock from cashless exercise of purchase warrants Accounting Policies [Abstract] The Company Impact Of Covid-19 Impact of COVID-19 Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Significant Strategic Collaborations Property, Plant and Equipment [Abstract] Property and Equipment, net Goodwill and Intangible Assets Disclosure [Abstract] EX-101.PRE 9 xbio-20210630_pre.xml XBRL PRESENTATION FILE XML 10 xenetic_i10q-063021_htm.xml IDEA: XBRL DOCUMENT 0001534525 2021-01-01 2021-06-30 0001534525 XBIO:CommonStock0.001ParValuePerShareMember 2021-01-01 2021-06-30 0001534525 XBIO:PurchaseWarrantsMember 2021-01-01 2021-06-30 0001534525 2021-08-06 0001534525 2021-06-30 0001534525 2020-12-31 0001534525 us-gaap:PreferredClassBMember 2021-06-30 0001534525 us-gaap:PreferredClassBMember 2020-12-31 0001534525 us-gaap:SeriesBPreferredStockMember 2021-06-30 0001534525 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001534525 us-gaap:PreferredClassAMember 2021-06-30 0001534525 us-gaap:PreferredClassAMember 2020-12-31 0001534525 us-gaap:SeriesAPreferredStockMember 2021-06-30 0001534525 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001534525 2021-04-01 2021-06-30 0001534525 2020-04-01 2020-06-30 0001534525 2020-01-01 2020-06-30 0001534525 us-gaap:RoyaltyMember 2021-04-01 2021-06-30 0001534525 us-gaap:RoyaltyMember 2020-04-01 2020-06-30 0001534525 us-gaap:RoyaltyMember 2021-01-01 2021-06-30 0001534525 us-gaap:RoyaltyMember 2020-01-01 2020-06-30 0001534525 us-gaap:PreferredStockMember 2021-03-31 0001534525 us-gaap:CommonStockMember 2021-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001534525 us-gaap:RetainedEarningsMember 2021-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001534525 us-gaap:TreasuryStockMember 2021-03-31 0001534525 2021-03-31 0001534525 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001534525 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001534525 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001534525 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0001534525 us-gaap:PreferredStockMember 2021-06-30 0001534525 us-gaap:CommonStockMember 2021-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001534525 us-gaap:RetainedEarningsMember 2021-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001534525 us-gaap:TreasuryStockMember 2021-06-30 0001534525 us-gaap:PreferredStockMember 2020-12-31 0001534525 us-gaap:CommonStockMember 2020-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001534525 us-gaap:RetainedEarningsMember 2020-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001534525 us-gaap:TreasuryStockMember 2020-12-31 0001534525 us-gaap:PreferredStockMember 2021-01-01 2021-06-30 0001534525 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001534525 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-06-30 0001534525 us-gaap:TreasuryStockMember 2021-01-01 2021-06-30 0001534525 us-gaap:PreferredStockMember 2020-03-31 0001534525 us-gaap:CommonStockMember 2020-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001534525 us-gaap:RetainedEarningsMember 2020-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001534525 us-gaap:TreasuryStockMember 2020-03-31 0001534525 2020-03-31 0001534525 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0001534525 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001534525 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001534525 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0001534525 us-gaap:PreferredStockMember 2020-06-30 0001534525 us-gaap:CommonStockMember 2020-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001534525 us-gaap:RetainedEarningsMember 2020-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001534525 us-gaap:TreasuryStockMember 2020-06-30 0001534525 2020-06-30 0001534525 us-gaap:PreferredStockMember 2019-12-31 0001534525 us-gaap:CommonStockMember 2019-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001534525 us-gaap:RetainedEarningsMember 2019-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001534525 us-gaap:TreasuryStockMember 2019-12-31 0001534525 2019-12-31 0001534525 us-gaap:PreferredStockMember 2020-01-01 2020-06-30 0001534525 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001534525 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0001534525 us-gaap:TreasuryStockMember 2020-01-01 2020-06-30 0001534525 XBIO:DirectOfferingMember 2020-01-01 2020-12-04 0001534525 us-gaap:PrivatePlacementMember 2021-01-01 2021-06-30 0001534525 XBIO:TakedaMember XBIO:RoyaltyRevenueMember 2021-04-01 2021-06-30 0001534525 XBIO:TakedaMember XBIO:RoyaltyRevenueMember 2021-01-01 2021-06-30 0001534525 XBIO:TakedaMember XBIO:RoyaltyRevenueMember 2020-04-01 2020-06-30 0001534525 XBIO:TakedaMember XBIO:RoyaltyRevenueMember 2020-01-01 2020-06-30 0001534525 XBIO:SerumInstituteMember XBIO:RoyaltyRevenueMember 2021-04-01 2021-06-30 0001534525 XBIO:SerumInstituteMember XBIO:RoyaltyRevenueMember 2020-04-01 2020-06-30 0001534525 XBIO:SynBioMember XBIO:RoyaltyRevenueMember 2021-04-01 2021-06-30 0001534525 XBIO:SynBioMember XBIO:RoyaltyRevenueMember 2020-04-01 2020-06-30 0001534525 XBIO:PharmsynthezMember XBIO:RoyaltyRevenueMember 2021-04-01 2021-06-30 0001534525 XBIO:PharmsynthezMember XBIO:RoyaltyRevenueMember 2020-04-01 2020-06-30 0001534525 XBIO:ScrippsAgreementMember 2021-01-01 2021-06-30 0001534525 XBIO:ScrippsAgreementMember 2021-06-30 0001534525 XBIO:ScrippsAgreementMember 2020-12-31 0001534525 XBIO:OfficeAndComputerEquipmentMember 2021-06-30 0001534525 XBIO:OfficeAndComputerEquipmentMember 2020-12-31 0001534525 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001534525 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001534525 XBIO:OncoHistMember 2020-07-01 2020-09-30 0001534525 2020-01-01 2020-12-31 0001534525 us-gaap:FairValueInputsLevel3Member 2021-06-30 0001534525 us-gaap:FairValueInputsLevel3Member 2020-06-30 0001534525 XBIO:ColllaborationWarrantsMember 2021-06-30 0001534525 XBIO:ColllaborationWarrantsMember 2020-12-31 0001534525 XBIO:ColllaborationWarrantsMember 2021-04-01 2021-06-30 0001534525 XBIO:ColllaborationWarrantsMember 2021-01-01 2021-06-30 0001534525 XBIO:ColllaborationWarrantsMember 2020-04-01 2020-06-30 0001534525 XBIO:ColllaborationWarrantsMember 2020-01-01 2020-06-30 0001534525 XBIO:DebtAndEquityFinancingWarrantsMember 2021-06-30 0001534525 XBIO:DebtAndEquityFinancingWarrantsMember 2020-12-31 0001534525 XBIO:DebtAndEquityFinancingWarrantsMember 2021-01-01 2021-06-30 0001534525 XBIO:DebtAndEquityFinancingWarrantsMember 2021-04-01 2021-06-30 0001534525 XBIO:DebtAndEquityFinancingWarrantsMember 2020-04-01 2020-06-30 0001534525 XBIO:DebtAndEquityFinancingWarrantsMember 2020-01-01 2020-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2021-01-01 2021-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2020-01-01 2020-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2021-04-01 2021-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2020-04-01 2020-06-30 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2019-01-01 2019-12-31 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2021-06-30 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2021-04-01 2021-06-30 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2021-01-01 2021-06-30 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2020-04-01 2020-06-30 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2020-01-01 2020-06-30 0001534525 XBIO:PrepaidExpensesAndOtherMember XBIO:PharmsynthezMember XBIO:SponsoredResearchAgreementMember 2021-06-30 0001534525 XBIO:PrepaidExpensesAndOtherMember XBIO:PharmsynthezMember XBIO:SponsoredResearchAgreementMember 2020-12-31 0001534525 XBIO:PharmsynthezMember XBIO:SponsoredResearchAgreementMember 2020-12-31 0001534525 XBIO:PharmsynthezMember XBIO:SponsoredResearchAgreementMember 2019-01-01 2019-12-31 0001534525 XBIO:PharmsynthezMember XBIO:SponsoredResearchAgreementMember 2021-04-01 2021-06-30 0001534525 XBIO:PharmsynthezMember XBIO:SponsoredResearchAgreementMember 2021-01-01 2021-06-30 0001534525 XBIO:PharmsynthezMember XBIO:SponsoredResearchAgreementMember 2020-01-01 2020-06-30 0001534525 XBIO:PharmsynthezMember XBIO:SponsoredResearchAgreementMember 2020-04-01 2020-06-30 iso4217:USD shares iso4217:USD shares pure 0001534525 false --12-31 2021 Q2

10-Q true 2021-06-30 false 001-37937 XENETIC BIOSCIENCES, INC. NV 45-2952962 40 Speen Street Suite 102 Framingham MA 01701 781 778-7720 Common Stock, $0.001 par value per share XBIO NASDAQ Purchase Warrants XBIOW NASDAQ Yes Yes Non-accelerated Filer true false false 9703845

9281554

11527552

917826

841958

10199380

12369510

715898

809985

10915278

13179495

305088

327396

653126

609532

958214

936928

7957

27043

966171

963971

10000000

0.001

1804394

1804

0.001

970000

970

0.001

50000000

8773683

8772198

8746692

8745207

8772

8771

194319716

194133511

-179354709

-176902086

253734

5281180

9949107

12215524

10915278

13179495

287603

112927

478819

169676

287603

112927

478819

169676

524550

307900

1154279

667551

890704

787486

1821282

1715366

1415254

1095386

2975561

2382917

-1127651

-982459

-2496742

-2213241

238

192

1122

20735

28625

42997

80112

20973

28817

44119

80170

-1106678

-953642

-2452623

-2133071

-0.13

-0.15

-0.28

-0.34

8746692

6288351

8746479

6260841

2774394

2774

8773683

8772

194209794

-178248031

253734

-5281180

10945863

109922

-1106678

2774394

2774

8773683

8772

194319716

-179354709

253734

-5281180

9949107

2774394

2774

8772198

8771

194133511

-176902086

253734

-5281180

12215524

186206

1485 1 -1

-2452623

2774394

2774

8773683

8772

194319716

-179354709

253734

-5281180

9949107

2774394

2774

6311906

6311

188405830

-167188049

253734

-5281180

16199420

1188

-1

111734

10124 10 -10

-953642

2774394

2774

6323218

6322

188517553

-168141691

253734

-5281180

15357512

2774394

2774

6092432

6092

188240451

-166008620

253734

-5281180

17213251

1188

-1

277332

229598 229 -229

-2133071

2774394

2774

6323218

6322

188517553

-168141691

253734

-5281180

15357512

-2452623

-2133071

757

17160

13765

-143639

186206

277332

-1059

-167586

2200

-484190

-2245998

-2301460

-2245998

-2301460

11527552

10367920

9281554

8066460

1 229

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">1.</td> <td style="text-align: justify">The Company </td></tr> </table> Background Xenetic Biosciences, Inc. (“Xenetic” or the “Company”), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on progressing XCART™, a personalized Chimeric Antigen Receptor (“CAR”) T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The XCART technology, developed by the Scripps Research Institute (“Scripps Research”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells. Additionally, Xenetic is leveraging its proprietary drug delivery platform, PolyXen®, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid to prolong a drug’s circulating half-life and potentially improve other pharmacological properties. Xenetic incorporates its patented and proprietary technologies into drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what the Company believes will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics. As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,” the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries. The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (“Hesperix”) and Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various United States (“U.S.”) federal trademark registrations and applications, and unregistered trademarks and service marks, including but not limited to XCART, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which are used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated. Going Concern and Management’s Plan Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On December 4, 2020, the Company closed on a $6.0 million registered direct offering of the Company’s common stock, par value $0.001, resulting in $5.4 million of net proceeds to the Company. On July 28, 2021, the Company completed a $12.5 million private placement of the Company’s common stock, par value $0.001, resulting in approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0n3_dm_c20210101__20210630__us-gaap--TransactionTypeAxis__us-gaap--PrivatePlacementMember_z9AXKiwtX2t7" title="Proceed from private placement">11.4 million of net proceeds to the Company. The Company believes that these financings, coupled with the Company’s existing resources, will be adequate for the Company to continue as a going concern. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives. The terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its clinical development programs, its ability to identify and enter into licensing or other strategic arrangements, and factors related to financial, economic and market conditions, many of which are beyond its control.

5400000

11400000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px; text-align: justify">2.</td> <td style="text-align: justify">Impact of COVID-19 </td></tr> </table> During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus, or COVID-19. The pandemic has significantly affected economic conditions in the U.S., accelerating during the first half of March 2020 and continuing into 2021, as federal, state and local governments react to the public health crisis with mitigation measures, creating significant uncertainties in the U.S. economy. The Company continues to evaluate the effects of the COVID-19 pandemic on its business and while there has been no significant impact to the Company’s operations to date, the Company at this time is uncertain of the impact this event may have on the Company’s future operations. The extent to which the COVID-19 pandemic affects our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict, and such uncertainty is expected to continue for some time.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">3.</td> <td style="text-align: justify">Summary of Significant Accounting Policies </td></tr> </table> Preparation of Interim Financial Statements The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 and amended on April 28, 2021. Principles of Consolidation The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation. Basic and Diluted Net Loss per Share The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. For the three and six months ended June 30, 2021 and 2020, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive. Recent Accounting Standards In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. ASU 2016-13 is effective for smaller reporting public entities for fiscal years beginning after December 15, 2022 but early adoption is permitted. The Company is currently evaluating the impact of adoption, but it does not anticipate that it will have a material effect on the Company’s consolidated financial statements.

Preparation of Interim Financial Statements The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 and amended on April 28, 2021.

Principles of Consolidation The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.

Basic and Diluted Net Loss per Share The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. For the three and six months ended June 30, 2021 and 2020, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.

Recent Accounting Standards In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. ASU 2016-13 is effective for smaller reporting public entities for fiscal years beginning after December 15, 2022 but early adoption is permitted. The Company is currently evaluating the impact of adoption, but it does not anticipate that it will have a material effect on the Company’s consolidated financial statements.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">4.</td> <td style="text-align: justify">Significant Strategic Collaborations</td></tr> </table> The Company has entered into various research, development, license and supply agreements with Takeda Pharmaceuticals Co. Ltd. (“Takeda”), Serum Institute of India (“Serum Institute”), Pharmsynthez and SynBio LLC (“SynBio”), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through June 30, 2021. In October 2017, the Company granted to Takeda the right to grant a non-exclusive sublicense to certain patents related to the Company’s PolyXen technology that were previously exclusively licensed to Takeda in connection with products related to the treatment of blood and bleeding disorders. Royalty payments of approximately $0.3 million and $0.5 million were recorded as revenue by the Company during the three and six months ended June 30, 2021, respectively, and approximately $0.1 million and $0.2 million were recorded as revenue by the Company during the three and six months ended June 30, 2020, respectively. The Company’s policy is to recognize royalty payments as revenue when they are reliably measurable, which is upon receipt of reports from Takeda. The Company receives these reports in the quarter subsequent to the actual sublicensee sales. At the time the revenue was received, there were no remaining performance obligations and all other revenue recognition criteria were met. There are no active projects under the Exclusive Research, Development and License Agreement, dated August 15, 2005, by and between Lipoxen and Baxter Healthcare SA, as amended, (the “Takeda Agreement”), and the parties are discussing a potential termination of the agreement. Any such termination of the Takeda Agreement would have no impact on the Company and its non-exclusive sublicense agreement and the royalties being generated. <span id="xdx_904_eus-gaap--Revenues_pp0p0_do_c20210401__20210630__srt--CounterpartyNameAxis__custom--SerumInstituteMember__srt--ProductOrServiceAxis__custom--RoyaltyRevenueMember_zEsCCjMucnL7" title="Revenue"><span id="xdx_900_eus-gaap--Revenues_pp0p0_do_c20200401__20200630__srt--CounterpartyNameAxis__custom--SerumInstituteMember__srt--ProductOrServiceAxis__custom--RoyaltyRevenueMember_zpmeQqzbtHEc" title="Revenue"><span id="xdx_905_eus-gaap--Revenues_pp0p0_do_c20210401__20210630__srt--CounterpartyNameAxis__custom--PharmsynthezMember__srt--ProductOrServiceAxis__custom--RoyaltyRevenueMember_zlSvTlnq8sij" title="Revenue"><span id="xdx_90C_eus-gaap--Revenues_pp0p0_do_c20200401__20200630__srt--CounterpartyNameAxis__custom--PharmsynthezMember__srt--ProductOrServiceAxis__custom--RoyaltyRevenueMember_zkYMSSs1ShF6" title="Revenue">No amounts were recognized as revenue related to the Serum Institute, Pharmsynthez or SynBio agreements during the three months ended June 30, 2021 and 2020, respectively. On May 15, 2020, the Company and Scripps Research entered into a Research Funding and Option Agreement (the “Scripps Agreement”), pursuant to which the Company has agreed to provide Scripps Research an aggregate of up to $3.0 million to fund research relating to advancing the pre-clinical development of XCART. The research funding is payable by the Company to Scripps Research on a quarterly basis in accordance with a negotiated budget, which provides for an initial payment of approximately $300,000 on the date of the Scripps Agreement and subsequent quarterly payments of approximately $300,000 over a 27-month period. Under the Scripps Agreement, Scripps Research has granted the Company a license within the Field (as defined in the Scripps Agreement) to any Patent Rights or Technology (as defined in the Scripps Agreement) under the terms of that certain license agreement with Scripps Research, dated February 25, 2019, assigned to the Company on March 1, 2019. Additionally, the Company has the option to acquire a worldwide exclusive license to Scripps Research’s rights in the Technology or Patent Rights not already licensed to the Company, as well as a non-exclusive, royalty-free, non-transferrable license to make and use Scripps Research Technology (as defined in the Scripps Agreement) solely for the Company’s internal research purposes during the performance of the research program contemplated by the Scripps Agreement. The Company has paid $1.5 million to Scripps Research under this agreement through June 30, 2021. As of June 30, 2021 and December 31, 2020, approximately $<span id="xdx_90E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0n3_dm_c20210630__srt--CounterpartyNameAxis__custom--ScrippsAgreementMember_ze2VP8SzoJ4l" title="Prepaid expenses and other current asset"><span id="xdx_903_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0n3_dm_c20201231__srt--CounterpartyNameAxis__custom--ScrippsAgreementMember_zZVioIIBZmkh" title="Prepaid expenses and other current asset">0.2 million has been recognized as an advance payment under this agreement and is included in Prepaid expenses and other current assets.

300000

500000

100000

200000

1500000

200000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">5.</td> <td style="text-align: justify">Property and Equipment, net</td></tr> </table> Property and equipment, net consists of the following: <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--PropertyPlantAndEquipmentTextBlock_z86NSwvK5uN7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment, net (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Schedule of Property and Equipment, Net</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49B_20210630_z2nXVJJ0wRZc" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49A_20201231_zqCgulN7Wfbd" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Office and computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember_pp0p0" style="width: 13%; text-align: right" title="Property and equipment - at cost">42,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember_pp0p0" style="width: 13%; text-align: right" title="Property and equipment - at cost">42,289</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment - at cost">14,738</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment - at cost">14,738</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Property and equipment – at cost</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210630_pp0p0" style="text-align: right" title="Property and equipment - at cost">57,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20201231_pp0p0" style="text-align: right" title="Property and equipment - at cost">57,027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210630_zGJdtsYerPUl" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation">(57,027</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231_zC1eUqrrWco4" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation">(57,027</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment – net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_d0_c20210630_znTUb3QELrgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_d0_c20201231_zt9fLC2FxJ4e" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation expense was approximately $200 and $800 for the three and six months ended June 30, 2020. There was no depreciation expense for the three and six months ended June 30, 2021.

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--PropertyPlantAndEquipmentTextBlock_z86NSwvK5uN7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment, net (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Schedule of Property and Equipment, Net</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49B_20210630_z2nXVJJ0wRZc" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49A_20201231_zqCgulN7Wfbd" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Office and computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember_pp0p0" style="width: 13%; text-align: right" title="Property and equipment - at cost">42,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember_pp0p0" style="width: 13%; text-align: right" title="Property and equipment - at cost">42,289</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment - at cost">14,738</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment - at cost">14,738</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Property and equipment – at cost</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210630_pp0p0" style="text-align: right" title="Property and equipment - at cost">57,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20201231_pp0p0" style="text-align: right" title="Property and equipment - at cost">57,027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210630_zGJdtsYerPUl" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation">(57,027</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231_zC1eUqrrWco4" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation">(57,027</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment – net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_d0_c20210630_znTUb3QELrgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_d0_c20201231_zt9fLC2FxJ4e" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

42289

14738

57027

200

800

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">6.</td> <td style="text-align: justify">Indefinite-Lived Intangible Assets</td></tr> </table> The Company’s indefinite-lived intangible asset, OncoHist, is in-process research and development (“IPR&D”) relating to the Company’s business combination with SymbioTec in 2012. IPR&D is tested for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable, although it is to be tested at least annually until the project is completed or abandoned. The Company completed an impairment analysis of the IPR&D during 2020 and concluded that the following factors indicated that the IPR&D was impaired: a decision by management to delay indefinitely any further development of the IPR&D and to not support the underlying intellectual property; the failure to sell or license the IPR&D to a third party; and the reduction in market capitalization. The Company recorded an asset impairment charge of $9.2 million during the third quarter of 2020 representing the excess of the IPR&D asset’s carrying value over its estimated fair value. A reconciliation of the change in the carrying value of Indefinite-Lived Intangible Assets is as follows: <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_z87xvzuL47nl" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto" summary="xdx: Disclosure - Indefinite-Lived Intangible Assets (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Schedule of Indefinite-Lived Intangible Asset</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 58%">Balance as of January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Goodwill_iS_pp0p0_c20200101__20201231_zMVRu8nwSI3j" style="width: 13%; text-align: right" title="Goodwill, beginning balance">9,243,128</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_iN_pp0p0_di_c20200101__20201231_zIiNRG2Z1Nd6" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(9,243,128</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--Goodwill_iE_pp0p0_d0_c20200101__20201231_zYr1z0ENSFrh" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, ending balance">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

9200000

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_z87xvzuL47nl" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto" summary="xdx: Disclosure - Indefinite-Lived Intangible Assets (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Schedule of Indefinite-Lived Intangible Asset</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 58%">Balance as of January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Goodwill_iS_pp0p0_c20200101__20201231_zMVRu8nwSI3j" style="width: 13%; text-align: right" title="Goodwill, beginning balance">9,243,128</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_iN_pp0p0_di_c20200101__20201231_zIiNRG2Z1Nd6" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(9,243,128</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--Goodwill_iE_pp0p0_d0_c20200101__20201231_zYr1z0ENSFrh" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, ending balance">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

9243128

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">7.</td> <td style="text-align: justify">Fair Value Measurements </td></tr> </table> Accounting Standards Codification Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. The carrying amount of certain of the Company’s financial instruments approximate fair value due to their short maturities. As of June 30, 2021 and December 31, 2020, the carrying amounts of the Company’s financial instruments approximates fair value due to their short maturities. There were <span id="xdx_907_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0Nn17SxdlX8" title="Financial instruments fair value"><span id="xdx_904_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyuf0p31Mpz8" title="Financial instruments fair value">no financial instruments classified as Level 3 in the fair value hierarchy during the three and six months ended June 30, 2021 and 2020.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">8.</td> <td style="text-align: justify">Stockholders’ Equity </td></tr> </table> Warrants In connection with certain of the Company’s collaboration agreements and consulting arrangements, the Company has issued warrants to purchase shares of common stock as payment for services. As of June 30, 2021 and December 31, 2020, collaboration warrants to purchase 0 and 30,307 shares of common stock were outstanding. <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20210401__20210630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zcB3g29UH9F2" title="Warrants granted"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_z8OMMJlNxfQ8" title="Warrants granted"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_z7EHbu7W7azg" title="Warrants exercised"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_do_c20210401__20210630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zraoy27PYmy5" title="Warrants exercised"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zkStBeCUOtqk" title="Warrants exercised">No collaboration warrants were granted or exercised in connection with collaboration or consulting services during the three and six months ended June 30, 2021. Collaboration warrants to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210401__20210630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zZ2Zxg9Q3Rp3" title="Warrants expired"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210101__20210630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_pdd" title="Warrants expired">30,307 shares expired during the three and six months ended June 30, 2021. <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20200401__20200630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zqzdDoLLnOpi" title="Warrants granted"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20200101__20200630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zipT6rMs8OP6" title="Warrants granted"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_do_c20200401__20200630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zGVm79wv5Eyj" title="Warrants exercised"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_do_c20200101__20200630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zvmH6Fz8sVCi" title="Warrants exercised">No collaboration warrants were granted or exercised and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dn_c20200401__20200630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zHX4a89P52Q6" title="Warrants expired"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dn_c20200101__20200630__us-gaap--AwardTypeAxis__custom--ColllaborationWarrantsMember_zYHXHAjkkD7b" title="Warrants expired">none expired in connection with collaboration or consulting services during the three and six months ended June 30, 2020, respectively. In addition, the Company has outstanding warrants to purchase an aggregate of 347,505 and 378,453 shares of common stock in connection with debt and equity financing arrangements as of June 30, 2021 and December 31, 2020, respectively. As of June 30, 2021, these warrants have an average weighted exercise price of $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_pdd" title="Warrants weighted average exercise price"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_pdd" title="Warrants weighted average exercise price">36.74 per share and expiration dates ranging from July 2021 through September 2026. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20210401__20210630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zcRztn5su4t5" title="Warrants granted"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zRCxVvfTiz08" title="Warrants granted"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20200401__20200630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zdneDZ5Sl8Ob" title="Warrants granted"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20200101__20200630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zPfN28iBuAy" title="Warrants granted">No debt and equity financing warrants were granted during the three and six months ended June 30, 2021 and 2020. During the six months ended June 30, 2021 and 2020, debt and equity financing warrants to purchase approximately <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_c20210101__20210630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zgQzi4UjRgLi" title="Warrants exercised">1,485 and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pdn3_dm_c20200101__20200630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zdyaGvsSUYIc" title="Warrants exercised">0.2 million shares of common stock, respectively, were exercised on a cashless one-for-one basis. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_do_c20210401__20210630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zKsjg490Eol4" title="Warrants exercised"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_do_c20200401__20200630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zz2w3gMsm075" title="Warrants exercised">No debt and equity financing warrants were exercised during the three months ended June 30, 2021 and 2020, respectively. In addition, approximately <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210401__20210630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zVRRfwNx6vfc" title="Warrants expired">0 and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210101__20210630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zQpCp4aIhxA8" title="Warrants expired">29,000 debt and equity warrants expired during the three and six months ended June 30, 2021. <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_do_c20200401__20200630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zHaNYNrh3xe9" title="Warrants expired"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_do_c20200101__20200630__us-gaap--AwardTypeAxis__custom--DebtAndEquityFinancingWarrantsMember_zWUPJyFPnXBg" title="Warrants expired">No debt and equity warrants expired during the three and six months ended June 30, 2020.

30307

347505

378453

36.74 36.74 July 2021 through September 2026

1485

200000

29000

<p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z9jovuMrJPej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">9.</td> <td style="text-align: justify">Share-Based Expense </td></tr> </table> Total share-based expense related to stock options, restricted stock units (“RSUs”) and common stock awards was approximately $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1yxpeJjZgp5" title="Share-based compensation expense"><span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zANqtDNdwSd8" title="Share-based compensation expense">0.1 million during the three months ended June 30, 2021 and 2020 and approximately $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRkBhUupRNhj" title="Share-based compensation expense">0.2 million and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYm6CUmBQ9Kb" title="Share-based compensation expense">0.3 million for the six months ended June 30, 2021 and 2020, respectively. Share-based compensation expense is classified in the condensed consolidated statements of operations as follows: <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zdJAvkNIsS52" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Share based expense)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Schedule of Share-Based Compensation Expense</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z96CfFRWQsu8" style="width: 11%; text-align: right" title="Share-based compensation">19,026</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zKve5DLKBQEk" style="width: 11%; text-align: right" title="Share-based compensation">12,936</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 11%; text-align: right" title="Share-based compensation">29,736</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 11%; text-align: right" title="Share-based compensation">26,294</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp3TUv3bs4U8" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">90,896</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zw11k9bzeQye" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">98,798</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">156,470</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">251,038</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630_zHKAjpT7WMfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">109,922</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630_zLgV5cb8Y6k6" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">111,734</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">186,206</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">277,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Employee Stock Options During the six months ended June 30, 2021, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z00b2zsEWRCb" title="Options granted">200,000 stock option awards to purchase shares of common stock. The weighted average grant date fair value per option share was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted average grant date fair value">2.34. Key assumptions used in the Black-Scholes option pricing model for options granted during the six months ending June 30, 2021 were the Company’s stock price, a risk free rate of <span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zz4DZeDD8Qdf" title="Risk free rate">1.08%, an expected life of <span id="xdx_905_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5j1XacrrsH" title="Expected term">5.88 years and an expected volatility rate of <span id="xdx_90D_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6y6pFdifhIh" title="Volatility rate">134.47%. There were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQNhLdxHrmia" title="Options granted">no employee stock options or RSUs granted or exercised during the six months ended June 30, 2020. The Company recognized a total of $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEHVMZRgaD68" title="Share-based compensation expense"><span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs6ht6Jz3ifa" title="Share-based compensation expense">0.1 million of compensation expense related to employee stock options during the three months ended June 30, 2021 and 2020 and $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcLZkdcLq6Ei" title="Share-based compensation expense">0.2 million and $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhXDJfOQ4fab" title="Share-based compensation expense">0.3 million during the six months ended June 30, 2021 and 2020, respectively. Non-Employee Stock Options The Company did <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zjGva0afh0Oa" title="Options granted"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20200101__20200630__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zZbOCxz3Yly2" title="Options granted">not grant any non-employee stock options during the six months ended June 30, 2021 and 2020. The Company did <span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_do_c20210401__20210630__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zKIxbC9OkFwj" title="Share-based compensation expense"><span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z79EvuS5bxja" title="Share-based compensation expense">not recognize any expense related to non-employee stock options during the three and six months ended June 30, 2021. The Company recognized approximately $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z1FHVBHhdZw6" title="Share-based compensation expense">4,000 and $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_znBzmVQU1k7b" title="Share-based compensation expense">7,000 of expense during the three and six months ended June 30, 2020, respectively.

100000

200000

300000

<table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zdJAvkNIsS52" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Share based expense)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Schedule of Share-Based Compensation Expense</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z96CfFRWQsu8" style="width: 11%; text-align: right" title="Share-based compensation">19,026</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zKve5DLKBQEk" style="width: 11%; text-align: right" title="Share-based compensation">12,936</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 11%; text-align: right" title="Share-based compensation">29,736</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 11%; text-align: right" title="Share-based compensation">26,294</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp3TUv3bs4U8" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">90,896</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zw11k9bzeQye" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">98,798</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">156,470</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">251,038</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630_zHKAjpT7WMfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">109,922</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630_zLgV5cb8Y6k6" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">111,734</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">186,206</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">277,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

19026

12936

29736

26294

90896

98798

156470

251038

109922

111734

186206

277332

200000

2.34

0.0108

P5Y10M17D

1.3447

100000

200000

300000

4000

7000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">10.</td> <td style="text-align: justify">Income Taxes </td></tr> </table> During the three and six months ended June 30, 2021 and 2020, there was no provision for income taxes as the Company incurred losses during both periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company records a valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized. The valuation allowance against deferred tax assets was approximately $30.2 million and $29.6 million as of June 30, 2021 and December 31, 2020, respectively. As of June 30, 2021 and December 31, 2020, the Company did not record any unrecognized tax positions.

30200000

29600000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">11.</td> <td style="text-align: justify">Commitments </td></tr> </table> Supplemental cash flow information and non-cash activity related to our operating leases are as follows: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zoS0DEWttas8" style="font: 10pt Times New Roman, Times, Serif; background-color: White; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details - Cash flow Information)"> <tr style="vertical-align: bottom"> <td>Cash flow information regarding leases</td><td> </td> <td colspan="2" id="xdx_497_20210101__20210630_zS7xeK3r5IEk" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Six Months Ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Operating cash flow information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">17,160</td><td style="width: 1%; text-align: left"> </td></tr> </table> Supplemental balance sheet information related to our operating leases are as follows: <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zamHK2Mrx8R5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details - lease information)"> <tr style="vertical-align: bottom"> <td style="text-align: justify">Supplemental information related to operating leases</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20210630_z3KW6qwj7Yzk" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance Sheet Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: justify">Right-of-use assets - ST</td><td style="width: 2%"> </td> <td style="width: 40%; text-align: left">Prepaid expenses and other</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">37,408</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Right-of-use assets - LT</td><td> </td> <td style="text-align: left">Other assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,957</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Current lease liabilities</td><td> </td> <td style="text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37,408</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Non-current lease liabilities</td><td> </td> <td style="text-align: left">Other long-term liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,957</td><td style="text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zoS0DEWttas8" style="font: 10pt Times New Roman, Times, Serif; background-color: White; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details - Cash flow Information)"> <tr style="vertical-align: bottom"> <td>Cash flow information regarding leases</td><td> </td> <td colspan="2" id="xdx_497_20210101__20210630_zS7xeK3r5IEk" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Six Months Ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Operating cash flow information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">17,160</td><td style="width: 1%; text-align: left"> </td></tr> </table>

17160

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zamHK2Mrx8R5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details - lease information)"> <tr style="vertical-align: bottom"> <td style="text-align: justify">Supplemental information related to operating leases</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20210630_z3KW6qwj7Yzk" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance Sheet Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: justify">Right-of-use assets - ST</td><td style="width: 2%"> </td> <td style="width: 40%; text-align: left">Prepaid expenses and other</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">37,408</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Right-of-use assets - LT</td><td> </td> <td style="text-align: left">Other assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,957</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Current lease liabilities</td><td> </td> <td style="text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37,408</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Non-current lease liabilities</td><td> </td> <td style="text-align: left">Other long-term liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,957</td><td style="text-align: left"> </td></tr> </table>

37408

7957

37408

7957

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">12.</td> <td style="text-align: justify">Related Party Transactions</td></tr> </table> The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez (as well as SynBio), each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021. During the fourth quarter of 2019, the Company entered into a loan agreement with Pharmsynthez (the “Pharmsynthez Loan”), pursuant to which the Company advanced Pharmsynthez an aggregate principal amount of up to $<span id="xdx_903_eus-gaap--PaymentsToAcquireNotesReceivable_pp0p0_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_ztbh07HkswJh" title="Payment for note receivable">500,000 to be used for the development of a specific product under the Company’s co-development agreement with SynBio. The Pharmsynthez Loan had a term of 15-months and accrued interest at a rate of <span id="xdx_90C_ecustom--NoteReceivableInterestRate_iI_dp_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zuSiFuyx2sXe" title="Note receivable interest rate">10% per annum. The Pharmsynthez Loan is guaranteed by all of the operating subsidiaries of Pharmsynthez, including SynBio and AS Kevelt, and is secured by all of the equity interests of the Company owned by Pharmsynthez and SynBio. The Company recognized approximately $<span id="xdx_902_eus-gaap--InterestAndFeeIncomeOtherLoans_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zPoouc6o5Ilb" title="Interest income">11,000 and $<span id="xdx_909_eus-gaap--InterestAndFeeIncomeOtherLoans_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zniXX6BkIE1c" title="Interest income">23,000 of interest income related to this loan during the three and six months ended June 30, 2021, respectively. The Company recognized approximately $<span id="xdx_901_eus-gaap--InterestAndFeeIncomeOtherLoans_pp0p0_c20200401__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zHOYsJKs7kGd" title="Interest income">13,000 and $<span id="xdx_908_eus-gaap--InterestAndFeeIncomeOtherLoans_pp0p0_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zy2LFPwW4VHb" title="Interest income">25,000 of interest income related to this loan during the three and six months ended June 30, 2020, respectively. Effective January 23, 2021, the Company entered into a First Amendment to Loan Agreement and Other Loan Documents with Pharmsynthez, Kevelt and SynBio (the “Pharmsynthez Loan Extension”) to modify the repayment terms and maturity of the Pharmsynthez Loan to January 2022. The terms of the Pharmsynthez Loan Extension called for two (2) equal monthly principal payments of $25,000 in each of January 23, 2021 and February 28, 2021 and the payment of all outstanding accrued interest in six (6) equal monthly installments from January 31, 2021 through June 30, 2021. In addition, the Pharmsynthez Loan Extension requires monthly interest payments and the repayment of the remaining principal amount in six (6) equal monthly installments from August 2021 through January 2022. All other terms of the Pharmsynthez Loan remain in effect. As of June 30, 2021, approximately $<span id="xdx_90B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0n3_dm_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExpensesAndOtherMember_zjAcWMb33WFf" title="Prepaid expenses and other current asset">0.5 million was included in Prepaid expenses and other on the condensed consolidated balance sheet. As of December 31, 2020, approximately $<span id="xdx_90B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0n3_dm_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExpensesAndOtherMember_zTyBodQgtXO" title="Prepaid expenses and other current asset">0.5 million was classified within Prepaid expenses and other and approximately $<span id="xdx_90B_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0n3_dm_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember_zJZN1AFD571h" title="Prepaid expenses and other current asset">0.1 million was classified within Other assets on the consolidated balance sheet. During the third quarter of 2019, the Company entered into a Sponsored Research Agreement with Pharmsynthez (the “SRA”) related to experiments identified by the Company to support its efforts for initial tech transfer of the XCART methods to a future academic collaborator. Under the agreement, the Company made a $<span id="xdx_90D_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember_pp0p0" title="Payment for research agreement">350,000 payment to Pharmsynthez during the third quarter of 2019, which was refundable on pro rata basis if the project is terminated prematurely as a result of Pharmsynthez failing to perform the work. On June 12, 2020, the Company and Pharmsynthez entered into a Master Services Agreement (“MSA”) to advance the development of the Company’s XCART technology for B-cell malignancies. The MSA terminated and superseded the SRA. The Company expensed approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember_zjHzaCXO4Oi3" title="Research and development expense">10,000 and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0n3_dm_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember_zwlEXrZmfGlk" title="Research and development expense">0.1 million related to work performed under these agreements during the three and six months ended June 30, 2021. The Company expensed approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0n3_dm_c20200101__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember_zop7eQXcizFk" title="Research and development expense">0.1 million related to work performed under these agreements during the six months ended June 30, 2020. <span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20200401__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember_zczbtuXUjKS9" title="Research and development expense">No expense was recorded during the three months ended June 30, 2020. As of June 30, 2021, approximately $<span id="xdx_904_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember__us-gaap--BalanceSheetLocationAxis__custom--PrepaidExpensesAndOtherMember_zbNM2BNg0TR" title="Research expense accrued">40,000 was accrued and included in Accrued expenses and other current liabilities on the condensed consolidated balance sheet. As of December 31, 2020, approximately $<span id="xdx_903_ecustom--AdvancedPayment_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember_pp0p0" title="Advanced payment">25,000 was recorded as an advanced payment and included in Prepaid expenses and other on the consolidated balance sheet. Under the MSA, Pharmsynthez agreed to provide services pursuant to work orders agreed upon by the parties from time to time, which services include, but are not limited to, acting as the Company’s primary contract research organization to assist in managing collaborations with multiple academic institutions in Russia and Belarus. The Company is required to pay reasonable fees, expenses and pass-through costs incurred by Pharmsynthez in providing the services in accordance with a budget and payment terms set forth in each work order. Additionally, in the event that a work order provides for milestone payments, the Company is required to make such payments to Pharmsynthez, or third party service providers designated by Pharmsynthez, in accordance with the terms set forth in the work order, which milestone payments may be made, at the sole discretion of the Company, in cash or shares of the Company’s common stock. The Company and Pharmsynthez executed a work order on June 12, 2020 (the “Work Order”) under the MSA pursuant to which Pharmsynthez agreed to conduct a Stage 1 study of the Company’s XCART technology under the research program as set forth in the Work Order. The activities to be performed under the Work Order are expected to take approximately 20 months unless earlier terminated in accordance with the MSA. Under the terms of the Work Order, the Company paid Pharmsynthez $51,000 as an initial payment for trial startup costs, which amount was credited against the amounts paid under the SRA. The Work Order provides for additional pass-through costs to be invoiced by Pharmsynthez upon execution of contracts with third party sites, which will be further credited against the SRA. The total cost under the Work Order is currently estimated to be approximately $1.8 million. Through June 30, 2021, all costs incurred under the MSA were credited against the amounts paid under the SRA. Additionally, the Work Order provides for milestone payments of up to an aggregate of $1,050,000, or, in the Company’s sole discretion, up to an aggregate of 1,000,000 shares of the Company’s common stock, to be paid or issued, as applicable, by the Company upon achievement of milestones associated with completion of early stages of the research program as set forth in the Work Order. As of June 30, 2021, approximately $0.1 million of milestone payments has been paid.

500000

0.10

11000

23000

13000

25000

500000

100000

350000

10000

100000

40000

25000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">13.</td> <td style="text-align: justify">Subsequent Events </td></tr> </table> The Company performed a review of events subsequent to the balance sheet date through the date the financial statements were issued and determined that there were no such events requiring recognition or disclosure in the financial statements except as described below. Financing On July 26, 2021, the Company entered into a securities purchase agreement in connection with a private placement (the “Purchase Agreement”) with the purchaser named on the signature page thereto (“Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser, in a private placement priced at-the-market under Nasdaq rules, (i) 950,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), (ii) warrants to purchase an aggregate of 4,629,630 shares of the Company’s common stock, with an exercise price of $3.30 per share (the “Series A Warrants”) which expire three and one half years from the earlier of (a) the six month anniversary of the initial exercise date and (b) the date that the registration statement registering all of the warrant shares underlying the Series A Warrants is declared effective, and (iii) pre-funded warrants to purchase up to 3,679,630 shares of the Company’s common stock, with an exercise price of $0.001 per share (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) with no expiration (the “Private Placement”), at a purchase price of $2.70 per one Share and one Series A Warrant and $2.699 per one Series B Warrant and one Series A Warrant. The Company received aggregate gross proceeds from the Private Placement of approximately $12.5 million, before deducting placement agent fees and offering expenses, and excluding the exercise of any Warrants.

XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2021	Aug. 06, 2021
Affiliate, Collateralized Security [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-37937
Entity Registrant Name	XENETIC BIOSCIENCES, INC.
Entity Central Index Key	0001534525
Entity Tax Identification Number	45-2952962
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	40 Speen Street
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01701
City Area Code	781
Local Phone Number	778-7720
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,703,845
Common Stock, $0.001 par value per share
Affiliate, Collateralized Security [Line Items]
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	XBIO
Security Exchange Name	NASDAQ
Purchase Warrants [Member]
Affiliate, Collateralized Security [Line Items]
Title of 12(b) Security	Purchase Warrants
Trading Symbol	XBIOW
Security Exchange Name	NASDAQ

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 9,281,554	$ 11,527,552
Prepaid expenses and other	917,826	841,958
Total current assets	10,199,380	12,369,510
Other assets	715,898	809,985
Total assets	10,915,278	13,179,495
Current liabilities:
Accounts payable	305,088	327,396
Accrued expenses and other current liabilities	653,126	609,532
Total current liabilities	958,214	936,928
Other long-term liabilities	7,957	27,043
Total liabilities	966,171	963,971
Stockholders' equity:
Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 8,773,683 and 8,772,198 shares issued as of June 30, 2021 and December 31, 2020, respectively; 8,746,692 and 8,745,207 shares outstanding as of June 30, 2021 and December 31, 2020, respectively	8,772	8,771
Additional paid in capital	194,319,716	194,133,511
Accumulated deficit	(179,354,709)	(176,902,086)
Accumulated other comprehensive income	253,734	253,734
Treasury stock	(5,281,180)	(5,281,180)
Total stockholders' equity	9,949,107	12,215,524
Total liabilities and stockholders' equity	10,915,278	13,179,495
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value, Issued	1,804	1,804
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value, Issued	$ 970	$ 970

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	8,773,683	8,772,198
Common stock, shares outstanding	8,746,692	8,745,207
Preferred Class B [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock shares issued	1,804,394	1,804,394
Preferred stock, shares outstanding	1,804,394	1,804,394
Preferred Class A [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock shares issued	970,000	970,000
Preferred stock, shares outstanding	970,000	970,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Total revenue	$ 287,603	$ 112,927	$ 478,819	$ 169,676
Operating costs and expenses:
Research and development	(524,550)	(307,900)	(1,154,279)	(667,551)
General and administrative	(890,704)	(787,486)	(1,821,282)	(1,715,366)
Total operating costs and expenses	(1,415,254)	(1,095,386)	(2,975,561)	(2,382,917)
Loss from operations	(1,127,651)	(982,459)	(2,496,742)	(2,213,241)
Other income:
Other income	238	192	1,122	58
Interest income, net	20,735	28,625	42,997	80,112
Total other income	20,973	28,817	44,119	80,170
Net loss	$ (1,106,678)	$ (953,642)	$ (2,452,623)	$ (2,133,071)
Basic and diluted net loss per share	$ (0.13)	$ (0.15)	$ (0.28)	$ (0.34)
Weighted-average shares of common stock outstanding, basic and diluted	8,746,692	6,288,351	8,746,479	6,260,841
Royalty [Member]
Revenue:
Total revenue	$ 287,603	$ 112,927	$ 478,819	$ 169,676

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 2,774	$ 6,092	$ 188,240,451	$ (166,008,620)	$ 253,734	$ (5,281,180)	$ 17,213,251
Beginning balance, shares at Dec. 31, 2019	2,774,394	6,092,432
Issuance of common stock to vendor		$ 1	(1)
Issuance of common stock to vendor, shares		1,188
Share-based expense			277,332				277,332
Exercise of purchase warrants, shares		229,598
Exercise of purchase warrants		$ 229	(229)
Net loss				(2,133,071)			(2,133,071)
Ending balance, value at Jun. 30, 2020	$ 2,774	$ 6,322	188,517,553	(168,141,691)	253,734	(5,281,180)	15,357,512
Ending balance, shares at Jun. 30, 2020	2,774,394	6,323,218
Beginning balance, value at Mar. 31, 2020	$ 2,774	$ 6,311	188,405,830	(167,188,049)	253,734	(5,281,180)	16,199,420
Beginning balance, shares at Mar. 31, 2020	2,774,394	6,311,906
Issuance of common stock to vendor		$ 1	(1)
Issuance of common stock to vendor, shares		1,188
Share-based expense			111,734				111,734
Exercise of purchase warrants, shares		10,124
Exercise of purchase warrants		$ 10	(10)
Net loss				(953,642)			(953,642)
Ending balance, value at Jun. 30, 2020	$ 2,774	$ 6,322	188,517,553	(168,141,691)	253,734	(5,281,180)	15,357,512
Ending balance, shares at Jun. 30, 2020	2,774,394	6,323,218
Beginning balance, value at Dec. 31, 2020	$ 2,774	$ 8,771	194,133,511	(176,902,086)	253,734	(5,281,180)	12,215,524
Beginning balance, shares at Dec. 31, 2020	2,774,394	8,772,198
Share-based expense			186,206				186,206
Exercise of purchase warrants, shares		1,485
Exercise of purchase warrants		$ 1	(1)
Net loss				(2,452,623)			(2,452,623)
Ending balance, value at Jun. 30, 2021	$ 2,774	$ 8,772	194,319,716	(179,354,709)	253,734	(5,281,180)	9,949,107
Ending balance, shares at Jun. 30, 2021	2,774,394	8,773,683
Beginning balance, value at Mar. 31, 2021	$ 2,774	$ 8,772	194,209,794	(178,248,031)	253,734	(5,281,180)	10,945,863
Beginning balance, shares at Mar. 31, 2021	2,774,394	8,773,683
Share-based expense			109,922				109,922
Net loss				(1,106,678)			(1,106,678)
Ending balance, value at Jun. 30, 2021	$ 2,774	$ 8,772	$ 194,319,716	$ (179,354,709)	$ 253,734	$ (5,281,180)	$ 9,949,107
Ending balance, shares at Jun. 30, 2021	2,774,394	8,773,683

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,452,623)	$ (2,133,071)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	0	757
Amortization of right of use asset	17,160	13,765
Gain on settlement with vendor		(143,639)
Share-based expense	186,206	277,332
Changes in operating assets and liabilities:
Prepaid expenses and other assets	1,059	167,586
Accounts payable, accrued expenses and other liabilities	2,200	(484,190)
Net cash used in operating activities	(2,245,998)	(2,301,460)
Net change in cash	(2,245,998)	(2,301,460)
Cash at beginning of period	11,527,552	10,367,920
Cash at end of period	9,281,554	8,066,460
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	0	0
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock from cashless exercise of purchase warrants	$ 1	$ 229

XML 17 R7.htm IDEA: XBRL DOCUMENT

The Company

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

The Company

1.	The Company

Background

Going Concern and Management’s Plan

XML 18 R8.htm IDEA: XBRL DOCUMENT

Impact of COVID-19

6 Months Ended

Jun. 30, 2021

Impact Of Covid-19

Impact of COVID-19

2.	Impact of COVID-19

XML 19 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

3.	Summary of Significant Accounting Policies

Preparation of Interim Financial Statements

Principles of Consolidation

Basic and Diluted Net Loss per Share

Recent Accounting Standards

XML 20 R10.htm IDEA: XBRL DOCUMENT

Significant Strategic Collaborations

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Significant Strategic Collaborations

4.	Significant Strategic Collaborations

XML 21 R11.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

6 Months Ended

Jun. 30, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment, net

5.	Property and Equipment, net

Property and equipment, net consists of the following:

Schedule of Property and Equipment, Net
	June 30, 2021			December 31, 2020
Office and computer equipment	$	42,289		$	42,289
Furniture and fixtures		14,738			14,738
Property and equipment – at cost		57,027			57,027
Less accumulated depreciation		(57,027	)		(57,027	)
Property and equipment – net	$	–		$	–

Depreciation expense was approximately $200 and $800 for the three and six months ended June 30, 2020. There was no depreciation expense for the three and six months ended June 30, 2021.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Indefinite-Lived Intangible Assets

6 Months Ended

Jun. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Indefinite-Lived Intangible Assets

6.	Indefinite-Lived Intangible Assets


Balance as of January 1, 2020	$	9,243,128
Impairment		(9,243,128	)
Balance as of December 31, 2020	$	–

XML 23 R13.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

7.	Fair Value Measurements

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Stockholders’ Equity

8.	Stockholders’ Equity

Warrants

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Share-Based Expense

6 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Expense

9.	Share-Based Expense

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Research and development expenses	$	19,026	$	12,936	$	29,736	$	26,294
General and administrative expenses		90,896		98,798		156,470		251,038
	$	109,922	$	111,734	$	186,206	$	277,332

Employee Stock Options

Non-Employee Stock Options

XML 26 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

10.

Income Taxes

As of June 30, 2021 and December 31, 2020, the Company did not record any unrecognized tax positions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments

6 Months Ended

Jun. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments

11.

Commitments

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

Cash flow information regarding leases
	Six Months Ended June 30,
	2021
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$	17,160

Supplemental balance sheet information related to our operating leases are as follows:


	Balance Sheet Classification	June 30, 2021
Right-of-use assets - ST	Prepaid expenses and other	$	37,408
Right-of-use assets - LT	Other assets	$	7,957
Current lease liabilities	Accrued expenses and other current liabilities	$	37,408
Non-current lease liabilities	Other long-term liabilities	$	7,957

XML 28 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2021

Related Party Transactions

12.

Related Party Transactions

XML 29 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

13.

Subsequent Events

Financing

XML 30 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2021
Accounting Policies [Abstract]
Preparation of Interim Financial Statements	*Preparation of Interim Financial Statements* The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 and amended on April 28, 2021.
Principles of Consolidation	*Principles of Consolidation* The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.
Basic and Diluted Net Loss per Share	*Basic and Diluted Net Loss per Share* The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. For the three and six months ended June 30, 2021 and 2020, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.
Recent Accounting Standards	*Recent Accounting Standards* In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. ASU 2016-13 is effective for smaller reporting public entities for fiscal years beginning after December 15, 2022 but early adoption is permitted. The Company is currently evaluating the impact of adoption, but it does not anticipate that it will have a material effect on the Company’s consolidated financial statements.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

6 Months Ended

Jun. 30, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

Schedule of Property and Equipment, Net
	June 30, 2021			December 31, 2020
Office and computer equipment	$	42,289		$	42,289
Furniture and fixtures		14,738			14,738
Property and equipment – at cost		57,027			57,027
Less accumulated depreciation		(57,027	)		(57,027	)
Property and equipment – net	$	–		$	–

XML 32 R22.htm IDEA: XBRL DOCUMENT

Indefinite-Lived Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Indefinite-Lived Intangible Asset


Balance as of January 1, 2020	$	9,243,128
Impairment		(9,243,128	)
Balance as of December 31, 2020	$	–

XML 33 R23.htm IDEA: XBRL DOCUMENT

Share-Based Expense (Tables)

6 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Share-Based Compensation Expense


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Research and development expenses	$	19,026	$	12,936	$	29,736	$	26,294
General and administrative expenses		90,896		98,798		156,470		251,038
	$	109,922	$	111,734	$	186,206	$	277,332

XML 34 R24.htm IDEA: XBRL DOCUMENT

Commitments (Tables)

6 Months Ended

Jun. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Cash flow information regarding leases

Cash flow information regarding leases
	Six Months Ended June 30,
	2021
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$	17,160

Supplemental information related to operating leases


	Balance Sheet Classification	June 30, 2021
Right-of-use assets - ST	Prepaid expenses and other	$	37,408
Right-of-use assets - LT	Other assets	$	7,957
Current lease liabilities	Accrued expenses and other current liabilities	$	37,408
Non-current lease liabilities	Other long-term liabilities	$	7,957

XML 35 R25.htm IDEA: XBRL DOCUMENT

The Company (Details Narrative) - USD ($)	6 Months Ended	11 Months Ended
The Company (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 04, 2020
Direct Offering [Member]
Offsetting Liabilities [Line Items]
Proceeds from stock offering		$ 5,400,000
Private Placement [Member]
Offsetting Liabilities [Line Items]
Proceed from private placement	$ 11,400,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Significant Strategic Collaborations (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 287,603	$ 112,927	$ 478,819	$ 169,676
Research and development expenses	524,550	307,900	1,154,279	667,551
Prepaid expenses and other current asset	917,826		917,826		$ 841,958
Takeda [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	300,000	100,000	500,000	$ 200,000
Serum Institute [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	0
Syn Bio [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	0
Pharmsynthez [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	$ 0
Scripps Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses			1,500,000
Prepaid expenses and other current asset	$ 200,000		$ 200,000		$ 200,000

XML 37 R27.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment - at cost	$ 57,027	$ 57,027
Less accumulated depreciation	(57,027)	(57,027)
Property and equipment, net	0	0
Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment - at cost	42,289	42,289
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment - at cost	$ 14,738	$ 14,738

XML 38 R28.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0	$ 200	$ 0	$ 800

XML 39 R29.htm IDEA: XBRL DOCUMENT

Indefinite-Lived Intangible Assets (Details)	12 Months Ended
Indefinite-Lived Intangible Assets (Details)	Dec. 31, 2020 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, beginning balance	$ 9,243,128
Goodwill impairment	(9,243,128)
Goodwill, ending balance	$ 0

XML 40 R30.htm IDEA: XBRL DOCUMENT

Indefinite-Lived Intangible Assets (Details Narrative) $ in Millions	3 Months Ended
	Sep. 30, 2020 USD ($)
OncoHist [Member]
Indefinite-lived Intangible Assets [Line Items]
Impairment charge	$ 9.2

XML 41 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instruments fair value	$ 0	$ 0

XML 42 R32.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Details Narrative) - $ / shares	3 Months Ended		6 Months Ended
Stockholders’ Equity (Details Narrative) - $ / shares	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Colllaboration Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding	0		0		30,307
Warrants granted	0	0	0	0
Warrants exercised	0	0	0	0
Warrants expired	30,307	0	30,307	0
Debt And Equity Financing Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding	347,505		347,505		378,453
Warrants granted	0	0	0	0
Warrants exercised	0	0	1,485	200,000
Warrants expired	0	0	29,000	0
Warrants weighted average exercise price	$ 36.74		$ 36.74		$ 36.74
Warrant expiration dates			July 2021 through September 2026

XML 43 R33.htm IDEA: XBRL DOCUMENT

Share-Based Expense (Details - Share based expense) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 109,922	$ 111,734	$ 186,206	$ 277,332
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	19,026	12,936	29,736	26,294
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 90,896	$ 98,798	$ 156,470	$ 251,038

XML 44 R34.htm IDEA: XBRL DOCUMENT

Share-Based Expense (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Share-Based Expense (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 109,922	$ 111,734	$ 186,206	$ 277,332
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	100,000	100,000	200,000	300,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	100,000	100,000	$ 200,000	$ 300,000
Options granted			200,000	0
Weighted average grant date fair value			$ 2.34
Risk free rate			1.08%
Expected term			5 years 10 months 17 days
Volatility rate			134.47%
Non Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 0	$ 4,000	$ 0	$ 7,000
Options granted			0	0
Options exercised			0

XML 45 R35.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Income Taxes (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0	$ 0	$ 0
Deferred tax valuation allowance	30,200,000		30,200,000		$ 29,600,000
Unrecognized tax positions	$ 0		$ 0		$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 46 R36.htm IDEA: XBRL DOCUMENT

Commitments (Details - Cash flow Information)	6 Months Ended
Commitments (Details - Cash flow Information)	Jun. 30, 2021 USD ($)
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$ 17,160

XML 47 R37.htm IDEA: XBRL DOCUMENT

Commitments (Details - lease information)	Jun. 30, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Right-of-use assets - ST	$ 37,408
Right-of-use assets - LT	7,957
Current lease liabilities	37,408
Non-current lease liabilities	$ 7,957

XML 48 R38.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2020
Related Party Transaction [Line Items]
Prepaid expenses and other current asset	$ 917,826		$ 917,826			$ 841,958
Research and development expense	524,550	$ 307,900	1,154,279	$ 667,551
Research expense accrued	$ 653,126		$ 653,126			609,532
Pharmsynthez [Member] \| Co Development Agreement [Member]
Related Party Transaction [Line Items]
Payment for note receivable					$ 500,000
Note receivable interest rate	10.00%		10.00%
Interest income	$ 11,000	13,000	$ 23,000	25,000
Pharmsynthez [Member] \| Sponsored Research Agreement [Member]
Related Party Transaction [Line Items]
Prepaid expenses and other current asset						100,000
Payment for research agreement					$ 350,000
Research and development expense	10,000	$ 0	100,000	$ 100,000
Advanced payment						25,000
Pharmsynthez [Member] \| Sponsored Research Agreement [Member] \| Prepaid Expenses And Other [Member]
Related Party Transaction [Line Items]
Prepaid expenses and other current asset	500,000		500,000			$ 500,000
Research expense accrued	$ 40,000		$ 40,000

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 154 210 1 false 36 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://xeneticbio.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - The Company Sheet http://xeneticbio.com/role/Company The Company Notes 7 false false R8.htm 00000008 - Disclosure - Impact of COVID-19 Sheet http://xeneticbio.com/role/ImpactOfCovid-19 Impact of COVID-19 Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Significant Strategic Collaborations Sheet http://xeneticbio.com/role/SignificantStrategicCollaborations Significant Strategic Collaborations Notes 10 false false R11.htm 00000011 - Disclosure - Property and Equipment, net Sheet http://xeneticbio.com/role/PropertyAndEquipmentNet Property and Equipment, net Notes 11 false false R12.htm 00000012 - Disclosure - Indefinite-Lived Intangible Assets Sheet http://xeneticbio.com/role/Indefinite-livedIntangibleAssets Indefinite-Lived Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - Fair Value Measurements Sheet http://xeneticbio.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders??? Equity Sheet http://xeneticbio.com/role/StockholdersEquity Stockholders??? Equity Notes 14 false false R15.htm 00000015 - Disclosure - Share-Based Expense Sheet http://xeneticbio.com/role/Share-basedExpense Share-Based Expense Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://xeneticbio.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Commitments Sheet http://xeneticbio.com/role/Commitments Commitments Notes 17 false false R18.htm 00000018 - Disclosure - Related Party Transactions Sheet http://xeneticbio.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 00000019 - Disclosure - Subsequent Events Sheet http://xeneticbio.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Property and Equipment, net (Tables) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://xeneticbio.com/role/PropertyAndEquipmentNet 21 false false R22.htm 00000022 - Disclosure - Indefinite-Lived Intangible Assets (Tables) Sheet http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsTables Indefinite-Lived Intangible Assets (Tables) Tables http://xeneticbio.com/role/Indefinite-livedIntangibleAssets 22 false false R23.htm 00000023 - Disclosure - Share-Based Expense (Tables) Sheet http://xeneticbio.com/role/Share-basedExpenseTables Share-Based Expense (Tables) Tables http://xeneticbio.com/role/Share-basedExpense 23 false false R24.htm 00000024 - Disclosure - Commitments (Tables) Sheet http://xeneticbio.com/role/CommitmentsTables Commitments (Tables) Tables http://xeneticbio.com/role/Commitments 24 false false R25.htm 00000025 - Disclosure - The Company (Details Narrative) Sheet http://xeneticbio.com/role/CompanyDetailsNarrative The Company (Details Narrative) Details http://xeneticbio.com/role/Company 25 false false R26.htm 00000026 - Disclosure - Significant Strategic Collaborations (Details Narrative) Sheet http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative Significant Strategic Collaborations (Details Narrative) Details http://xeneticbio.com/role/SignificantStrategicCollaborations 26 false false R27.htm 00000027 - Disclosure - Property and Equipment, net (Details) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://xeneticbio.com/role/PropertyAndEquipmentNetTables 27 false false R28.htm 00000028 - Disclosure - Property and Equipment, net (Details Narrative) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetDetailsNarrative Property and Equipment, net (Details Narrative) Details http://xeneticbio.com/role/PropertyAndEquipmentNetTables 28 false false R29.htm 00000029 - Disclosure - Indefinite-Lived Intangible Assets (Details) Sheet http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetails Indefinite-Lived Intangible Assets (Details) Details http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsTables 29 false false R30.htm 00000030 - Disclosure - Indefinite-Lived Intangible Assets (Details Narrative) Sheet http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative Indefinite-Lived Intangible Assets (Details Narrative) Details http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsTables 30 false false R31.htm 00000031 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://xeneticbio.com/role/FairValueMeasurements 31 false false R32.htm 00000032 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://xeneticbio.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://xeneticbio.com/role/StockholdersEquity 32 false false R33.htm 00000033 - Disclosure - Share-Based Expense (Details - Share based expense) Sheet http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense Share-Based Expense (Details - Share based expense) Details http://xeneticbio.com/role/Share-basedExpenseTables 33 false false R34.htm 00000034 - Disclosure - Share-Based Expense (Details Narrative) Sheet http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative Share-Based Expense (Details Narrative) Details http://xeneticbio.com/role/Share-basedExpenseTables 34 false false R35.htm 00000035 - Disclosure - Income Taxes (Details Narrative) Sheet http://xeneticbio.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://xeneticbio.com/role/IncomeTaxes 35 false false R36.htm 00000036 - Disclosure - Commitments (Details - Cash flow Information) Sheet http://xeneticbio.com/role/CommitmentsDetails-CashFlowInformation Commitments (Details - Cash flow Information) Details http://xeneticbio.com/role/CommitmentsTables 36 false false R37.htm 00000037 - Disclosure - Commitments (Details - lease information) Sheet http://xeneticbio.com/role/CommitmentsDetails-LeaseInformation Commitments (Details - lease information) Details http://xeneticbio.com/role/CommitmentsTables 37 false false R38.htm 00000038 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://xeneticbio.com/role/RelatedPartyTransactions 38 false false All Reports Book All Reports xenetic_i10q-063021.htm xbio-20210630.xsd xbio-20210630_cal.xml xbio-20210630_def.xml xbio-20210630_lab.xml xbio-20210630_pre.xml xenetic_ex3101.htm xenetic_ex3102.htm xenetic_ex3201.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "xenetic_i10q-063021.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 154, "dts": { "calculationLink": { "local": [ "xbio-20210630_cal.xml" ] }, "definitionLink": { "local": [ "xbio-20210630_def.xml" ] }, "inline": { "local": [ "xenetic_i10q-063021.htm" ] }, "labelLink": { "local": [ "xbio-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "xbio-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "xbio-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 281, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 50, "http://xbrl.sec.gov/dei/2021": 5, "http://xeneticbio.com/20210630": 16, "total": 71 }, "keyCustom": 9, "keyStandard": 201, "memberCustom": 17, "memberStandard": 18, "nsprefix": "XBIO", "nsuri": "http://xeneticbio.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://xeneticbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Significant Strategic Collaborations", "role": "http://xeneticbio.com/role/SignificantStrategicCollaborations", "shortName": "Significant Strategic Collaborations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Property and Equipment, net", "role": "http://xeneticbio.com/role/PropertyAndEquipmentNet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Indefinite-Lived Intangible Assets", "role": "http://xeneticbio.com/role/Indefinite-livedIntangibleAssets", "shortName": "Indefinite-Lived Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Fair Value Measurements", "role": "http://xeneticbio.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Stockholders\u2019 Equity", "role": "http://xeneticbio.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Share-Based Expense", "role": "http://xeneticbio.com/role/Share-basedExpense", "shortName": "Share-Based Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Income Taxes", "role": "http://xeneticbio.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Commitments", "role": "http://xeneticbio.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Related Party Transactions", "role": "http://xeneticbio.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Subsequent Events", "role": "http://xeneticbio.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Property and Equipment, net (Tables)", "role": "http://xeneticbio.com/role/PropertyAndEquipmentNetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Indefinite-Lived Intangible Assets (Tables)", "role": "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsTables", "shortName": "Indefinite-Lived Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Share-Based Expense (Tables)", "role": "http://xeneticbio.com/role/Share-basedExpenseTables", "shortName": "Share-Based Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowOperatingCapitalTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Commitments (Tables)", "role": "http://xeneticbio.com/role/CommitmentsTables", "shortName": "Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowOperatingCapitalTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2020-01-012020-12-04_custom_DirectOfferingMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - The Company (Details Narrative)", "role": "http://xeneticbio.com/role/CompanyDetailsNarrative", "shortName": "The Company (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2020-01-012020-12-04_custom_DirectOfferingMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Significant Strategic Collaborations (Details Narrative)", "role": "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative", "shortName": "Significant Strategic Collaborations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30_custom_TakedaMember_custom_RoyaltyRevenueMember", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Property and Equipment, net (Details)", "role": "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Property and Equipment, net (Details Narrative)", "role": "http://xeneticbio.com/role/PropertyAndEquipmentNetDetailsNarrative", "shortName": "Property and Equipment, net (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2019-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Indefinite-Lived Intangible Assets (Details)", "role": "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetails", "shortName": "Indefinite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2019-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2020-07-012020-09-30_custom_OncoHistMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Indefinite-Lived Intangible Assets (Details Narrative)", "role": "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative", "shortName": "Indefinite-Lived Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2020-07-012020-09-30_custom_OncoHistMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinancialInstrumentsOwnedAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Fair Value Measurements (Details Narrative)", "role": "http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative", "shortName": "Fair Value Measurements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinancialInstrumentsOwnedAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30_custom_ColllaborationWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2020-12-31_custom_ColllaborationWarrantsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Share-Based Expense (Details - Share based expense)", "role": "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense", "shortName": "Share-Based Expense (Details - Share based expense)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Share-Based Expense (Details Narrative)", "role": "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative", "shortName": "Share-Based Expense (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Income Taxes (Details Narrative)", "role": "http://xeneticbio.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:CashFlowOperatingCapitalTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Commitments (Details - Cash flow Information)", "role": "http://xeneticbio.com/role/CommitmentsDetails-CashFlowInformation", "shortName": "Commitments (Details - Cash flow Information)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:CashFlowOperatingCapitalTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Commitments (Details - lease information)", "role": "http://xeneticbio.com/role/CommitmentsDetails-LeaseInformation", "shortName": "Commitments (Details - lease information)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2019-01-012019-12-31_custom_PharmsynthezMember_custom_CoDevelopmentAgreementMember", "decimals": "0", "lang": null, "name": "us-gaap:PaymentsToAcquireNotesReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2019-12-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "role": "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "AsOf2019-12-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - The Company", "role": "http://xeneticbio.com/role/Company", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "XBIO:ImpactOfCovid19DisclosuerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Impact of COVID-19", "role": "http://xeneticbio.com/role/ImpactOfCovid-19", "shortName": "Impact of COVID-19", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "XBIO:ImpactOfCovid19DisclosuerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "xenetic_i10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 36, "tag": { "XBIO_AdvancedPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Advanced payment" } } }, "localname": "AdvancedPayment", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "XBIO_CoDevelopmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Co Development Agreement [Member]" } } }, "localname": "CoDevelopmentAgreementMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_ColllaborationWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Colllaboration Warrants [Member]" } } }, "localname": "ColllaborationWarrantsMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_CommonStock0.001ParValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, $0.001 par value per share" } } }, "localname": "CommonStock0.001ParValuePerShareMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "domainItemType" }, "XBIO_DebtAndEquityFinancingWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt And Equity Financing Warrants [Member]" } } }, "localname": "DebtAndEquityFinancingWarrantsMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_DirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Direct Offering [Member]" } } }, "localname": "DirectOfferingMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/CompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_DisclosureImpactOfCovid19Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impact Of Covid-19" } } }, "localname": "DisclosureImpactOfCovid19Abstract", "nsuri": "http://xeneticbio.com/20210630", "xbrltype": "stringItemType" }, "XBIO_ExerciseOfPurchaseWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise of purchase warrants, shares" } } }, "localname": "ExerciseOfPurchaseWarrantsShares", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "XBIO_ExerciseOfPurchaseWarrantsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercise of purchase warrants, value", "label": "Exercise of purchase warrants" } } }, "localname": "ExerciseOfPurchaseWarrantsValue", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "XBIO_GainOnSettlementWithVendor": { "auth_ref": [], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on settlement with vendor" } } }, "localname": "GainOnSettlementWithVendor", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "XBIO_ImpactOfCovid19DisclosuerTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impact of COVID-19" } } }, "localname": "ImpactOfCovid19DisclosuerTextBlock", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/ImpactOfCovid-19" ], "xbrltype": "textBlockItemType" }, "XBIO_IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock from cashless exercise of purchase warrants" } } }, "localname": "IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "XBIO_NonEmployeeStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Employee Stock Options [Member]", "label": "Non Employee Stock Options [Member]" } } }, "localname": "NonEmployeeStockOptionsMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_NoteReceivableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note receivable interest rate", "label": "Note receivable interest rate" } } }, "localname": "NoteReceivableInterestRate", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "XBIO_OfficeAndComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and Computer Equipment [Member]", "label": "Office and Computer Equipment [Member]" } } }, "localname": "OfficeAndComputerEquipmentMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "XBIO_OncoHistMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OncoHist [Member]", "label": "OncoHist [Member]" } } }, "localname": "OncoHistMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_PharmsynthezMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pharmsynthez [Member]" } } }, "localname": "PharmsynthezMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_PrepaidExpensesAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Other [Member]" } } }, "localname": "PrepaidExpensesAndOtherMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_PurchaseWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Warrants [Member]" } } }, "localname": "PurchaseWarrantsMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "domainItemType" }, "XBIO_RoyaltyRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty Revenue [Member]" } } }, "localname": "RoyaltyRevenueMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_ScrippsAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scripps Agreement [Member]" } } }, "localname": "ScrippsAgreementMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_SerumInstituteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Serum Institute [Member]" } } }, "localname": "SerumInstituteMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants weighted average exercise price", "label": "Warrants weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "XBIO_SponsoredResearchAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sponsored Research Agreement [Member]" } } }, "localname": "SponsoredResearchAgreementMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_SynBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Syn Bio [Member]" } } }, "localname": "SynBioMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_TakedaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Takeda [Member]" } } }, "localname": "TakedaMember", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XBIO_WarrantExpirationDates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant expiration dates", "label": "Warrant expiration dates" } } }, "localname": "WarrantExpirationDates", "nsuri": "http://xeneticbio.com/20210630", "presentation": [ "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r338", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_AffiliateCollateralizedSecurityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Affiliate, Collateralized Security [Line Items]" } } }, "localname": "AffiliateCollateralizedSecurityLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r34", "r36", "r73", "r74", "r153", "r159" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r116", "r176", "r177", "r283", "r315", "r316" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r116", "r176", "r177", "r283", "r315", "r316" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r35", "r36", "r73", "r74", "r153", "r159" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24", "r276" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities", "verboseLabel": "Research expense accrued" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r22", "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r14", "r38", "r39", "r40", "r307", "r321", "r322" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r37", "r40", "r43", "r44", "r45", "r76", "r77", "r78", "r239", "r317", "r318", "r349" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r12", "r207", "r276" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r76", "r77", "r78", "r204", "r205", "r206", "r246" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r187", "r189", "r209", "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share-based expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r189", "r202", "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based compensation", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense", "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r61", "r132" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Impairment charge" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r70", "r105", "r108", "r114", "r120", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r234", "r240", "r253", "r274", "r276", "r298", "r306" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r31", "r70", "r120", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r234", "r240", "r253", "r274", "r276" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r190", "r203" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Preparation of Interim Financial Statements" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r75", "r101" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "The Company" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Company" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r20", "r276", "r323", "r324" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r57", "r63", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r57", "r254" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowOperatingCapitalTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the net increase (decrease) in operating capital in the operating section of the statement of cash flows, represents the entire footnote disclosure that provides details regarding the net change during the reporting period of all assets and liabilities used in operating activities.", "label": "Cash flow information regarding leases" } } }, "localname": "CashFlowOperatingCapitalTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r68", "r70", "r88", "r89", "r90", "r92", "r94", "r98", "r99", "r100", "r120", "r142", "r146", "r147", "r148", "r151", "r152", "r157", "r158", "r161", "r165", "r253", "r344" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://xeneticbio.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r229", "r230", "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Significant Strategic Collaborations" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborations" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r28", "r141", "r300", "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r76", "r77", "r246" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r171" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r11", "r276" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 8,773,683 and 8,772,198 shares issued as of June 30, 2021 and December 31, 2020, respectively; 8,746,692 and 8,745,207 shares outstanding as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r67", "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred tax valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r61", "r133" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r61", "r133" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Expense" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and Diluted Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r43", "r44", "r45", "r76", "r77", "r78", "r80", "r85", "r87", "r97", "r121", "r171", "r172", "r204", "r205", "r206", "r220", "r221", "r246", "r255", "r256", "r257", "r258", "r259", "r260", "r317", "r318", "r319", "r349" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r248", "r249", "r250", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r154", "r155", "r156", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r186", "r249", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r154", "r155", "r156", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r186", "r249", "r281" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r154", "r155", "r156", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r186", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Right-of-use assets - LT" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CommitmentsDetails-LeaseInformation" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentsOwnedAtFairValue": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.", "label": "Financial instruments fair value" } } }, "localname": "FinancialInstrumentsOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r123", "r125", "r276", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r61", "r124", "r126", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r137", "r139" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r71", "r215", "r217", "r219", "r222", "r224", "r226", "r227", "r228" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r72", "r86", "r87", "r104", "r214", "r223", "r225", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r60" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r60" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Indefinite-Lived Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestAndFeeIncomeOtherLoans": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest and fee income from loans classified as other.", "label": "Interest income" } } }, "localname": "InterestAndFeeIncomeOtherLoans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r303" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r55", "r58", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Supplemental information related to operating leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r70", "r109", "r120", "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r235", "r240", "r241", "r253", "r274", "r275" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r17", "r70", "r120", "r253", "r276", "r299", "r309" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27", "r70", "r120", "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r235", "r240", "r241", "r253", "r274", "r275", "r276" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "auth_ref": [], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.", "label": "Other long-term liabilities" } } }, "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r57", "r59", "r62" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r41", "r42", "r45", "r47", "r62", "r70", "r79", "r81", "r82", "r83", "r84", "r86", "r87", "r91", "r105", "r107", "r110", "r113", "r115", "r120", "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r247", "r253", "r301", "r312" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Liabilities [Line Items]" } } }, "localname": "OffsettingLiabilitiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "negatedTotalLabel": "Total operating costs and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r105", "r107", "r110", "r113", "r115" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CommitmentsDetails-LeaseInformation" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Non-current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CommitmentsDetails-LeaseInformation" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r263", "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CommitmentsDetails-CashFlowInformation" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use assets - ST" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CommitmentsDetails-LeaseInformation" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r49", "r61", "r133" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Amortization of right of use asset" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r314" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5", "r122" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current asset" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payment for research agreement" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payment for note receivable" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class B [Member]" } } }, "localname": "PreferredClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r10", "r157" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r10", "r157" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r10", "r276" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r18", "r19" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other", "verboseLabel": "Prepaid expenses and other current asset" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from stock offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceed from private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r41", "r42", "r45", "r56", "r70", "r79", "r86", "r87", "r105", "r107", "r110", "r113", "r115", "r120", "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r233", "r237", "r238", "r242", "r243", "r247", "r253", "r304" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r22", "r136" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r138", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r21", "r134" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment - at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r8", "r136", "r276", "r305", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r7", "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r7", "r134" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r185", "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r185", "r268", "r271", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r266", "r267", "r269", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r212", "r282", "r328" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses", "negatedLabel": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r13", "r172", "r207", "r276", "r308", "r320", "r322" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r76", "r77", "r78", "r80", "r85", "r87", "r121", "r204", "r205", "r206", "r220", "r221", "r246", "r317", "r319" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r46", "r70", "r102", "r103", "r106", "r111", "r112", "r116", "r117", "r118", "r120", "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r253", "r304" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Total revenue", "verboseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule of Share-Based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r189", "r201", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Asset" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r22", "r136" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r190", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r60" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Warrants expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Warrants granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed.", "label": "Warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r188", "r191" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.", "label": "Volatility rate" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.", "label": "Risk free rate" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r66", "r75" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r9", "r10", "r11", "r68", "r70", "r88", "r89", "r90", "r92", "r94", "r98", "r99", "r100", "r120", "r142", "r146", "r147", "r148", "r151", "r152", "r157", "r158", "r161", "r165", "r171", "r253", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://xeneticbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r30", "r43", "r44", "r45", "r76", "r77", "r78", "r80", "r85", "r87", "r97", "r121", "r171", "r172", "r204", "r205", "r206", "r220", "r221", "r246", "r255", "r256", "r257", "r258", "r259", "r260", "r317", "r318", "r319", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r76", "r77", "r78", "r97", "r283" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://xeneticbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of common stock to vendor, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r10", "r11", "r171", "r172", "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of common stock to vendor" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r11", "r15", "r16", "r70", "r119", "r120", "r253", "r276" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r69", "r158", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r172", "r175" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:", "verboseLabel": "Operating cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CommitmentsDetails-CashFlowInformation", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CompanyDetailsNarrative", "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CompanyDetailsNarrative", "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r29", "r173" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r29", "r173", "r174" ], "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r213", "r216" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized tax positions" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted-average shares of common stock outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35711157&loc=d3e42546-110969" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.1)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r329": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r330": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r331": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r332": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r333": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r334": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r335": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r336": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r337": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r338": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r339": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r340": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r341": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r342": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r343": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r344": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r345": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r346": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r347": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r348": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" } }, "version": "2.1" } ZIP 55 0001683168-21-003464-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-21-003464-xbrl.zip M4$L#!!0 ( ,R##%-- N!060H +M= 1 >&)I;RTR,#(Q,#8S,"YX MH. W:MFU:KA'[Y^6]_1?!W^?=R&=U2XCH7J,'MG8\:G^(F+[_+8YN-B BV%E2<7TJJS:OA7C/V>2GO!_._/ M?,+?S;KTVY"P]UZS_VURW\8?/UNXH^9G9R?DU^^SZ;C[9M!U?[R;OQG^_OML M.++LV1_LTR/_9G\.FKR4]HB,,0(LF+PJ:?M"\YY.C[D85DZJU5KEV_V=Y=.5 M L*+F4O9]U7DM?/S\XI?&Y%F*&=]X4:B3RNZNH\E64B&6FJ@ITPJS.PE>DZF'JDC%AZI:+<8,,L.>"03\\[-(!)4X)*2R& M1.DN*R?8)FOE13T?,\9A@, @#4MTV61"801 P5\N=5>Y$-PE/5 >Z0<8FGG2 M=77EAL/\4D+4N2H%CUH.2/4E.61 &?6;"T=A#97UF/.T]:C7H/?ES7 M[^H/-TUD?6HV>Q8Z^L*PYU!HZU\'@'(4$45S":T3S;!DVKU[[Y_*E]UVAVK7^BYG^_ MM'J_'G M@.L-EJ-;ES\5'90QO1G%M]N@>%.W/J';N_;C84SZV(TGF"W&6?## M[/5W.O:#_,KETA,$?O1&!(6L>^K%%AAO*^BX?$J=FU.S7]VF_!OR( M#Z [?VTU0,*>NM?RQF,LYC#/TR&#U,G&3-5MFWM,43;LP!1B4Q).+@5IS5"< MIZ$(I6HL$G)1+!A%DO<5HM@KEH*(B@RI?<-=%_?Y4D!6@,X(3:V:@2:!QT(D M6I:YIZ!T!(?P5LWKS-%1T40ODP]$!4CD59K=7TN[/Q*#,'/00M!_$&BSIUYO ML; 94G;IE#@ML(P-:=\E=2D7VP%KJG9:'8H$HD+BG<-QB*OR- MX'N"M:_\&#/ 8'65V?&G:<=K(<%.,TJ*V5-OYZ5PFV9HM3>9>3XAX:=_O#^I MO?N DG[ZNH1%J2L3P2_5M=H;6K,CGW5-W0I8XIBHQ R<+S.[,9)T)UCWU9I>X>N>D@R'\ MZ@G,)&2+<:2=6VOV4@7Q!*2MI3MUM>7Y(?'AC4G,8].5-J=O.*##/B M1X& O?5ND?Q]FYR_6.Y_DDTP"^?^Z"AZVM?MQ)RDLH^&I0M^,QX95+@(GOU!R#715.A?XSA5$1C!BB35!OCJ5#F 8U5GDZ-I:+$ M9GPRR7@1? [C9ETXNS2 BA*;DE"MIS-CE#T%-V&T]Z,I<3J;%SSD M$YB1R.P])(]S#Q"LVEF+)J;H=6[]@:88^SIGMMM,M&9@,IL,RYMP\?RE1:,! MR$8)X0>8%JZ_@P"*%,$H0V@&R'1RG\3'U6(1/6"3=W*_>DHK3&U&:8-S___O MV4[_HU?L+AD@__/L"_T%\%5)4OU]?"DL&PDRN"K- +=R]'7N;V#:\6SL1B1: MM.'S;!_JM#?"AB,16-@9*9G/QT&(ORE$B:Q$RD<"%%6:O9-H!NEV9 E57L)D M%_QM+!I) MFAM^_UZ)/X /?Z<_DK\$P[E0B&6^MS==GA!<^W#';5^4@47_*D=\95U4KIV4 M3VO',^G$FFZB1.R&S92(^+90(N<*AU7MRSQR_>!WIJ*-&J^",#:]DK-"7"6C MDG(L:QMULA='/$,?7]@6"JV_DR)/J76<_F^Y5>?PWWX2\TTZ2)(E^K%=1TE? M E(,E(@K $3?"_*,SK'Z6I%M%5G3-<)[1/R 3]\\\IN.H3GSM]BJQ]5J#:(T M?QNT0X2_17!/QGU]H85<7XWR M1VJF6%6S"RI;MJ"3B:P/!?%K4C[.J]T%U6'ZHC:I,T>_=04]5BS>05@VH@#= M3IC#;/Z)RK3RZ=)=4%6_)!6_);5Z;5Q#LPMF-$A?A>_$J/DM99 KP6JXVIR" MM+M@U@-G3 MI.-X/P^1D2T%Z#8V)Z"0/O^KFN*G5NLMB<@V,"2HZP?7T%V5;.BX5"W;!WD> M45C,7\#"CX!YFUE$J:#FD:I1<-%K9)R18GN['-)_1;-:4GJZ'7TQSR(MOA5\ MK \(72)E/F21W<\3L;. Q^<_2U<7U<[K(%! 09S+KB7$X5-DY=;C5>ET^25@ M7]8T,H&('IFI:Q< 7*!;A/(9LZF*Q+S$0K=XZ4='VC#Q^VW6=5\;^J37\YBD M@^?^DOV$1; V]$:8A5%(VU-ZYUK?*?U(Z'"DB%.?$H&').K+'4'MQ;3V)[2[ MUN/!WKO*.GP2;G.]@+_#80R++ W@;6 5+UNYM7]VYW_@BG2)3>A4J]%BD)$1 MJ;J@71R<&BB>Y7H;-'D!$^K.5$^"46>*],X6%U?VE9:=RTJP"PR/_P-02P,$ M% @ S(,,4X D2E&8"@ BW( !4 !X8FEO+3(P,C$P-C,P7V-A;"YX M;6S57&USXC@2_GY5]Q^T3-56MNH((9F7369R6P3(#G4,Y *9W?LTI=@"5&,D MUA:$W*]?R=A@(=N2 ;],JF9"L+K=C[K5W5+;_>FW]=P!*^1ZF)+;6O/\H@80 ML:B-R?2V]C2JMT;M7J\&/ :)#1U*T&V-T-IO__[G/P#_^?13O0[N,7+L&]"A M5KU')O0C&, YN@&_(X)7E[."5W!%^I^]\XM.C=C.&*0+;TMMXOU M1?"S(?_D8/+]1OSW##T$^'01[V;MX=N:N&]PVY>K<^I.&Y<7%\W&GU_Z(VN& MYK".B9@V"]5"*L$ECJYY?7W=\*^&0Y61ZV?7">]QU0C%V7+F5W'*^(@D'K[Q M?/'ZU(+,U[KV-B!QA/BK'@ZKBZ_JS7JQ3#D4)_,#=!%A,T$) MG>,!Q+++%8U8HVC.;^H-)\.%<"O<< ]313JKPE",&+6^SZACO1 M:))9%H:J#;W9O4-?CE>-PNET&.8+2 QF6QIVJKOW.%>+<7ATA>UZ\UHG1M+X M4\DS6L[GT'WEQH.G!$_X@B:L95ET21C/ !ZX9BR,M-K,QN5DLN]N-F)\':,I MMMK4<> S-700YAQ.)?.#2[G/8:\M8HLENA#6/D!,)ZB&[&36R1?E!!/,$(_I M*V3W",\:IOC902W/,XA]IO2GDO<>8M=/V[X@Z"W=C>_0"9E*=#+;S.S>\_?> MHQF/VW61J-G=]4)X7ZU,B12GLSC^$8WA6N]D8H:>,";,,3.RGIBAIY+B$3DB M"O+LBKV.74@\[OE-O)B.[G2QXME#?RTY].[*9*J2QA<;NTX;P_**90D.?@RY M[]2*;D1<5(PP$SD;E_P\H)FT.KH<_)"98(D$)\Z6.XA!['@#Z(J\:*4-'!JR MXC+ K((?SC%G3Q#<]D!7L$==C*S&DYZ135&>S'#*,[(I6'IC)1S*+]=QUC#OE%PN".=?_*W5&;!"VKW%&8S[PQAQQV/-F7J)8TATPDU&9X M(B=J)^[<#X89TA,#+CG*WN?N !TG>!*+O'=_68TD*Y\T^2WH6$O'A]OG?TL4 M:,T0#QEVR$> ,"_J,,S$\*#2U@1U499;B@GG'X.1N.) 0+"I<\W-0_J)2^=ITQ5,#8V1-#IK_"8U$+P=,9\ MXM*:KLE@2-/"# MS'7$+@:46+H%DC"\&DLB01.I$*NGD3Z&S]C!#".]OXH;6^K*W1PQ>P_P51S@ MZ:-SPOBR5W:R#O97>2K@ZAD7E]==(CN+C:60E+WLLZ@I'7;U-!61U6C]5VK1 M)*CA!YU_/X",9Y#T*9DRY,X[Z)F91,LL/"JTEO3:,YR1ZFDU^;D$57MQ8TO> MV4P0GU_;%\P_&$[=R:B#R_80*4^%*-N7)*C5LREQO$:)B5+4D66O>F.-)(&L MGCI:MHT%<.@\\!UPC[3A K/=D[TQ"4X2@9ERKLI7C@9R]73T*(YO";*[T"68 M3#V>GRWG2_^HMX,FV,(I0=6$UDQS;\O7G/E$5$^)$5G]?$ $N&B&2(>7J%- M=:=//6^ V' RANO4'48V1F;J?5>^>@^NSZ)>A7DR@7-]9,8^_+UU@R MT!BEU*NS1VD1.TMNJZ\_[Q*6DJ61EN])$ M?2C)J 'ZZN4FFU>S'2YURYYC@CVV>29$JS8M8=DQPE1QAC-0/=5M >YR80-? M$1UI,*UY 1E4]JQE00F4XVJ6>0E)Z]7TCCZ;F'@XJ MVXZTH0A%WE, A1Y(U7523)%V3$CJX)TV*NG+2Z<2;C8&U;Z MPHF3>G^QI#CI2FYB34#I#;+Z&U?#QA32;N[=(;NYT7C8_L_G8;_3?1S]#!?4 M^PBZ_WWJC?\G;^Y*W<:JS2PDW.\/P=UNC3Z#^_[PC^KL8KEM"Z0/KFA6@>R[ MUR=/O$>T7:,MBZ?8FNLJRJ\Y'J]!TL-OOT-,AF2$&(]/(AK]@=ELTW$O1D&"(HV@[)KRX7K1(:OJ*MN] M<2GJICPGT:RMI/%EEXN/7E'I$U$]Q?$T7Y1140=M?O=(^)QT^";*([(07DE- M'N(VV9G8E%UC/EK-!TU;!R#[$#M+YF1G$AQ_1($PFLGI^ M0VS2OHB.WD(_*8BRV^V1,7.![YB\C(!^1B:N]/27=M.4O;+Y%8,TBF MZ)'O/+N3";)23N^*EJ/L[5(Y\[Y_#I1]-53L8$CNH2D=>GP0[WQCSW*H:-3! M_QC/$-A2Y'A:D]A24Q+OUWWQ-F2 3D![^+77\0ESE#)C2TU)]NM]V0-F0O@( M.[#C!W8,\\1DWFXSBJ=YH>")@-AR ONL5J] MV>EW\ZUBY1'"G]_\>MG\\!'L/VN8A[S)33\E>=\I\OJ$_J8+*+7B7,Q9;0@J M2?A>M5Q! 0*27"L":I=0230E^DD4.4JF;18JB:E$P8 <^/1 9I!K-$QH)2I) M&Q/W0C(0TI4>LE-#]Z4:ZHQ#-S@+/^5;[3+K-BJARA(!P=F&4[X@,O8?E= < M$!"+ :5M4RK!4()CC/\N1N[D+J:2P$J C- 5)FAJ6U-)7"4^1C8XX"S@ ;9, M.UK +JH1,BV9*B%3 MPKR)_RU$80?W4(WBNU)R@ SXBE)@MD:K$CPE&4C8E!7O(\V[L$J E'P@>>-6 M/*8#FK-*X,RRA!!5XA8N? ML=^KA$3)+.3T;F=A@B.8<)8@PK-P7(GM8"50:=O\*"9'< .X*#R9>\1*H#(< M"B1;8%"+$/^)MMSVSB2_WY5]S_PO%5;P]_GH[,WID8$\"]N.-_]\]-OD>#"Y' Z/##\P/=MT ML8<^'WGXZ&__^Y__8=#_?OFOXV/CQD&N_+ER48#H#_&#/QGOWGPTC>-CA69_1YZ-R6_WPTVS MBR!8^9].3IZ?G]]X^,E\QN2[_\;"2[4&)X$9A/ZFM=.7T^2_F/T7U_&^?V+_ M>S1]9%!S>?ZG%]_Y?,2>FSSV^?P-)O.3MZ>G9R?__'H[L19H:1X['C.;A8Y2 M+M8*C^_LX\>/)]&O*6F)\N61N.DSSD]2<38MTU_M8,.0)7YW$O^8)74$36>$ M]IU/?J3)+;;,(.H@4HD,D(+]=9R2';.OCL_>'I^?O7GQ[:,4I\C8!+OH'LT, M]B\%>JL6[5&!8STZF*%[PGX^N<2T\U)9(\8%0;//1R^4@+;_]NST_?DI:_TO M.:)@O:*=V'=8'SPR3O9XLF!CU['- -D7ILN,-UD@%/ARL51;:$_F ML4F0%RP8I^GNKP"WN4:U8:\S6M*'^J/9:,5&(-IQ=X-"W%1K6DP";'U?8->F M@^7U'Z$3K/?6!FZR-:TN37]QX^+G_:$IM52?#LN5Z2E8.T=6U].'M%4KH.KA M)\<^/OLH$P.BKTN>2;AN#9[!5=L=Y^AP*9H!*V MVGHG?2EGCN<$B,[I3\@>>G35,'<>733P?86Y3Y6_+GEO3(=$*[ROR/1#$H\= M,B&%3+7US_.C]V1!Y^UCME"SKU]6;/25R@1RU-?CZ$D$2KV'0UJ7%/?(9;,@75T%ZRDQ/9^._"JCF(ROOKGBT4=_A%3UZR<54T'T M[G8*15=B;FM.4)-Y&JM-#<"JDDKXVM@'%(3#&2H>;5\ MA0+3>)Q],O%7DZ"M*G&M5"W MO'(+#7@\U5]1*6L#*Y$4S30BQ](L9!E-AA66)PJM-"C[+1T.T'Z"0TTT[?U5 M[215VQ');Q(K58%'G!4$R!"EB2J6&GH7R;>@31 K?$3'MD,-[$>F3!Z4LU': MBN,%)Y3T)*$YX3;0O-R;AQW;>&DZ%84N<[<@ESE9$5**6_IG3F[T$B"Z8K13 MR5F#ZCG=P D8>9*3/S..60(_9.,M_1A3)H*DHKC8RCW?9=EK3,J&\U.-9Z;_ M&*GMD^"$#9$GR U\]EAI]&5 <_8AE6Q&\'(' M$R?FQ$*=LC:GHAT9F-#5]^>CL].M="ZFR\+/1P$).4;H!+A+U_333._@Q>'U MQJ*^999:X>3.QD7XQ!@ 0$&Z3CCB%\7*.E$6W4$K VU2#L(N/-=@2O[(?^\&(X>F!^%O>CIIV_H M1$^]DB@\,T8D\KR_)@O,$CB,6XVY ;3RBU\ "<'[@'?2 1S==AW> $S&(;$6 MU)?]QCQ!ZN *,> 3/_!><&UL+I 9'+!JF4)\9+V9XZ<3&SGQ6$4_1 #$BW7D M/*2KW"EMD6-Q2I*E>'C7LIGW6&;Q1(>L7Z/JH@KVOD&\19Y6-D@%FSU#VU?I%%< AIMT1YA[-'3^(%YKN/5IA(H$E2]E3-$HJ0"#\V"X(_PA-0A5RURHX%(A[ M"@5/"PB-=RTOBEBV(C*>"AQ%ZI[BP54# N1]NX!,%LAUDU(>%4C*]#T%!5 $ M@N5#=[!$E9575$MU9#8LKP""Q".EKSVRY"0G&C"\0JB[AD@0C5 1%KRTZ^]@(K/CC:X M"X'X."4K4O4, :[XH.5;P QU$UL]3]A(!C@H@"BTYY;%@E_3] MI-JPVO"7OZ.U"(8":2]QX.D M&2,QY+-B8.VYTV<2SY<%2D[2447"5 +%KR MP&/1IN;+T*8])=HGQ"PHAP1@Z24R(EU @%IRP6,)69T\6>%,]/^2;>,DZTML M"Z<2(6,OP9)K!$+6DI\>RSFP;8)\/_F'Z74F HI#WDMX(#T@4.HIK-H=E+?5 M0'G[2D!Y*P:E)9\=DNZ\&BCGKP24DNZ<<1F>)GH.X!(.XS( 4M M0#A:==L3V:+Y;D3&!#\Y\>%W,DP*''T&AJ<*B$ZKKGW:<^*%B,J;$E/V&8VL M"B *K;KVB6!C[ >F^W_.2K8VYM'W&9&R(B N+7GZ21]AP2"H<"Y'TC/KEV4' M#=Z2.\_FK@%!)MSULQ1],W=1=-#:+?GFMYCEP1;8$T;4BU0]LSI7?-#R;;G8 M;*^F#PXJFY][9NN\W)"1=][24M'(WZBX5!ZVX2/TDL@8D$_EDO;,^+ .(! M MN$\1Z!:).1U3@R+:)D]%L M!HWX,'W/\) H N+2DFM<$&_H^R$B5=$I_PE)CLFHS)>OF(77CC&(>P9_:'- A:,D+SDG%-WZ. MI&=F+\L.&KPE+SB5^OK%6IC>','U-CS*GID?5 %$H27O>#L<"A5O]*#OYNC1=>:Y,][X(' 8>HH'I D$S8]M[>".]@UF#MV[H1_X MH'!)>P8'K ,(1%M;NT/;"9 ="WCC>*9G47=S>U\+@(F$JV_PJ*@#(M5J/OH; M_C9FR#3QQZR8T='E-\!6'J&D5P7$*!6,]2_8S?T I-$Q=<$>'^XI+T$ MA*<#"$2KR>AD$\)F!HPO#A3AP>?H)2P"54!T6DU2#SVFE<7.J[TR S.15X0. MGZ.7Z A4 =%IM2@]>IDOJ6IS+*[CR!'V$HNR!B $K=:B3Y:FZUZ$/E7 %XY: M.<)>0E#6 (2@U6KSZR4BX:*1!$0EY9<^U&P M0"2[ HQ$8\J(RG1D7#W#2$D=$*E67?OL\2?""3]#US,T 5 ^[?JN8_#1]>Q M;EQL"OV0#%DOK5^4'S1^J][ZA>E])^$JL-9C@BV$6"K-W[RW"NZA4@.]!$Q= M,Q#*=K>6;T]&CDY"]D=AX+.!ETHK#+\(^'H)G%0A$*^6CX/SMYM)D7VQOD\_0JZ87"&(F7/#+24%E^OCOZ6^[/7=>=N:WEK'!N;I >[KF5T=W5]-[F^8I\FH]OA MU6!*_[@8W [N+J^-R:_7U].)\<-OGAGG3_Z[QJM==K])HX2LX J-#*T6MX#T M[OH6@4'SK]7ALI;#92W-HG.XK*69,P4.E[7TY[*6N@8Z1!SD7XP)6_$0NFAB MMXS(OE'NP"%)?I@5?_I1]0L.Q@=J)CH.*;M@>/ M["PXBQ?'2 CS= \?NH%#>3G'$1="H.,A+98T"9:HXE @[PH.V,H\-'A"Z[ID M,_V%8$E ?^W6Y )38KZHX$31K:'I>+DRG?0B](%G1VF1G)(P#@K,/8%)51-P M7:;1&*8X=O5JS!(:OY9TQ.[&SW25.^Q9,A"XY+J# 0L-!CEU>"-DKT)/EE%" M0]>2$=C=T+>.^>BXU%QT\>W%J^X%=JED_O4?(3N/1+JB4FU!>[ J*0+!64LI M82UP*B^)89ZN(-L%"1#+*LOF6JH0]QCUXGHC?VRN6017OB#@TFN FO+"3: ! MA%$MY8A[841"9)>5%<+$9^D94@(E1.D>O<;#*N.@!OC4-OZ)8>HX7I 1-UJJ M3A>F=XN]>8#(\@H]!BH+<_4V^K0245$%1+7CX$1Ė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�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
<7DM='TJAQ/N7-U MA-Y8M.:'\MH]W4 S3 LV"\$N]V C*>WNW>G?JK):K^'^TV'=[['44=V^=I,M MIEAN;]?R+&>TD+@C3OS[W^7 1< $@:HHPN2"P*7B1T?\5I5/)[RP/2^$4K^[P R15=.#6F *=,[S=IB0V<%OW^*MFM?#U,/KLO:Z_0;7A^R@T1.PETZ&\>BW]<8Q.DT:76Y^7UMD MZ:3\N-J3>LWOC)8)^]:U+2W%UE>RL?N\DNV-,_4NR;[>)68A4SW0%7$)L3<- M"2*B]NZOK N#!>;#A8.F?F"/P*.[7B)/6V'4HSUV@M&M,.IQY4^"T:TPZG'E M8408]8[(JSN]';'Q+?NC_]*]R EHG[UP9A+ AR*X[/$%\ G# M[97A/*Z,23"Z?G"]K^O_HHW0YK;X\GDZ';P,*.&8H#*8Q&AA8S2)T<+&:!*C MO2$[<3 6P#NZ+*QQHVS[KMZNEY_5WWS,-GA77#?[=@0B\=1#T<""0K+]T.\W7=]6[+5U;\[V;;EN"*=+28;MY'2>9.X M,+1]6J!P0MWM=FHC(&^T&[/1T?PHMV:Y)/46-D8S"49#QFB2F@H;H[M+37D' MSV7_B[A??G#C8?_K'^;'?B_B7KK0Z2W=GF@+MP.*_3T&-#19$.&N\G)$Q$ZKCI$5BD/&YP3TAX6"0,6B"3D'#7) SC]FJ? MO$9$Q]@YFDVG:28?N.(\#*9:HPWOJEZ];WR]/WWPXY+%-9O*3K7+]-4T.(-;\N1;U_%&(E, MK;JN<:L]Z'RP*]"CZ:A9>[PO-\N59O>Y&/$MZ$OU>017I.^_S6;@ZRS#,RNQ M%0*_MB6[9Z;-+JS=6[O.A(F":]++W6A2CQ*>'_WAK\'EGY^%JOC&U&C8/3_3 M7)KFV, E/ G[OQT=&F+OT#07N%@XX:"WPT&1]2#-LGDZFTTG/!5KG@JE6^&N MDL!LKD"S&9;.%3?.)VS&5D$3P0E'1:6E8M83-=%6;TA;Q:*W:J*HHF"FL"Y7 M=("*\[558]CE\02JV_0"DV;3G+_GPP>> 1^?_]NBFX\P!G% M,L!#;6F =*J.7JA;=< KM/4!3;60)O4<2@ )X%%F.M,PG &][UU+)EEKDG8? M4;P C@!0?X231(IJP)"\!A\KE 0//6B\3 UYS:#4WOMWX$7H"+B7-R'^0?@" M/;S_HEN_D0TX[&Q0/4GA%4&"-W4GE:6?O@5\[622+]W)/-WS9*XCGOE:HNF M:O7RZ6ZFMUPZO.'$=QC<7M)VX,J->J5:;U4K%/S6:ES7*J4V_-%JPX^;:KW= MHAJ75+G4NJ(NKQN_6KL!]L.=XR]\#%E#SIIC&#*8DG(VZM+,18=EN<[XN?': MRJM_&U<&:#!S +.,R!.@!!S_A4I1:R*7HEP+/UE_K<%TZ,FD3&=I88VK?F9. M-;K_]+X9>5+_4TSCW4IVLF_)DGW+,7^E7]7NGNOWKX)G(X!YYVEQWC7!X#H> MVZ?C4B%;?RG^_OKW)KLI&%;DLP4R9Z*L #=7+U]T+NQ;J5O2*W4#C_9UJ@J. MNSBI;PI44.912K6(O*UX,5STA7ZI-V;Y,#!U" ME8L(2@9<>@<;91HG,GTK- MSYY*+?-ZOZFISQ)(X<7H#B+HFM(8(HTW ,)4-">JFK&S@5U)$N.N/> MU_R#=EFN/.8*T9Q>7<$=EK_M,G"7MXT;JM&LWI;:M?I7JE1NUW[6VK5JZVPY MCCWP:HWM+20K7.7@ \8)&F\NR;JX!-BC)QGDX+($EF[ E\>7PV)G_$MHUB]+ MPO/5/1=B-:WM4N1RGM=83<\D>T8TW#\^*FKV,>\KLO[K,RCK$R:MV,Z8HLVS M6INUJK4-U?H]I'KM3):CLM=6F_9NZX^: B M2#*:.0705C?1WF/VE1FE?]]<%,7=]!XX.7>M!=^]I#FKH11;G/&G^'VUR\&J% MD7MVV)I-":G^:S M^2UQY"T#.9<,D#H4]Y)*BE@:J,#GXZE<3(2"UVH5P7SF[B\CTIF+\N%E/-P MXE-!A&[X%U"9%*_KR-@OBZQ":OB.T,*=J;". Y6OC9 7FLRQ:3J?RT8B=L5I M2]&OO*0TE!8R#)DD,W])1O\GN8EQ5MX&/]K,SZ<>A'/92(V0EY!A&"E\5>0$ M2NH%P)S1FXU"CN:8W(':C35P MMH/V]-N;"W>"$F)=7-V)*LCZ"=$MMI+3$!?[/#H8RFN)[THR"1$A1)Z)=_\8 MW..O)^'ULK][6U+N\\H#TN>B60(TQ2LB)4_!3B+;$"+;17XI"0*0D_ (89U; M)"#I&>_.DFQFO2-*G8%NJV6I_RW[JWG_?-GN[4(M6>Z3I9GL)G8]#BI\>XQ&X"GE\G2VL*U17-T9U7_M37Z$%XS# M($'03.16\K/N5+G 9[.7?YG,99A]/8((J\\VJ;,$^):L@<;%K7@)7C+M,@(! M]CJ7I^#7;X#CS<*;-+?9D,67D3EJSX\#OV]UOB!@5QMO3!X2"5?LN81(P_#U M5::0H=EB:,1<&NX5-]I#QSJKW1D8EM+"RHL;%CKC_GWU6C#K?P>9[EY[0=># M[+^\8>X.3L@=[N=RF2Q=]+S?91NN3NBWFQWC-,/2F0 )Z?SWOF9;S;?8MT0Y,$ XGX"S"/LQ^XGK0N&9RWL-57038Q M:\ O))5PRQNHVNLAG-NP; FQ(27SVW7E^^//6N-I5WOZQ%P0F+"MP(9C3XEE M1_YWB_X8VH EZOYX2;)/M;Y%]<]6F.M(K'J* M-Z@N>I 4W#&$W-%'R'?(_D:$O.US>)OE4FEVXUT,ELYRN&G/ZK3\T02T.R8A M6]R2A R=SN7I(A=)3F(KOW&)CQ!CIRU>T$3L0I(6QVSU]3=B"UPFO4EM?E"U M;S<@<10_PKG,H"K??G=MC;&J,:;-:K]U$ .FRN M]A,RAMEYI4 SN=Q&N8) 9$Q4?RQ5?]5=-F0.AU91%"]CAKN4U9>:8G$3+@9T MES1<-LW&[3#-W\MA[G<%.G75NFLVK\DIX]+U](PQ5:M?-FYO2NU:HYX4,FS( M#>F975$#::" <%?/.C*<*OWQG?[8_IWE,K4_Z7UM%KAM/RE3 !XE'7HPO&_: M:LP1)08G!1*;OAYU5F2#]D^;)+49^ TO*FDB)=6 MCS'W!E-%T@59U4T-S9CMS.V?XL^R_,OH9_9X;GK&@K?*5]7*W745=PRI-^HI M8M%K]9_5EG62NEZA+FOU4KVQW4B[V0-VF0R$F'+:@;>;E[XE;LBXKA M%>!SJVM=MW- #K#GZD$V$8VN;6/(.(]@P-TVK-Q#(\Q\T@AS#XTP\TDCS'A) MSOK=*ZE]M*\L3-I7UAOM:HMJ-_Q:+=HQ$0Z@)DT7 G2@,+K1@D ]Z& MF2YD\+^(N#@A58')N,+T]0?KC+6"\2W/%*XNFO(&S3'71^%4;;O5]+P:7QN0 M&2WNJ^U7=ND$/>7?E"N='KYZM/$/ B!A7=;N2KOD3@HW G'3(*DWVF;&J8 3 M9N$N.^,"_ZORI\1\;_6+ELM8MAQ&:@+7+(@>+O'6LD;^RV5.,PL>^73- (4T MX1WI/$)9GYOS8I(K"'W>F*[['BD(I("ZD%1=D+"S ._7%.&4^H"SO1SSV7Z" M_,5^?O].U2B('BC[6YN#[&\_TA!K"*HV5#42/T@*>98$#S@+4D?/O,B3 V#6 MT7MX (*X 8A^GQ_0U VOZ[S0-W$#"H!#@@B&ZDKJL,]#I"@@D\@K98M,@<-M(N /&@8;(DW'5\:!ER=2 MY;YD*?.28D@/2*'P4<.A 0MTU@X#.2NCVM10Y@TC"XQC@YI%N9G@D M:S)*'@V&?> _>SD$^RX4T>_?B>@9R>H05M =D6%:V$0-=4"XCGA-Z /' 3\: M)G")@_KY1R9TP"776*5W,8_AI 5I44)&[:/!B'\"#[/Q+/1Q/>:3^CP=&EBW MA_E$$4D-8NQ8-!L1##K4F6 ,XP,8P3ELM(QM *O M@H0<45WC82L%^T/G6G?F-"LI$:JFC#&1QE!.01P;::/P#QI*$#Y=J MZE"3$,@ J %1,Q\H$>@'CXPF4DI3354>P1"V)F#SF8DB +3C5 @@'@](& C4 MC$NL,0$\M8Z$@,WM@8E^4H 3P#;".._?>2F(E[X$_ U, QQ&\<,AHA:XD.?P-#2P-X'_C>.IEK+QZO@:P> M(QS[2WCY$[),5;UN487'P\'ZR-AN$DT0(I&6$ L(9J +Q\6R?N"J6F(2!98 M7P# UAG3)D0K"00,:V)Q=JD'52/]%7']/*B6ESYOD-371.7:0J_##""J74N: M%*/A>H]"KI#M*>DK(.ZLFT+;HWGX*/3$A;$_?T'.PR"$]F>F[GQ&)L,3 M^+M(F DQW[_T52Q!ZHL"V-#-KBZ)$J]A67F[FMKEN="4*('#@667U,,X?]% M!'"F'_H82>_?65A*+6*)IJZ0CBMH7ZG6:6GJ>3J?3DP_QK<'-:@/=Z??3S]2 MU]* )+/G/%?J[ON4Q6 (2P7X0H,M]_1-&D8=JJ^@[-MN%38_E?W0=)Y%, G/ M3%UC DAK- #M B/3U-=!]VKJ_#B?3P<$0*EG % U=>I.(9.3BS'TR4MWIZW3 M":IZ")0H]ELT7D1 SR?@YP?L[1"=9O5@(-9(L#X +PU_9"K68]BAG;YK/:XC M[5D"CX=\0AQ]ZS@2U34-O-] R392L,Q@)Y"F&K#B*QC.]L,G)IFFJAK(_CW! MF/4-GJ$V,%T?88[!MA-O8IB6^TNX287I//7-*54")6'9+SM&<"R1: H&R;Y@ M#W=$-/UT<4!PS!$:9C=P<0>&AD;:GHNHH[%2)QMP(.X:-U^^7> M N2O*B9X605^UA2"W!M>X1_(SM#$WVC*O'(L\?-T^13$MK)))/*ECP@3XO\@ MPC%X?XTXMCH)H,'G4'" BS?;P//3IJ$R_P!A[ .,@I4G;U :C^T@UD\&;T4B M>#O7H,"_(6(P4<(3[%O=)T;$[X&E2HJ)&19BWP=".\&B'? T<#9I]XBH$418 M%-\S+) I[)!9L^._O/8 R9HD73=! F9BV#Z/W3OBRXDS4.-6UX 9B,]!@V"; MB7\A64I+\>#F,(+5(WL"-?Q.QG*U8["'L9&E -PI@'I @ \08Q+?+[E6,/3 M>V ) %E T^SJ)NXB08YDD.7R@H"L-MZ"=0,]5B2JJ0GD.<^AV87 M>^S8Z=>D9XQG1*XT!1W4(\&(3L)E +7GU%81-K'-QFSD"]]HB%PM3:(9B#'! M=88W:#R^I08'B%?T%:QP"FJ:JB"!W!],96@*[]'3LXXRKNFR$BT\]=_<*4,- MP&'&SK'+7%AF?[(21ZW.\Z>[8(;&@%-8;A#U7^:485B\)-V4";&!RO^=S6(6 MFY0J=X9!1TAUQT!%F;RMB.2;3Z4P&:FN ):N4 &^OE $:>HKK-U -0"OQ57\EO3@JOI@#7+=/,W=:U@.M=^:W$SN#?[V',BR_BQ(!>5 ?Y5.RF+>OYO5 MO28PI#C-,L[KLTF$/U'[]"2= "[F7^P23/*GSK2K-/*5^H(37G-:&-LR01K: M^1;BR2J8\/PD:S:Q0;:%Q/D@8B%)?LC4P&(3\]>U=POMC#-V>NWT+7X85F!( M ]+^B)AFG-4AV5,,1,\T3 U-[9.U6!$-\5%(8@?8.LX9[TE[!J#*V:!BK<=K?P2F%FDD.V MB3$DT0_"F1Q2J&:Y;;H5>DP\!]N@P@@3QX>F\*T=Z@"_"(_BH $96,TX/AT- MGRDDY3N-6+IHI-KI 4QI394CCQ46*UU?K$I7RR5>W,]&I*,$$2R%F.^-Q\\D89*X>=;9["!#G.V.YCZ[27R_& M?_-HUQ"OAG5)75=AKJYKAG'NNE>M._/GW_YM/O!]>&%6?$V!R7;&A=J/X<_> MN-J3I*.L!2NLK@6;XNL"I/Y5&N9O[U\N70?LPJH2FTY4[8Q_FZ/FMT):^EN: M3K1-_=AT\$IG_%TSOE[?7?QLUZ8LN&EEV5HJZ"9[D:GJXEWN1\C%--NIH$\S M=4OG(98Q667BX)G@0*.,6\^Q1>?X#]*6U"Q-CH&L?+/'6'V>%MJN:R%T&*HY7'O"& MKV+E1V'%P(DV2NRD7]]"GJ!)NF1O(P\ W@<+C0/$XU.3..+$N]6DGL"U8HB# M(3(T &V&A&86:"-@+JYUHDL2_3J9:?(.(HB;['I,1&6":U69"1$M= #RJY^-D.XFK6OE(T4YQNX);>U<'(D^<6YXNV(84(C][ M?/P4R:"3")@4Z]AE3O-SVK'J=&H+259$B\&8;.QXX(%W$&5J$V30KK$LQ$S3 MXU9:29^)AW&V!9M:O&N'GE7Y&?.3$VN2E,,+LN)XU2 ) VQC "[@65.S4E)# MD$)),*PP53IFG/W^R-X]-*2+7P'/S[6VY!=O8X_3> M/0"(HYNU:NV5'5Z-7OLGYRUS '0EF1@7%U%3-J()D5 MQXR['\O"LYWQ:W9PP2J_GAY?HY$\!Q]SY,[E.N-?VK Y+G_-RY6\?5N,7:4% M)"=M,*0!=3E1R:W)CB56?3:5CV-C>N%$J,\13\E"VB3I/;O/^X+M_9"@>>H+ M.A:;Y)-Y96+Q-5.V;_?0T ,I.,3&WO8S6A#V::1%!'G"Z6&+!QM(NHY).*E^ MJ9:=.A9B8VG'W5&'DF+3>C#9=W?2RXB4B"EX@T&V@<#[T"2+[;J$64%XNQ8K M"5(Q2<[%@$66("WD'' MZ?^I>AO">@5IB.E _"+BIDTICU/AX'.2'6,7\8A7 5CWIN"IJ\9CLE^"-R;L M @'W2@>\:!4\3'8^8/@!_X1L9$Z19:,>(,&N#[" C'AL+BT/S:&"LV]BDX%R MJ("GP.\YU)3D$?B'5K4@+N#!-\3.#=$S@3UPI8,UPQHGGHG*!6+#UW;9(3"! M">%0%P/*BU9)NO((?IE5T##9*UH]-,:U=5:;^-96R<.$1[Q\VI*BX,+]Q1++ M[Y.EDGH.<#_QH83)QGZ:M7;V 8Z9_2Q,=QC%BG_8G+4I:]6'#<@8^-L2,)8\ MV;*-8=53]'YM>4)+H#%Q(T8^WFS&?2?FLMJE795 MF_JN\AAN\X^;\Y-[1Y2K 73>RXLW.&-4' MV:M\D<]\R^U4"S"=<>NA]H.5KYNO>O?D'+OZUAYW19)-3&I\U<6UJNO8\%($ M^'VJ@WT5N).J)!,;Z2[!$*XND1VLZ!@K[]^!;TP.U9'F*\[W=H6UG=1QUR6! M8$-(KSLNM=6Y#(DIGAQS0CAKA(TVZ LROAZDF@[G6G'!HTB2AZY,I^4US2<( M[26)-JD7%V67A#Y(SW;\0&I5+??-=OG)R]CALK**!%X+E*&=(R-N(A[,!1RU M !M-H5?LS>+260U9#BG(;PK7-5HE+_AY?1I#O#@.&*Z)23E@Q$$31<2.E\X) MS+Z&K*RS+KU20'NCKUN^'O7-5!"59BP?S*! M"*ZB>(M20#ODE^*=CJKJ)!./C\I-3I@!2]IDHI?3EA@=*R&*#]G-^<,"+PON MX-)_221=#Z](FC4("3()XX"X[I9SUJS! ?=,^5'ZS;P6?E69J&S")H4K%YWQ M:X:5AY?LX%F,IM1F,\ *G?&?/'?/U>3AW[MB5%9TF\*9HF_A3*4SYLL/I?S/ M[\/1]SW7S>0[X]YX].M[AKL1*83_?(+ MSYIRJ:1Y]:)?.#G'G35F-V):V!?D-5'?:4"Q*V^MIEC>&,?@C!IV6Z:;$EY( M>/_N0H6?]IDJST>HNR$YF.5DR4NMN\EI3SQ-BDW3%)!B.A'N?*&95IXQ197Q M/K(5S>%#HVUU" R>YG(?SZ@;J_9@X)1YSSZ*4XQ>8V**63'%@RE9>>J!*DH] MR4IF.A4-)&ULY^/5!T5R=FL$:Q+[1!=V. >J;DQS*_@XEH[L%.FD%( 4 1AS=P2845I&%?GE0'X#T),A+. M))/= ZM0!3OLQ!''3_4D?!:#I)3UZ35W0!P2&TZRRVR6A!T<.0R,8<0M;*P@ M$,\,/KFU[[#0\F;:]\&N4G$P*4VJN9R!:#*XA#O:DDT5PW4@P@XT)<,JOR A M!$_A4ST:)J43GGJGU-?H>3IO+W:1=YX<^7M&I>G!A6FG=;^BBLI,&CKP*)VQ M.3*RI0N&*^79R$WRL1=19/9>1 '.'_/_V7NS[L2190WTG;7X#[I]=Y]5?0]V M,P]=^_1:V,95KO*,77;5BY< ;*%1&FP#;_^1D1F:@8$9O+P<,ZN-E(J,S(R M,L8O*O?UYU]'Q[=/G3_^]6=.--V2F?U Y>FF\RJ3Y>:LP3.(N7!D:[!0NN%B M-)@0#>QH)/[DK'=L?# MQV#/N1 1Z12LP1GXL+0H)Z*CREYD/?B ARY!W[)&.DC',0\7Z'NJ(1T?[_M M*?!//BB-">&)$>D0_A�E]VRZ)\(DG@,5F!\F]%[\FLR[(@)_-B^2K#9+?U M!".>;O#;4M9M5@J*,.4,F0=1(+RB[("[[(U \H#>>=:V#;R1X=ZO!#,L>XC. M3FF"Z13G,%CP\A??@W_SS]&@?)XLY*0K;0_QS=W/T!0"$'4MS3 8 M'!5((X7YGE6+;@)K-YVZ-$:R9B,8V(B=/]0VIA<$^S,5+S$+U5&L<,EO,5CR M:YDV7L .B@DJU$>/0[#(G"V3%_FR%\[9^L[,)L-=";[ 9\YG(*J#2ZJMFU?? MAMIAWZT.YH_,*@,6:YE4Z%L,%OKR.O/ O/G?XJ;V\LK?[&YA=NTY;G1DQPH) M=BRWJ1T[/+IL72KZ[8%=7/:.Y3:^8Z79.T8)9LP:0P,+3S--(IQKYHL8)8V M9'S!"P2CXI!'WN%.IR*\DIW)*UGW=&?7S2M/ZD6V_L.PVDY^J;R2=4]W=G.\ M$M>:93FGVX?[L>X=Z]0;>_W[FP,LOEGRCN4VOF-QS=;7=KJSP=--&F8Z%58_ MAN0/13>#;0B/R1AF%+[V?3-[ZBNZA_0%NH4*ALR(NX_0ILGPHA$L41E2_5-; M48>LK0ISI7 &+870=V7'F9P$XA7))[GH/N,%_/$*!;_WI.?D:"L M;JV-.]JL4UB8YS9FI$\^KQU7-MU/!F #6;:"S+ ]<23,>W48XK3L1PI&5YTXD=X2_S[,<>#S<]8@%G%BN.35):P="N..)9; # M@ MI*3A_CG:*[KFP?"U.D*_#[%W'6%C?)4/4M4-?+&<;UO[^_8G3UH\K,7(V MX1WOK6B1.W[)*X*#O1FH]7FOZ[:JGWL]>SOY*= M6>IZ'GZ>-)M6KMD_+*_'^HT]\TFUKAU+::/F]03*D:7H\6I7I/O=*M3\U[6, MR;OA/^5;._W)N_ JIC^1^C$G>6L7,7$/UKZ(4R/&B%K)'WB09N;_@+HX8+4* MKO%&1E/ ? NY7$-AA5 XP3!%-,$7Z(A8?'Y++YT*.'(D+Y,U8/.]#9?]&=9> MC40 /9N)*/?A3BCI5"#@)'M=5 X9_BN]=<9B[YXMX3=TQ) QEHZ_+M"'CN + M=]$NLB@"-D' SA61?BZ@.KA(QFC=.$,<[S\%'W(L(NPYE(K!WR&F(J8P?.UO MR.HRE9U86$"$:D>D\=UTBE<-LJ$X$"YE'L@C"BZ'/ [PC2_1#[U%^T[#'1.H27I$L-2%DJ/*R]X M](F@:68-Y'D:",V2D5.V1? JG7*#L)ZEC1L;7JMP.1PJ+=/!DN$\'=)<#5T( MB'P2"7SY*BG9DV#P!UK:^)Y-I_HL/YT72S#%-,YU*ML66H>'I">&JNE2@\C:=@;*P M3X!<&QJ8XA6L/?&<7VX3 "YD.>0HTQ\&0W;AA?I7U3V_3C@I8"BK,=[JH*7. M/E77.S[G5^-YB#1[>8"*S]&=HFO%_FS=?'O(?7D^KOFLI G1=87-QIJM;DU9 MRWP!JOAY+P$Z>'(XRG\G17A3"!/5\HD+?PY!.N4F$4AU$C91[252A9V9%6=N M!("G%60G3DZ@\1EZ9>N4GKC/\N?NU*,PR[R4493\C_-J<8--A&5-1OT'A1>N!UBED'O1>G[]4(VCH[U?@X?^(NN9 :(]%E5N[=V-BU>-^L5^X_?P;#70J0O# M2I^VZKFKQL#\55P-$/8+2\IRV8DU98=WXV;E^N'H\:'U/=_?2%'9.RP=RV7G MJ1W+PQU;/\L[O_J'3ZW."FO':G?C_>;>Y5.I??N[N.32L<+=^/FXV+^\+AS( MA?LUEHZ!W&A=VK\.+$T?_Y+?9.G8.6LF.<*&6C;Y M&V>[M6\_\Z=/I6'E(_E_QKZ=YWS'Z"+$J +0\:P/,RXKH'%6,"X_VP$+"FJ$*Y++/F%T7R%Y]5J*8G M\HFI:OFT^?3XO>2_/[9.VL,KVMEK["_HUI# M31[]@]X[^%JSW5_]GJ.=5FZZ/KUPE2MD M,GPFG\Y@1Z$ZQT^+%'P&=(3C:9T)G!M+3C@4R'+_]T<^L2T3\[VXR0IGW7]; MIO3WO^2R2T30R/"O;-W")D*].[MB>8@OD_IY]E(==C/_B?R(FN51M)[K0OIF%9 M?I?M[%?V1M$VE6S!\-0^7Z[[-/=_4JZ6OV=@C#X#]R6&R0S+#ENCN0G6Z,S> M@E,6G<0C.FM9<[L7(RD8Q7PF7ZW%.!1C>21^\Z=Z&);.5MGYV(I[SM\W6X5\ MU:^/K5XD3E^H2QXZ)JP-]6G6\>(9_VV]6#>:=9$EUIWF/A(+25KW:9<<\.0A M)\;+3L,\E%BUX!4M7">O\N6'(U?,5 K5F8=CO:KZ$MFQO@8)_<;940CLU\V. MJU:"HU^?L,F4&9/[++9:+&TYMFNMNK^(_%V0.] MUC[E%A%,6[Q/7$ILR3YM4D<[QA;:V#9LX+!4M8XR-&'E',-_>^Y&OU%<]^9[ MX)LN_%M3\!_ !'4&N,;:)TQBD#OU]$@4(ZD^"3/^\JUC6S\5\_S:RV&:2JF7 MW(&?IK/WLA:[%0(KX5WXUS9Q7GTMG,<]N/LYY?JW:=ZTC>+;YKQUB^#Y.&_= M"EA4.N=95&Z&7D;QU>D+S0?#>XD/"[TG=0RGI2E+]5R>*B)-$[D_ZY>[^M5U MJW#1.#9[_1F* T7BIO/^Y 6\3*TX5>:0I6/%-#JRU4_(S'Q?Y^9F6NOB1NXZ M>:2Z*(]P"6G7NL?[^!DQ@!GY1:@7Q"6:=QP+OLU6[TNC-1UTR^W9/I5I]"O.U\CEZR U4$F MG@9E,IOJ$W GQJ;9KSU6QL?'C_(LPH>^7UGL^\%BIO'%H'53^6F=%CN]M6Y\ MI)9]Y57I"\PPFIKUXCGJB8K. _44G3BQ.B!&_?C?=*C_V?]^.+XXO5E%-,O4<_\#D9'.]+;Q5;6P MX3.^L /Z'#;_G0P-+8"KC\XO_T<>##\?N/TR_% #<>7#+<=2=1R[;0Q:+I@; MJQ$7?32Q%@Q-F5W)'9^ !A6+N@B ;$2\-M5DY>5]15>P_!X!-%A5.^M_397: M;=5L.P/LCM>F/U ;8T5R.RRW9=.D'M[8(0$(@BTA6'\TJFO#EH$$3(@@=U26 MJMH<\["EB G!4)HB6P@A@/V#00?&!B,:QU<@B#YJQP"4T!2;]8J66T!20P]W M;7"?P?HX_RIE7=9&")K $Z$]PO"B:^H_S'*R1$6=NT@W:UKJPAUDF!XA? ]Y M(Z(ZQ#ZM=/Z!B=#51QW>6B-?=W D0@=V>^1C,81 M0=1&M'9LN8P/4+6@1GN"I>::IA! (U6-DR'YF:U)5C5,F\ >VUA$CZTY1$U\ MX#.$XV'W5;-#$(/PN@O5IR .%K71T/%X/6#"N3Q4;3A63'.(($P2VB;M#9T< M_PX!TYD]RNZ=JL&3E#IR7]NGMZR[H5[2RUQYK[C*>RV02N$)/Y)]X9MT;W0B MWQOFO@93"V4:\>/MHMV>G72[@X>F\[7J:H5'X97,4KCB%S+)#*BX9D#-GX(6 MF%A"XV"G-+F@M389.M4M7 W@XR!;"&Q0V#HZ1:;".ZB+Q["!IA5S](@'O%8G M7)2D4R1+&"8(PD>"E"#CN(-,:S))LRO5B9_TMJJI :1*)KR\EHQ^^<3;#LRX M E'8("P(._;6BDLEPG?;2NHB1/+\67?&(;A"F^:;(,9'QU!>46B8HKRG?C MSJA^^O-"5TLWI23%%3.)NK82B^VI+GA9(GBI^B=VL*9.YECCCS@_[8K[PDQ^73E5_:AX5/"A.\6K&:[LE.K4O)XU6 M?"#.P9VK+2NL5\ODBX5,+C\[OVJSN;"Q)\M3';8ID%V)83!OIMBV[TX]#46E MPQQWI)Y>?LG_RIUVRA&.\VF,*XQ*Q\]\IHMV[6RY70'G"1&_H."+U/8DJNK9 M5(#9DY&-4* PS+0_S=PXVSAM'IK]&#&I,-"_L(Q<1;QPFNA\(['!U?MH#^'8 M_T"+P5,WK4G>63]\U-3W[L;77QZZO;+>KZNK[YS^WIVOE8T[7[-WXQ^]\D5) MRW:[#[4__D7FD(@[_&UM+>E=NUQC^PGO4[/>-K/K63O@*@+380]A(&(Z%:%B M!EO^-/3?\X]!"+TL/J:AFY&A MA;5DBX^ [LT>C,D\>7[D5/?KK,L,_@FFJ%AV.D4CX35/WV?T1F_*(YC@)(I8 M*,[KXLF]W+YY^4BS*QW3>#FQ'.QM\MLQT!5$&\HQ<*F9"Z,VH=NF4RJR,F'R M\D[-Y-YD>\\3:0"II1I/* 7#=V^,G8_QF%8SYL,N;PU @[EG6M4@B"V M#,=LB_Z2)LS,T!F\*=M1V C.^,B>P(B*WA[MIE-LQ@4_61W=:%F*^4BO\[^+ M**I[* +L[T(PP]NPQ_!G&SW]:EZKG*LWGCG;K^=(/8VGC42.:[5%\Z2*S*UWDR.EFAX7< MR7 \UR*GZOE)EIFLFG+RS%>>=;+P(K)K7<0":2GQY[N-P26X^QC6IR>&PY>@ M=\6R: OVD$^>S>)V)=B=B;UY<#>^NKD:_3C=KUY\[V\R620YO%[U;OSTW*QG MU=NOXUQW_7.>;[:UNW'AXO=M[6NV\V6\FJ;U2YSMWMTX_U3[Y>1_?2]<5=8FPHWF[L:5[/?"#^7!>/CV 3>Z+KC1W)QPHW5U\-4Y__%K/UL,AQ"6 M"#<*[-T9:-E?M\>U;U<>HN]+\$;Y$*M'%:W?C7\W#P;[I5&G.&IOBR!9O2^N M:1OMA[ZA86-T+'ZP1Z=@7LV',YIXC+NQ6GJ\O72^W)0N5^.C2^9M><>.N^K& M'7<@)7JCK_;UX'E<^E;]XU\_]W #3F)8Q7I6SN?7",X^]O/3NLE01MU9ES/(F4E-?L[ 2D-_+ZPZULM0 MA\]THJ!?^S 5;RZ"YP2F3*?CFM?B)\GP/C3+&ITUT22H<-,FF# T?'1ZZ#- MF[2Q?_P[M>PI0O_&O/0/ _V\&OJ'X--61G\X)(5L7 TXVX0)YX]<1WXN"CMFKOJRS;GO6%Z+# MD7Y.G=4F-OI]T?Z/VWN%7KYV_;5VF(\R N_,-KU_[_H)D%LF :IG)R??M-/G M[D5U#@(LA0-.#;[2>$JL:,&5QM>64[FIR.->=,'*LV*V52MNR8=K7?)2F=R4 MC5&^3JZ]WEAZ:]I^Q?G]F_'Z8O>:IX7]?9GJ\[<.(+8XKK./[& MV&YJQ+>X>W74F'$@/E;_AD_"*]G[E772GMDQ>Y+E1EJIZ)1KF)X(IY*_L&T; M& /+ SU[59B3T:;9P2@5-H:.%EU+^_,;EMFU*(N'AME55!LK5;B^N )%XE?^ MUW.O=E&X'!;B;M4AU@].#W6OGP#+5"MBS45OW1NZ/2,K7Y$0G=?^W'IZO%"L M+LT>GQZ7YW8Z9[-9G9>GH, Y37:=DO>\2\_!I7:TV.I,;K?6G-VR7O\./A:/AQ7 MK1_[,4S^.LS9"++6JU7BET2-W-N@QB(FS=OAA057O^Z]7Y9!-]EP"T<,$UAN M<5&@^H9LA8Z^BIOJZVU1KM;.2_F+F*MYHKVTE*OY)318ZM7U\^OMU_K]P\-! MI?5J;:>W(Z^61Y!UBS"$?9C;=A)&T[*<1 @$- MC,H,@6D.%:F2TT>YZL5A6 MF$&"65Q(JVB6AR]:[,K]=,KO$\,ZM5[/5'I8RF)T7Q[\3^C-.5!: H'8'O'4 M?;VW#4D (:=#DHF^S/E0K&1*V=)<*1D'*TK)V-Y=":5FK'Y7*M5,L528-T*=BZNGRNKC)%,,]?B0R\D=C[4E-&5^[0RF6* MU?F%WZ[Y7K&4;AE:<*S6JLUVMQF99=9\->#R;NK.O?\$MLU8D\8-E69+\GMHNH M^1M3OVSDNW'MWGAT3LQOY\K].L#JXF&VWC%676WC6'6EN['^]5V[&40;G[,M2=J8H%M8(.VY?3&IAH<:9Q/_.W" M]Q)1RSWG:V(#T?W[I;LP C6\QF7!:H3:D!O!9[[=_^H-/;=/TT>ZMF]&@H[3 M2RX6659B_3#ILNJGO^V#T\Y3LU.=9UG3^[V MHJBJMJ8597=SG M_?LMX?_<1O@_27@$]S>RHY472[2$5E[2'?TY*.]?#_8N:M];V["C48MD;3LZ M.=U?[*CH/),X8K_&BJ.$S1&6,@&A'$[F$.SCXVM1(7IH&S@[]HY.\/C().F4 M9\UMLOV,CV88&.91D]Y7"L+/#CQ]UHT_/F3, M[8W.-5E_<9/M0.KJ)N9\-^Y\JS\^G!Y9S5)^:HON.'M$].06/TL!O7R13MW) M6BNLH =WN/7"9RE15^[\W?AK\ZMY/ZKV?_0J2;IR^^GHWR)!U+?4E/MC^A_3 M7W5']Z1MMN/G12U:6,$5#JAU)IS[6&*!2,&S2MI,PFXT,=^+Z]1R16;,"=-Q M&@$=)Q%E(Y]Y9>MO@H:WLM4G;I^]#:R57S9I487:1AY:Q4)GMB-_*PO]V-&5 M"( X!=+LM3[E"]4,_[^_)L$7-Q>6,]O=&VXVE@L3@NLGFW$&SUKKW Z42&O+7"WCJQ[U M^5!BF2F>2Z:VE5LZ_QV^A/\FAQ:6R'_?'Y72P?'WO8O&P_;SWU37_1KX+Y^I M%5X5_Q7GY[_I3OWE<1[Q^?:SW%3__^I9+E_+5%X7RRT04)T>=7AW+#Y%JN@+?9E?%%TQ98T%0CL#55%U<7,U4:M6WR\4+N Z6 MH3HGX]\Y-9EM8MS)"O6:&#=7*F>*E;BREC?"N?7-:.!OGG,GZ^5KXMQ\*9?) M%E8BE*2LT7R>KX..OW^OWPZO*S4EW M#N_:G&M9N[Z\!!&K/\D/YU?)1 M1&-= A_E7'5N/F4VU7NNHK45Q^(C-ABTM=636E1UES% GAT]D' MTBD&HXX%I)%*I*7T&HW=B! V/?V(X..',,HNX/?B+Y>2%A?G:M\MOC9HQX6&4D&U<9Z MD+J8YVQ.:'\4?T2^&$;'JNL(JJ:(?>"-J:Y@418C&FZKS#;&[AN=2_C8(7SK M"#,)%=8;+%\OCXL$OY>"@>M'IND?B,K#2Y*R_M)5N@KVY>KB3]W'Z MN6/"\G.[V3@W'?'XGQELE(/A9ZK9U]1N+&?$HW$M1*\&_]:58@YR=QW[Y_)Y MHG2?NY7;IFE]=5E"?!7T&G.P6&.*^7:+ &+@L(\4V8Q4RRV1@G_\6]JM5B-@ M+J*W"'[>8AD'OFU^-#083T-0F4FRX&#Y._[#_>K*I$%Y5!X>=M1N_ZCO;OV/ MX&)7+ [B%[ME J$ ED5;?0+/98BN8^+[Y7$KZX..T? M=YZ_F@-5GJ*\3X.$QC&/0!50.LP(8I-E:H3O@Y;H3+1XQQ)@MYB5N !E!Z8E M'^H'G=ZW0F0IJ\>7?0E\_@("=(G08W-OX'SXAU-W[:4M1^=O."K<% %\'FPO MB@@\\7V0/_C0MJ5]X&8(O)B6TOO=RV"Z9GA:MY M"40/'94/+%Y.:.LG:W;APV>J4 M?N:K=:.XI9/,WHV?'\_RP^K]X_'WRI9.LGXW'IR9!7U\KVNGVAHF.7MZ_\_. MCG2H*EKG'^E<[BF?X4N_'45O*S"AO+2S(P+:'?4QR!(_GO1:]]X;BY\B2"I&C:0GLGPW+O7- MF[Q\=KS7S6]8;*PHZKP>N%L63PS:'\V\I[6N6V[AVQC)_M<[VG\>%G]HH_ZH2%%;O0-OXHB?V'=@JKZ'- M4P?PY,-3.T$'03HEO(CSVQ5!AV&<5%G,E3;,+MS(;L9A^G[TW-JOG3T9A<_K,?Y M%-_J)SG#+91T7)R:]1?K0RR];!N7JRSI>^/!CXOKW$-E2WV(Z]G&RK1MA!N_ MZXJ%!5H-3<(#7WWC(58C>B4_>XC*D[H*^;N837OM;CQJ/GVWE:^R^EQ;1\L@ M;AE^- WR6OCDLAOO&E2^&]_TBWLG/[O#PDGUCW\9RTC ,PC>PJ3?^VP7=#"7 M@$BG@H$'?(]G;D]+-7)/*!>F>XJN=%5[NBTPOO_Z4+D8%[X_GGM98>>F\:A: M*N]RH+)MM'$;I\?Y$\X@J+>/'P^?'[_>J/M/ZF(S:,P[@TC1IGV0RQ^95Z/] M_?9",XB5D]-G$+RQQT_??CE]V:D7.Y5D,YAZV4Z8PP)%PZLP(>:QG BXV,3$%\V/_[FF-CL$1022W$-KY9A]['T M134ZUJYTH'05>@B&P(H%Q69)OYHJMS )554L#.UV-=#&:'1=L>E9I=O%/X&B M9X.E9YBRB?X9^*.)D1E+:BGVDZ+P=B:R:8[PV_+ <'1Z*?Y3M";>D5S60 N$ M@6U\<>B80\/"N> ;."8;BE=6!$GA/AVU&[&*2*;"%J:@R]@S1<90DMR35=VR M)6PZUXDC2H"XZ51+T53E$::LVMC#96# ):2I#VB'VGT0@+K!Z!4WUI.J:?1 M"ZUFN _!EF5SG3:SF)'2J00M[_S7H-AN.")U&L%-0JZ+[]VI1^%D&I+"I?W" MN7K=*%P;7OIH@'MBYC[KO":83O#LUJVS[@NJIR/9$(6%$UMJ+Z0J2)Y"[F[\ MNR]7;_MRX?QG=^-4S>[D\CN%W,NIFJ_MQA6DAZA*Q7M1M^^!TB8;52KDIEN# M;T\3KL\@"9N%2Y=TRI[A'/*,Z5=!Z;B/BC^&[:/O1O[( MRWKS#\$$K6&IY%:8KO8E_30_$\_C&*YL@H]99XY MQ9W*];IZS0[Y>9V)6[!.#PVP^T"UJ9O6;!^-'[YF^HMWX_9Y]\O557:O[_37 MY*7Y<-($G32YC3MIBG?CXU^'M>^EWT^] WC$QS/;YJ.);PR^HHNIZ0R'&H6T M02MORU9?ZH(B 2HWDTE"2<*P#_X*6CK>UE0XYP6%#,<4+0M!H]<4&8T2K+I? M1?/"9!E!*Q!/L/Q#6,J96.B^/%2!:B]M0%BK^D59HH_"^N]-'WDXOU"PP'A%[R5T$?:(IKOU?ZUX>-(Q?Y^>EUJ3V?_NQ MK&TJ/=GL>$P;:OPWN[F.F$:Q5KF+<_(U*\_*]X)9.L+N%3&23J1.!A,N7]PJ M:\IX4YL$Q69U+O? NL.V?!W&1!*;M+J/40^S-7S'ZY+6XJG*J]G3[>\3M92& M6'Y*N8^Z.^].-;R7OY=+4D7WN'AMDGC= MUV3+4KLJ:Q'P2K3I0.!@=6IU8Z+^=XD#G76O+87B3JY_?Z5:8*1YJ\MS-)T= MH[OC6(H(O>Y(S:N7J783FL6>FPKIG*(A%SG$#$Q.FE0@N:V:9&@7EQJ C2B1 MA4JF& LRMX0V;1[+^CN2'5)Z@;)LADW2XFT&9QZ[G#FG$7B&;,;'67"("$/- MS413Z+I:%JID:J4X3+*76[J5B9+NF!N*HWU,L=%7+>IBF8A_>K+I.B<+U-MM MT*OC))C4%I]Z\4=>SF?3-V(KI-4BO+8_F]=.#;W]Q5^1"/.Y3Z8Z3PIWXP-'/6M=./>Y1O>-.4\2?7GUV0J7S+P] METU[Y(/^3)"ZX)<'G[SF-(;_Q-(;*W3BO'EW< M]K-?\@5XA/./1 PD^3G(G>5V)#6L-]W.GQS5+N/4W$&TI$.G[,=FSUZ MWI?-@372X0X<2Y_@HT]P)M YVQSI>ZKQ5T92Y'8?0=?YG@UISY[ZAJBPQ6WK MJ\-T"J>,2<28]VNJL@8S:/<1>J C=4%<81JR+768B/#B'F&L][JN.[(F75*J MM007XR'<94#BG>\4/L%7$ J:5^%$DS/3J:ZJP2^T8GRZV=C'84Z0:%*N+-IZ M8)[R@ T"O]:'IJI)^2JO[UU_VL(";EYJ^#A\[YETZALQ$L MK\!D^H?G[=*]8ES_Z+U/E*_"/"A?<%ASUR>:K7^S>E6OL';Y*%^@)RL_G@^S M#WOM;,Y+'7H)RE< ALLX.KGY6KC*/5C>MJ\>_VL/5C7\.CXMG-A&J[4!D;(B M?6)BHQ-?F6G7<$RXK7X[<+)/^GOL,U_O0,2T'P7)@5)A9NQ\L*Y([C^A%"RD*].D>YJ&! M&@%7I]Y6AW!I>^54SA#'BQ2I^#-@1(+ E5%O_W94$PZ=K5B7<*&KCW@$/,R$ M7$TDJ.5JE)%_-],2V1OY?PD"*OA7PE$4O %]@T2A&/:- T_EJ@O:"R0&N]7/ M5KX^6$_??*6Q;)&DNH!NA"J36-\L%\ L^L0E5N1JHH@0_D5I^@)^(6;1_)=I MBWJY)Z$THZT6<$E+\8KF6(6:.QVJS).PV 9C7UAKV'':-GP"[J X[3&=:AL[ M_O=#!X0IM:RT+7(F0.X,U+ES7$DT&7E:?V'//@. M6_$V+=!%2#WR6H<$H4"VB:V=IGKHC)[SUJWBLO5ID)4]JDSK2W*[=W3VSV1R M3/-HK86+9_4:F,X7.,CXDQZTWI.Z[+\:2SF84D?2=P:N8'/-TI'F8>^()?+ZW]D5XM,H,A_8V*9D?"XW/X92;3&NF(0B MMTUKH@';-L45^0+,R&9U"!5_,E7=A\D&>FX"^"SA2IT M$PFN="K"H[E%>'0R3-LV\>C7LY_6M^]6Y>%+9XT\.A'C;6.2:RJ/QDNNZF)< M,0GU;9NX8I0_/CQ_NBG^^+K.^VPB9-S&)%=I*E>L3G"M&UI@HF]B/?&.!D&V MP%*E;[+N(& +W!E>U^VPYR.=XJZ/0]4$TM?1>T^F'?R1=&R7$8C2+*Q//QP8 M;<<7!PEJU4Q[]BFZTSTG4N/95G0$O!$^%,IS'Q@=6!--&Q/OF-6/IB0S'X$? M@1M _>9*=W18&,.E0C:?9Y<6&V#B.^Y4).!D#2E$-O03+"'_%RK\LL:8#?1R MSTO#9T?C_H?Q.@9C*,Z#< ^AO:#Y'RHMD_VUZOLKSDJL%2UU-#8+GE@-'RK>>/PE&K*J#XV6"IU:!J!Y5MB_2[^?KU]<](J%&X. MNS[@MTEYMFZ6&B5"SG3WS:;\RSPD,PDE1IA&@V7T>RI-M@D$%@^B2/D+Y*80 MV>"07@:&[!G@K4Z!,;J0 T5*XGC$(/K,,@5>>D:R&_5;K_.,7(WVC,Y%S[X] MVYHCDDWJ"M_^(R+Y3TB;%X7P;(?IYX2_&'>9*'77DTRS 6Q@U>R(F*T4%[)-IT(Q M6W=7);&M/IME>@2W>5D7]D:@]>DS(FC.H+':"H9^\:1UV7)P@-O]^N65-*!^\)9$:^@Z-E:2RFVYHPPH M*U73Y)9ARK9A[DK7;F3.C;R%2#* ]V"8J:B0D=#GD7YN&FW%LMSCH'=\'H"M M"A+/%$@\43XF0BQR^SSBS1TDGD&I906-ERZ?HJ4-I>F!8]?&-H*'IC/SA+(L M!Y1MIM)U] Y%,(&R<#=B_%(&\66I<)S8$8"_WB.P+/P%K3%59Z7M0[2]\"1@ MGJ5%^9&6H]GAH)W4E56-YF-@D!")0J,^&>;#KG2F,U,MEQ=ZJ-_M$4G/#$F3 M$]FB;!$07X\J0MQZLN03EQHG34]JX#LLF2,NRAZ7BLE./PH&W=",WHAX=&\' M<\9 6*)D1%Q<#FN;3L''?"02B:B*"4JYPDQJ$&)!9SR_?N>*(<8S=K31QK:$ M$&=\O&N%,^ZTT-/NY$D MMM*8/B+_>+1 MN)G-WR;1]C6&'Z+M_J8KE-2^@D[6>7-* K(4>5"7Y! U(OS(3THZ-34J MMEFO[*J_XOD;3YKU3"AU&?>0="7J4=3!SJ_"51*H>D%-BLK:+/&. _P@G*A8 M\$JM@*B&5<66/@;]K_ DN8/RSX1BJOKA\7SS+S) T>SU:'F M\]:JO/@7G\%\&NG2@:%DXIP]D "F$VI2I%HB9X)14L8,2MDR=/*:=17K.M\:H@KIJ!XM40[#KA#+TFIDH&NGI]C\,_X4 M&TLA!RH\)!)9O$T%V/6(6YAT'Q5L!":&[ M>2Y6T$<7(L] ?H U..V^ETX2\D]F)*IR0<U$.-BR@P'*#O?TI4X< O9A$Q&_HB-S8" M'@"MX4@[0R;VQ(GC*6(42P4Q09>!:*%F^QK'L;O4W;E7N M[&V#>G3 G$(*6M+ U)!)@=R8H1^%N_-W8^YD_K3U]4]8":11%H9FKK/[V2:E7AC>- MAKVA1E+)9UL$VE[(C>?;^T:SN/6TW;\;W]P4N\5Z/K?WI;S.V;X,@:0X$8$D M>S>^.AM=W7XO=CO]C0"0O$>8D>*<,",W^_7S;*7>NL"^F2N#&8$/[2E6^V%P M^?,VOQ24D;5AB8 8N:FI%U;YZ^^>@,6\WC\6VW^M&!<"/0?86-0_>!%+B]N;VI7US]/GH*=T@[FD^$R8OXH\;KP6FBGEIL#FP_1. MKFW'?AJ$FC+$_&CT5+5-M87FI:(93V_$O8.G0/V7P8<#F4!N_RO:HKW1/L^4 MAXB>EO*4\DN>=HA.]#;6,JK,C=[NR_Z, W(,&KJNL( -=]P.3?61H*) =>09 MBC[WU[D8Q8VZN&XPUY,COF32E=3?DNEH MN$.?U+^D6FE^H?7>E[4N 8&*LDKRZ7/'('SPD_Q7,.D%\7E4N+TMC+#P MY0A/GCM?DKGXB4^MO_Q"F'O%@4 J]N4CUG8E(LI1_+M"&1 ^Q!U.:D%#8@%M M)-(D(LM&5UA':6LR'C9%U$:C1T/O,#D &ZC^Q?XY-)4=3%Y6^$^QV\I<3H5, MN9)@,Z78O<3H8F0SIS(=6]8>FU9H2UEQK=%3R''H0;2&29%AWFKA'H_P!;ZH M&XPSV&X$Y D_DN?B2'I'@*(]+GV\%>5W*XP]D;?HW A.H_SJP.Q8UFE^MURK M>:_P50>>\?W@OAP!(U%@CSN^T]W*2,Q* Y["D #5+;NO@JQ$S[4B@L; ;<2](I3'P*28^<(9UL<)^&&8O=B7 ME>,4;*[CW0R =I]1E3NX&S]?-JY;Y^=MN;R:WG\;6O7'5[ROD'HHQERB4O@Q M[L>X'^-^C/LQ[AL<-S#BM,A,*129^0C K"4 4YH=@%ERF&7ST917<&I<5[1\ ME\W6_A#NY:.KQ@G[9IXLOAS8E2?UT_J7QDGC](J;LTWIX*BY?]UL'IV=2O73 M _B_^O'/YE%3.CM,IPZ/3NNG^T?U8VG_[/3@Z$H\=-EH7A]?X3/2V7GCLHX_ M-%^%G)GLR]RO7^,RZI<_I=.SJP:L\4O]\N#H](MT>'9Y __<.3X[^X[_W;RJ M7Q$-E[ODR5-;'QVN^I2I20@(&&G#G!],+'F2S%%:7K>T,8SZW%_V.>?0!0Z M\9%*W[#KEA[+ZL^U^$P>%I MVS!1=DM=N6UG,%58N )\3Z++PJ0_8IMWC@S!"N%I& YLC?G(N# OFC T+([8 MAB^V' OF:5D2^=:4'LNJ'&JR#IOLCOJHZ [L.B7HWK-\09YG!W\@T$3NR\". M\ZU[YCUC"5E\#&\Z&[/XKNO&HX+);*:ARX^JZ5B4/;Q_]N/H8 >1#'J:T9(UH B\3.G= M'G:=A14-BB4"O&9#(F]=C',O>=A-SQ7;Z8R>3 M7P[Q&CDYAXP9V$E$CA7I\>A;QPQTV20?W8/D5RUGW()FC-[+1DBP&.F/)0 M<4#46I2\"FJ"8@NF='05R"7MT1O$HC0K$55T3-@)[N@&=@9=6NTXE&@-=S + M*+ F,!! 8YU!C F5,NU]B@W]N"3APY11L-AGW08SBKM& SE&Y8ID1.7@"0 MR5N[3XK C80GU,#M)$ G@X*CV#A%9LG5>M]%?['DKF*S>Q8N('BB34$QFB C M7 #MQ9TS$I)=$"R@P,BQPY@+"; CFK6D4S!5V%$BR&?W9G:O/N(R//Q,S+/* MIZ[1=BR68*X;3YB4;(A".$&9Z.[SG(FX\PY?93'*P-%=;[QBO:'\(U#E4(BU M98KBV*3&^#017NSC8851C1'+'6'TI%P1V&E^/N$%?CXSXD^X/^&_67W#T3KA MOS(V#O\5#W7X;YY*)'YQPW]T0AZ5R-B\5B R.F;VQWQ4' SW!V!O_ANJRBIH ME_Z?Z/;$D!QHD72%$UT\1&=>^(N!/),<*SX:HBYN]XDKGQ2)S]\+(X=TB:[& MCKK(N9FB4LMT-#$4Y2A5?L@"3A M^4LD(U"Q\'+[77TXJ/\^&AHLZP%.JDXD<73V;[C)'RS^%W[QL8H@<=>W90>C MB*BHF_0_<%: @4TO%NU.=L9$86>",^6U#+X>I!T5@YL4[F1Y MBY%+8 [V6% M%3P,0&MB-3)33((W+#0P)'V"A:1NM)PV =LY.Z3$LDY#H'R,+)4IM(>N&K\O MU'AZZ-*[K\X\Q=]O^)X<_(\\&'[V@,F8Z,!= TX.IP<@=\1C^V*CUYCL-)R$ M@$G!CFL^(&%@).6)\N(F6<3(YS%_#EM/8@D9UY< F@FP&&I4C$8^$3'-RJSK M(__<)QKJK$R5VYA33768R4M-6ZH$]0L8ID\Q(\^%.O +L8PDA($LZ0X!&!C= M=&J2'*"<*K;IN)X6JU/'XE=6_.Z*+I_)X#_TFSR*ZSF03;S"<3L-DXO--I&+ M"4ZT$63-50VQ#HP).;_8XUQ/IP@L&V9:TG;]\Q92JXLY3*WV^=LG/9@OSGIP M:MI (),YZ5QC/S6[(W(E/BP8(+$^0NZ,9*Q#?E&1,! M\P.NS'-#&]V".>>SU^*3OS=&LD7)0D8*@;B088FZ <^VBO-4OI55D^+)&8+O M==_0J #6\-(C?4F-ED@^YUIK)#OMK5 &M]UA.6^!I+SX5=/=)O(^!=W>$BET MGAUMRL@0/J\4@AT0#HD\5+'B6U@S[/86#I&A8Z*#E-WKK'R<>Y-$%"%BW[.4 M44G8: QMMVJ3X<7;_A"+;[7)OG:W@/M18?E M0 ]EO1/C_B;EWD_4:=LF0CJQ9)7> 5VIVH"'V+KHT418;.&%Y8$'QJ[!Z).K MY*, !<+M7/E]M"IZY-\!]<*L10V.>5Q2)0,AZ+?H7#MM MLA?&GZJ3C23J;.3%1&EFY8\TLTVDF97??9K9O'S_?AP46RYQ_9>Y7Q=0 CY! MRN]@"G\X+/[^;BD>E? A#GD^8:_99 @E:0(UV\:.7R,+83V2/Y4Y)#!=QY\H M\0[('E2M='C,O>XY#&],FH8;C_8E/;P'8K&<0XHT:/*3)5'3(8J;$R4^A#B_O@334"=9TAIP2)G(+WC2NF:@\JY;-W0X,*>]=D,4]6NY1 M>22T4K031>:Z"&9Q\/J*&BEQHIMS&%B!PV%()$\_@]4(2\>@C=I[-\ M*<$E&+FB*ZV'.5!HDKG16G@:1&_[?8@5X;<$9GF454TH")10@MF:"LD:$;BS MT-?19@G08#9O#<2BF MA3 DKB,Z@'7*DD#HM?= Q+!F:C-X<98J0>X3])RZ)'L/)!$NN*'3TN#VLD?^ MWCH\\YS=<-R3Y")^VY:B==\3B=J:K XL1A_>RI#E;-F@'2DL%P$3WV'%[\)' M3B*I8PR%, &3@S(&/=TZ0V#4CLYR9$& MQ&%_UV(&I8KS]"7^RSMSH/_)>P; M^D_,-G*$'>:W0#S$889D@Z>3%VXQU1M/H8H?%'FJ5!XEFRU95ZR=LV<-)!DO MD$(B55[S(FPT1SRM9['\&3D'\$"X*P-$2UJ'TLW6_\F/4568.SJ5#$E.S^ MX"D3A6>\[LPM(I,^>5% 9#_DTD<9U%G$O@)50]7=^@4?!A85M/V5$0Z:F+HP M+AQB*LE8/<$[V#R>0LHS 2-HZ)=@94J'[J]M?V%27=?Q9A:EGKITB,V'<]F= M[SQJ[B\:XD5I?D@NM^ 4GW:K54'$\,(VMX*GV=@7N;R[[Q(!U/)R-46.KJZ@ MOQS. +:']A#AX!S"9LB(&9<\NU.*)G?&9K+/K!^(YA>G4R+OF9JLN1G\!OZ3 M%U*P1C]B?9IE\-GVY4$18UP]?488GGWIH$:U.C ML([()/=S_ZY F+N:DP3B@.#.8>(S(DNRGMY\SSH<$S'V-596]P1/&;08DF^L MAPD(0@/$:D\6!75,RFK8.H'C#$ZK-R"86%XY=-X].&\VF=/:C@NSVOI<\4L4/39=10-$:@-4(B!,NI008M!2#/?RC#XJ)"@<1?85WO]'8*6 MA06U&<%Q$:RDG+>&B]:@\M@D*Z$B[:%MJL.A);D]2(]XWSG%TQI"CP@5@KK2 M!4N_/:6DKPQ&,HBRG;/'=E_5=?7!>/2-C:12#=8LKRWMP],(UXI%LI:HPB.N MH:LK0KA M6PZM=YR6#U*>LE0[<7/#(R%6',J+\BBM2N4K1U:-: M(T(3T1F<,TEYT-)"Y12Q2IN*1H2HZZ(*5M"U@#\(6B).$V/H['!=\DY]5$/- MNNW:6#J*=@0H1VHGH'7 1X[ BAD,-6-D>1@U! H%]R8F1QE80BNC1PH.OAA2 M,PB_AA)Y/,AR-(%X6 (1X7I)N0%,; C(T[W"8S7=,H'FR#:33) !EBO4*BP1;/*MI$FRKU7?+<[ M4S9:PAPG+Y\GR)UGT6RQ=(HT1N;%@)')_8)T=5L6^OJ>D@(OV\(-%UPG)8UX M_57\]*-FB-344.9?8G .HNX)RWPQ]5)%"'N?KBH:C/+ON6RR(*/\4W>;"O ZJQX1HF.@R63C&_#M@#!OE',I)NZ"YR4IAK./$XU+T/ MIX6ESI#;V+'[ABEJ2SAUKG4"PVK:-(HP'*YWF[N>L< -CD,!9\1@L#H#4(W= M3@VZ08$0\L@PQ#O%-#%#!9?>&M$/OKB32'ISU7 V=1+0.BL\,XV1K(D.* 18 M1>X:68(Q$*E 4"):)LM[@+K'@ OK-PNA_UEJ@3K8 \-$[Z"^9IC_X,5A*\R- M@.Y$8@]A;A+$DVNAJB'\LR!G2;=[1V<[N6PN!GCJDV5T5&< 4@4>U=6!T?DK MWK9&[P1^ P'#L*DZ%6[J'6.@4 $.H5^UL=OH#0(:^SP2-F99BXKD27H9T2B#2^*?($A5-WGGGWM%]K7<"PW!+ M->,9U%W5M%SO"1QT[G(]:]L&W@ X4[9PC7[B#Z)M#!>R)OK],)JJK.CSA&0- MO%ECE9I,E%&^DV8\";A)%]]*.(>$ \5?]42H>BAJQ01]GR5D)U,AVL&K;;C] M-87"[R@%B*4L!XQKPMT,E9H*&@OV84MTKS9Z63<\[#%7!$]Z_QT>7C_ $5:* MHS?0-.0.0OL1H!QZQ[M@ !H9'I5 9"\N%BG55@\"U+E>C [+>&/.*M'RQVWC M8TEL2P-=?ZFY=A@I#+3GX'9YU<4QVNSNVKS%ZP7_15<]*C]U+R&EP8&SK#>( M\DNYJ(C(Y8^$QN($8?K(\2I1,8 M*$!(COM(QD;RHZP9'$F*8Z+Y^KB' F97?<5W.S&D/#Y=&AE9@UFHM!Q0>BE1 MER)IOBUL(;H.#2^;)LML0 ?ZU*V*WP)69,"I'8!\0F L"B4/@;?I!F8F"%&# MZ_N[TI["(L@\Z,HCA?QCJNG&9CE"7$OQ=XUD65HA6;T,KU-F 6 6 MEL9(1C N'=CI*=R^@6MSRH6VMFP!4_$ZSNN&%T'G"1;<:FMSP0TGP!,^WOFQ M5!::P&BY>%2*?=+KT:GJL_)"A$Z*??7X/7L JB=Z ]*I0HXNVRQJLH)?*"C3 MV,=1F-Z7>A9[ MP*2_4._S68S9AA/!GF2OA:%KF]\8)DB+KRRY[(R"BF#KN\! M+G5*XU4T$;WSW7_,;J(>E# 3CR8<*\/UGI!#39P'$-I*!U4+#@W/K@4#3ZY7 M=(=YUK*7E!',S(.#C-B"=/0&7O+% "X[$/A !O*A4::'SS\4!-]#O4' \G[$=N^7"80<&([%M'\ M0;P-07Y+5$9+:8TV-P&\:EM!'PD3<\B[)/#Q73+SI608;=#VQ!GZ\B:GKGPN MM'O6YI,L4YWDKZB8]JP5*]!P@;2Z4&< =P:>*L&.D@?GC6C0%L86"#.5O22* MTXC[;.[!?P0NIYQB2NK@KC-,L&!,Z^;/VOXN 0.Y;1HQYR?#!\6Q7,9CQ\+5 M.GAB&?7(96E50&YE5SIB:^-"Q;]''&:3[4YT&^"*DS6&AK+"6 >L_C#D<>/TJ)B\= MP0>8!Q>U)4^I):R2V+2YZ$F*X9\)S168JMR6K;[4U8PG:W>=25#K3[MZ2U]) M%'RO?@3?-Q%\KWX$WU_CB6K]N_I67MO@\<(V:>J_5/<#NB'3#WB.LM2(JDOL MDD!-];]_J_^N;X*"(.OYYA7KU^(C"5ZJ/@?3A M4F+]=%?4)Z3>G8YS:R?7& MF4]F*9,"?4D:7LK_;$&D8"Y9GWQV4QVP2\U[<76OV6I_RA6J&_]]?,?>D. _X97:ENQ=P,?MGU/J:<-@O*?5I M)$*%$ZR@_)_SR(J$\D&H"S&3_>/?_X1GDG2T\'!\"_/52J:<+4Q87RY^?7$3 MFVJLOGXZY7+Y3"U?^:#3+#I5BIERI;R-=(K]\%3BQ,]AZCB3R%(J[E;^7"Y5 M7B1);U@X.,%MP/M;$2I).%GB0Q?XF,TKTP6B,[JDYB2+],\DM)]GG$$QU9KV4PE&]F;A/=H$A?"]JZ] DI[L1I1LM[#VG/9 M0B:?JRZX],0*W0*:Y(O4Q[B5%G:3>3NWZ8[-SR.9K@Q,3C"FZ)>OF5,_Y3+% M7"F3+[U/&97+9&NE3.%]2JE"KI:IEM^#E,K7=O.;EE+);=ECP^)M#;V Z,IU MZUPFEZ^ 3AN1YIM0]&O5?*98JFW!5'+%4B97BS#/IA3]7'$W[/&N&(H MZ0^KW@?*A^OE8S:;DQ:;SV8JA=)FE=A-+K^:*>??[_(_53+5 M6K)$HU58;VNQ7C[E*[LO-%"7>I%NL<+P,9O7,IMUVR71VS#/8'I/%5O2P.*> M=<#R053?Q'*0WI,ZAM/2E,5S&R:/XC/@L^5,N3+3GT-#+20.MYT$M5(A4R[. M]/2\60+D8/W9PLRK8N+ZDUU3"8BPBB_&K[@\._R0Z./1]@BOINR&5=B(#, E M5G2LN7R&+\%#!J.RX\GEQE262ZG6!'7]G^QN'OO[:E26"6.P;*8,EH? ;P7Q M&_.LRL.A:3Q38;%&[^:\WY-]/XNU[2K6<+-)( (6Z[U(X2'W[U3B',S3#+:!P M*!B&<$;P !:'1!=?\FK,.U1-_(3 $^(#ZK)CM[NN\7-K'YVY2@1ZZ[4"N33 M'/C J1IN5.^-E:>Y*_X?>3#\'(#[$NA)E_33@8?HZ"+@)#V4TO0SB8DJ?_(3 M60J>R, 9Y< /C+=1(*=3HJZ+LS1#EF#U4RU8R)-$Z#ZL(P^UXV%K<1N@$::< M"XHONG/!?[81GQT1,#W$'W>Y_*/^I:93[EI%_=YZ*\D*N=C^$JLJ)5MQQ9A_ MO:*H)%XK6$X%3'FE95"91&;Z"@I?EKRH?=^9X )Q-=NQ](*D]U>'M_22NU6; MYEQNE,NQZ>QGCFVA&F(IYB,V5G9A?*A-K@N@;/BPBR*VNYN /]U,F:_F0#P] M 5.@4*IF"M5(S'J!U/U-S#Y7RF;*T5R0Q+-?4VI$4]9D4Z#V/6)$;EL M-5,I1DIJ-A:?R^4SV5+$W[]=OC;8)S!8%-Z_20G>'ZN+7&:R^:T)&6(A5M03 ML\%H=^"&HN#V:P[[%%#6;CAS;9/+SV?RQ=>0=YO8"\^R;">V1U#B==!7YI^= M4$JS?O_L)HDPH8AGR[VV(1N<]7B(=![GI.;.I:0EV& M@B&;B;TKTJD(YZC!B/+)T0=X23]EQFYWZ87)%SY!(6(PH+)N\_YO1[5J* M39V>$/'5W467T!QV5?1S<7O[N!^EKC0"VA8'YPUQ(I#0(F)@=-.@+8^1'[4)EN"Q&$:L:3@0(R>*187R=J M:@$3=+"'5F\BP7Q!P%8H4IY!:=IBBU<,'/&*@=4WG9\VE_6=-'^= M!!V44&9%/INEDP;:4)_E)\R^%'E8=5<*#,[N/,;7!#)'_0%0$X,9\99A[1&< M;]Z\PV0M-QB/TN?9Z5MSKQ-V$6P#@[J9_T?^S/_WPJBAN@=7^2 !'6;:7":; MS;Y(E0N/6,,1W3MGYF5 ?0G$;:#&7@9^[4D-+8Y2*%!MHX9[>L<2K[&V?^[C M@3-"$\,V IVPZN2NC#IK3M =WX2(CT=Q;JK/T@G;^B"0_F/V":W^%]]S&;[=(%HC/:&$QS+I,K%3/YRC: MIGTJERN9TE9 R16KY4PEOS7P2I7\;H(-6EM2\ +P06\4J#F7J>9SF7QU49C( M5PT$"JNOY$J90OE=PJ#FLJ5,+;?HTI>43+X6(*'RYE%0/[":7W!,\YE:I90I ME1?-_'_5QQ167Z@"!7*16JSWL/I2+9\I%Q<%Z7Y-0BI?C*I(VVK03A!#TP"< M7R/SP=$KUD"/G@VM]!:/'JP^GRN\H.#J5:\^7RUD2MEEU)IMN^#)Y:/8VENH M'L4XU3X MS]FLP5.M-<#N(W-#K8&Y[JT-=ZI7"9;GK./V"HG4RT4=[<,Z> # M=]OSK((M5EO4%EN27K#!Y5>SF5QN&>Z4U[G\3X4*K']1W/'7 KQ=+.]&HL\? MP-O;K\9\S&9[[),W#[R-K:KRF7)^IJ1XL[C30()>J72 MXM#CR2ZJK8+>+D6;XFP]B,O&ZL\^/LT_'?CH%&B5?/8#6F4#T"KY[ >TRJL[ M>V^U \#4XL 8_/]"$(>!TF0S\6CC$?S_? 3_?WIIX@?Z_VL[)9-K:=]A+P . MCN]">WA'*7(R2NE4 ,(_OUMC$/ZY>0]-+N-"_5<6.&Z(';$(WK\#M(G'^<\D MG/>ZD/[]M]8'J'_R>LFE@_J'"_X_N_/O[[P/7W!WIRN4PV-ZT( M+:EO92-="2K%3/X%70G>+*X_\G&E-F=X>873R>8RU6@X=;M<^1O!]<_7,I5Y MD?17.)MR)E^;,T?B ]<_<5@9I-5[;N9=+B4)HFQA$N+[QO6?6'OYOI#])U1] M;GU0B/ZX5;B];P/]>I9/9578UQ*#OD;_\&:QKZ4 ]'4ZM4'L:\FO82.^<"_@ M]$N^:YQ'+ W/// ,AQE7!D/-&"F>QVF8(]R>C>L;O"UY1.Q4%RTH39O.R^K$]8 M6,[#J0U AB^$8 X4B8'@Y21Q$J*7+T6;VO31V/P!"0&@2^_GD,P#?EXL M1,#/Y^.]T'C5[,+0YY(*QV0=T.<)KFN"^LZN1:-=EX[ZEKZ2**:BB-_=2L4 7;[\YZW7*97VC>!E%,E9N M4N4*6FJ11A_^3,-$R46[$HS>E]':1#O.&3A,5>PH7;6MDGT4UD0KM=VB^Q79 M3J>FW\?)QRU[3:Y@7.E :2N#%MR:A9Q(P[HQS MX/MBA^?90K2DVS9I^-R%R'F&)H*C^:QLE$B6HM"5T75LQV06_4 >P;?9MIFR MBG8^-^)A#6(M,,30,2T8WR#;AVQYI:>V)5D#(:V386\)Y4HS]-X._'E .@Q= M.X$YD@*&PS&6P-6W'$O5%5C]4)/UK6R;MV%;XHRB@DZ_>D!)@;,$O#F0[V%T>R3&P5>8*("=Z?7%N(;XPHZFZ@^8 MUJS#N7#(/9\!8T9IV5)7U64=-3$+'87FT,!SPS2OEL$_GW%-=73=^1<;6H^A.]@QVC1B@L)HZI>63 U,AZ\PP1, MRD?B=-%ARG054#8UD*0KM^'H6HL1"*;B4DCB!**%M5 &/')J//&%@@:"-PJ^ MSZ\Q4ZB1[E$>PFQ5O!&'5*A %YVI/B)EQ2GO=A63'>#PB<9-FNM(4]2 W: # M1=9CCG%H:6>ZIZ<4?9*5Q^!0DY'^4][-NOGR\-T>"$=BS8YJXG[M&P-0(Z2F M;8")*5;#^VGAOV"G_E/RZ48@]% 7 ;'=!K6 YNA8-)5O#HC;?-5WEZ#.IRD4 MMP#9GO.]MQF3!/7)@CAU6WT+7PC-0 MB-. L0.L!3X#(X'N ]N.TT9)ZLS>H*_&$WS;)&(@'^/U#&\_*9Y>Y:E3GFX8 M493@.T+!\FM#J@ZO,N6*]6O%AV&ZMCK@-P2LQN;$E?614.Q< K"%=10,]](5 M";?A(P9FX%I@)Y%"7)K3$;JNW.XC.<6.492;386F%A>,%J%P*Q,^N"K>!B") MV4S1GD=OF.'=::@>1G5*TT2'-+M(Z557:G@^;5?>921L(&@,\$729\T'8!1/ M<&?@3SK=Y2R&C3*QI8P,K@90WH*AK?QZW +UDDS;?=2X#K&Y':N,\?HCU-'T M(3UI'5;V>A9,J^W2:AV+7=?>526["TX;OS40Z MEJ=38#CJAKY#2G*[#\O%9 K+,H#M;2'18B*UN]*06ZP8S0KD<"U26!=U3@OIRO;F^]]E9VMZ3JF^,=1K=# M5^MXMZSC*5[;RSIO*PJW1;&^_$>L;Q.QOOQ'K&^;3Q2[*7AVN .6XUD+/LBS MPBG(9PP&JDW6WFN&$JF3WSGD;[<#MP7JS91%Z$_(%:7;12\FKU/PO-RN@R!/=W M &UC.LWIG?@3S QBWRX$8?R6\]RY* U M>$^#??QW#AIT6Q3Q-V!&*#9>M19QQK2!#LHH M5@F"1@+YI^(B?"AT,9M58:DW*N7=@/)/ IHX[7JWN2M]J=?/60"!/4JR3OBW MYO@\W#N=GN\^D)DP1^XWZ1RA3Y&[ MYC""82'"4L8?]'>%=R:FM1J+_V!6+L5UQ#Q8Q-(_%5BLES- KYLJ&0GX( L_ MB!"#""&Z824#XT+NY:5(CM[A =BV:K:= 1ZU-I^+B"4GF(^,,5T638(5J!AA MP]@)TP'%U81!I(Z*,3NA^F%XRQV8MM3DX'G!V;C':"A.$#+ MURS9F9DF_=(I(?[8L]NH8P8<:VNXX?Z+T#Z2VOF_/^2[; ZES]_XEW^/KAHG MG*+2__R_U7PN]UFZN*Z?7AU=U:^.?C2D^ND!_N&8_W_L^DHZJ5]^;UQ)ET?-[VLI1-B@LG[#TC=0=^4BB_S[0]-X1$0@FTJ:L9*8 M)"%"*?*'6J"68CW $4@\.%)MV;$HG(NCR43Y?/:S-9 U33&Y#&,!X0'LTHA^ MAYWY)%N4]*BS0W3I@-S(Y5L[>8%RV!!%-_6V_=>;N*.3LG0NAJ6++DOOGYU> M79X=-XF=SR_/]AL'R,!O3KV$CS787<$OX@,F=-'TV6<1:7;5G6/"0P<-CS=' M [SO!FX>5L:[&B@B2)D4GI:23NWW504AY)2V0V6D8(RK;3B$G[RT2,7]T6 _ M_L4<3/3FH:O/Q+SI*3OBS8Q[F7=H4LP.A;$Q,8,R+_%J['C;UO9OV]#=-BDJ M"BPI5Y!WM[36D22TUA&DK^PT&(+5"EG;PW MTJRMR;!I)&$B$ROH+%@W:LSP5;]&BIJE21J_ADDYK.;:]+&L_^J+>P^-5]GV MWXCBRO-?GD(O)(!AFK^G+:-RA[QL.:V!:D]@9$FUJ'[:1'A+MCI0^.&?H!AC MPL 8_LUT9=:1-IRZ%+O9VDI=" MH>:@.:<*@G"1 :($*>)=9)YR2JQOM'G:KZ_(-J&8XJ?<<+0.,S6%B0E/,(L> M#S%S\R*;QOAY(V]D8A'9Y4K\Z.CM=S_36:H8':5&(\4[D M7'H<-[[4CYE;HG%P=/KE[?DE?'XS'I.%&QN4^GM>^8,Q8-?!3&!0B)9!-1FL M1D8WS(Q(^7W0C2=-Z?1 P44]._*JY+V)!3D*_$CF#2(V63;5=QR26QHU?\S. M5;&)+:^MP&(-7EV#11HLSS>="@_,ZANH#@'![%B*KX[Z/RH=CHFQ@V )ZBX" MX&K,1V@X-D/XZ'+7>V1XJ2WK2*T6A58Z:EM8+6"8LSEA(/G)C:2[989NL8I_ M,*K6X#'Q< 2_<0,A>'B+<8>W[IY>\GL?UO>OSB[?WL%- M$@CBW&^JUH-;_H-<^Z@:CH56Y_)2BN:)>+.JO@V%>S;&K*489LV[O'I]>MGX M71UU&!^\NMF W_E]]+;X^U3 M0U^WIR._NCR&(!N4IT;X#AJ']>OCJZ9T?7YV"L?G].CL4O)V_XT'\3:P[RO, M7PGN>V5J&.SDZ+0!Q_ZP.7,Y.+ D:;#F+&M,;S^__"_L&YIQ=P M#TYT([JM\69V8&B%O9TSW8K,]^+-)/?G'YS/YUP,2VQ@7"^=7I_L-2X9.](1 M2=0_8N;L11>16+P9OH)J[44K.&@T]R^/SCW!ZTT_29\3H.^,!B;3V6[!B1=R MN[G_+Y;4"Y-"EOIP1/_OCV=%5V")=\IS(9?-[?;MP1__[N.JNQ@GY5D:WY1N MUU1&TN&NU% M10=3L)>1SMTN:TPT1(GO2DPI*#;SM:FZIL*OMWN7QR*]!&[^3^I?F.W <_/W M_;GY@2(T6-,G=?*S36]!L,-GODHG>"OI:X36U#M/L]KL_JRIDD\5M5!(,D.+V[YG_^W4/Q,UA?]BP087!]#PV)8 MFN+ZR%7=V\.#U PD^,'/N5JAZ"_@\##OGCCBGX@E$@*:*M#":&1,T6,?HT@B MGS-E[;GV9'CV =,R8%-B-90^XI!XO.;)%>\>%%_':!-H)S= O=Q%WRJ]Q16" MU2F1)V?30WE&:$5*'/7(8LO\!--B828LZ2F.;=W^="N*P*_4V;>BC\R5-%3\ M2!K:1-)0\2-I:+O\MS-5U[+Y!B?D?#M@8!VQL7]PY_KB0ML=)A7MOH>[_C^0,P:AK MRQ9K\73+/!#2GFI8;:IRAC>/]/;N\ER90CZ7@A?(I.=RV63/E2;<-DE>#7W" MO[;E[=><_:Z#Q%M4MZ\[/3@C4B[/7 ?Q=D/2WO/\!EUP*GNC?X+QT87=^@M/ MX>_FW]*WQN'A9>,G><^.FHW3O<;EEYJNTG"GH-KVL6+5]XT(G-A+Z,DE4 M/VDTI?/Z9?/X[&;[N6V6-95LHHL*.W_P0AS?"162,:<[6K[-RN/%[SY4H.G' M?U7NDQ Y5Z(M?WSCXQL?W_CXQL'^0 MSQVI0Z.QMZ\.?YS_Z%L7G9_/G5*N4VLW:L6_R]IS_K'5/-AK]?K[1>?;N&0] MV^/"SW*A7>X\GET_?W^\[X__M]3O73_()\63IZ?GZ]^'^XWF4;__]]>GO=I8 M/SBU?QR>?#EWQM]Z]TR?S=ZU=*YMZS['._M?N M]LYO+QS54?8.]RW%N-IO/[?W&GN')]IU]?;RY-O-;>/RE_6M^..D_?LQVV\, MQ]\O6KW;>U,K5OZ^:->>E/,3PU9*M[\OV^>U;F>_5#XU;R^5SMFH^63_.OAF M_ZI_O_^R=][,JK>YZK$\[._]'!O[1\WORJ\O??7OLZ%R5KPNR\K-MW'_\/1' M]>GYXG]_'G]K7-[>WY9_?JX?:OOGS\,N/;[_O1Q7C MX.?O^Z_R[POG_R^ASK$0A0$ @![( EF%8@H1!0P[(2P=4=F1+0CA]#/O3?=/ M\)L@@]!&>&ST3,J!V \SO*NA67^_@.?(%JI)^\BV#^ W'@&R8I73T9KP8]$J MCQ6_Y(_0FZ6H=PXGCST^ A>$SJ2OWK+T2M?,T-'[(\@,F(AH:=O4&."@8 (" M7'WVTP.R9MS7EM"UQ7IDVFP_4\F_)-=O\6C.9$IT*TQ'FJ+$4&^\VOJT=I;$^/&.G0DK,7MXNUG900! M>/^CZE%N2;=&MNXZTT^!MK^=J*!6@JX#>43IP=K5<+]0UI_))LJ?\E:8OA?< MT=R&[VCR"CUB<#H&@W2^LL8OOPO*[*KCI37/EM@@>D28E90V'P3,\'9PZO2G MT='J"+X3>N9+^=9WXD2@WL>(J!448O>JL/G8:=SZ3+E*>C7KK V,/6@O80LL ML:-[8Y3?"7#+,2CSG5UMR!79\N9#=M*VX&-&.CJ#E*"QI,; CDQE*&N*N0$R,ARF+>9;#LJ1"XZ26/.A6Q\S??9&79=Q!7@;D2^]>2AQ1X M\.N'XLF!R*DE2+.IV32$&6^O&W5VZ9WQSK?IU% I7(;8@IF-++?([BGF?F5] M.\&Y>1DF)SWK7-J&)I;RTR,#(Q,#8S M,%]D968N>&UL4$L! A0#% @ S(,,4Y_M>4$[- 2-<" !4 M ( !834 'AB:6\M,C R,3 V,S!?;&%B+GAM;%!+ 0(4 Q0 ( ,R# M#%,4OT4*AR8 $AL @ 5 " <]I !X8FEO+3(P,C$P-C,P M7W!R92YX;6Q02P$"% ,4 " #,@PQ3RJCY#9$& "S)@ $@ M @ &)D >&5N971I8U]E>#,Q,#$N:'1M4$L! A0#% @ S(,,4S:L MO(Y_!@ YB4 !( ( !2I< 'AE;F5T:6-?97@S,3 R+FAT M;5!+ 0(4 Q0 ( ,R##%/ 5&G4D 0 *H2 2 " ?F= M !X96YE=&EC7V5X,S(P,2YH=&U02P$"% ,4 " #,@PQ3OMI(:L[3 I MWP@ %P @ &YH@ >&5N971I8U]I,3!Q+3 V,S R,2YH=&U0 52P4& D "0!0 @ O'8! end